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ABSTRACT
Fischer, Lindsey Gayle M.S., Purdue University, August 2010, Solid-Phase Synthesis of
N-Carboxyalkyl Unnatural Amino Acids. Major Professor: Martin J. 9^/NMMEKl, Ph.D.
A novel route has been developed for the solid-phase synthesis of N-
carboxyalkyl unnatural amino acids as potential metalloprotease inhibitors. The key step
involves a nitrogen alkylation of resin-bound amino acids with %-bromoesters. Alkylation
of the benzophenone imine of glycine on Wang resin was used to introduce unnatural
amino acid side chains onto the resin-bound glycine. The benzyl %-bromoesters
[BrCH(R2)CO2Bn], starting materials for the C-N bond construction, were prepared in
solution by diazotization of naturally-occurring amino acids to form the %-bromoacids,
followed by benzylation of the carboxylic acid to form the benzyl %-bromoesters. N-
Alkylation of the resin-bound, unnatural amino acids with the benzyl %-bromoesters and
subsequent cleavage from resin gave the benzyl ester monoacid intermediates.
Exploration of reverse-phase cyano-silica gel chromatography and preparative liquid
chromatography provided effective purification of the benzyl ester intermediates.
Hydrolysis of the analytically pure benzyl ester monoacids afforded clean products as
the diacids. The two points of variation introduced through the two on-resin alkylation
steps, C-alkylation of the benzophenone imine of glycine and N-alkylation with the
benzyl %-bromoesters, allow for the combinatorial synthesis of a library of target
compounds.
1CHAPTER 1. BACKGROUND
1.1. Introduction
N-Carboxyalkyl dipeptides have been shown to be active metalloprotease
inhibitors of the angiotensin-converting enzyme (ACE).1 Examples include commercially-
available drugs for hypertension and heart disease, such as enalapril 1 and lisinopril 2
(Figure 1). Both of these drugs are tripeptidomimetics that consist of a dipeptide where
the N-terminus has been alkylated by a carboxyalkyl substituent and contain a proline
residue at the C-terminus. Enalapril is a prodrug of the active dicarboxylic acid
enalaprilat in which the ethyl ester is enzymatically cleaved to a carboxylic acid in the
body. Enalapril contains an alanine residue in the middle position, whereas lisinopril
contains a lysine residue. Since these drugs have been effective in treating hypertension
and heart disease, peptidomimetic chemistry has been used to synthesize potential
analogs for biological screening. However, the isolation of these analogs has been
challenging due to the polarity of the amine and carboxylic acid functionalities.
Figure 1. Commercially Available ACE inhibitors and Generic Structure of Drug Analogs.
The generic structure 3 as N-carboxyalkyl dipeptides is consistent in many ACE
inhibitor analogs reported in the literature, especially incorporating the phenethyl side
chain as R (4, Figure 1).1-4 This hydrophobic side chain is believed to have a strong
interaction with the S1 hydrophobic pocket (Figure 2) at the active site of ACE.1
2Structure-activity relationships have been explored by several research groups by
varying the three residue portions of enalaprilat.1-2,5-7 Since enalaprilat contains the
phenethyl side chain followed by alanine (AA1) and proline (AA2), many analogs have
been prepared by keeping one of the portions of 3 (the side chain R, the AA1, or the AA2)
constant and varying other portions of this generic structure. A complete review by
Wyvratt and Patchett of the drug discovery of ACE inhibitors is available.1
The first potent ACE inhibitor captopril (5) was made by Cushman and Ondetti in
the early 1970s.5,7 Its development showed the application of intelligent drug design by
devising a molecular structure to specifically bind in the enzymatic pocket of ACE
(Figure 2). It was known that ACE was a carboxydipeptidase enzyme containing a Zn2+
ion. These researchers hypothesized that the active site of ACE may be similar to other
carboxypeptidase enzymes such as bovine pancreatic carboxypeptidase A.
By comparison to the bovine pancreatic carboxypeptidase A, it appeared that a
positively charged residue at the active site binds with the peptide at the negatively
charged C-terminal carboxyl group of the substrate seen below (Figure 2). The Zn2+ ion
is believed to assist in the peptide bond cleavage and is separated from the positively
charged residue in the active site by two amino acids, whereas the Zn2+ ion in bovine
carboxypeptidase A is separated by only a single amino acid residue. Due to an
additional amino acid separating the Zn2+ ion and the positively charged residue of the
active site, Cushman and Ondetti assumed the carbonyl group of the central amino acid
residue interacted with the enzyme through hydrogen bonding. The rigid structure of
proline seems to impact the strong binding in the deeper portion of the active site pocket.
3Figure 2. The Binding Interactions of Captopril and Enalaprilat within the ACE Active
Site.1
Based on this structural model for the active site of ACE, potential drug targets
have been designed and tested by various groups. Cushman and Ondetti tested
carboxyalkanoyl (6) and mercaptoalkanoyl amino acids (7).5 Succinyl-(S)-proline and
glutaryl-(S)-proline derivatives were tested, and the methyl-substituted
mercaptopropanoyl derivative 8, later marketed as captopril, exhibited very high levels of
activity against ACE. Since sulfur binds more strongly to zinc than oxygen, these results
implied that the mercapto functionality binds to the Zn2+ ion since the mercaptoalkanoyl
analogs were more potent than the carboxyalkanoyl analogs. Cushman and Ondetti also
showed that the (S)-proline analogs were more active than the (R)-proline analogs. This
suggested that the interaction between the carboxyl group of the C-terminus of the (S)-
amino acid with the positively charged residue of the active site required a very specific
three-dimensional interaction.
Figure 3. Carboxyalkanoyl and Mercaptoalkanoyl Proline Analogs.
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Research Laboratories and the Merck Institute for Therapeutic Research focused their
efforts on synthesizing N-carboxymethyl dipeptide derivatives.2 The original extract from
the South American pit viper Bothrops jararaca that is responsible for ACE inhibitory
4activity was known to contain a peptide with the C-terminus sequence of Phe-Ala-Pro.
From these results the Merck group first analyzed potential targets by keeping the Ala-
Pro residues of the dipeptide portion constant. They varied the substituent on the N-
carboxyalkyl group directly attached to the N-terminus of the alanine and established
that the phenethyl substituent was the most active side chain. Later, numerous efforts by
other groups exploited this finding by incorporating the phenethyl side chain into their
analogs.8-12 Two commercially available drugs, enalapril (1) and lisinopril (2), were
developed based on this finding. Next, the Merck group kept the phenethyl substituted
N-carboxyalkyl group constant and varied the two amino acid residues of the dipeptide
portion. It was confirmed that the C-terminal residue as proline, thiaproline, and
hydroxylprolines were the most potent, again suggesting that the cyclic residue locks the
substrate into the active site for highest affinity. The most active amino acids in the
middle position proved to be (S)-alanine, (S)-fluoroalanine, (S)-lysine, and (S)-arginine.
This study showed the first synthesis of the eventual commercial drug lisinopril (2) with
the phenethyl substituted N-carboxyalkyl group directly attached to the N-terminus of the
Lys-Pro dipeptide.
Pasha and associates studied tripeptidomimetics where proline was kept
constant at the C-terminus and showed ornithine bonded stronger than lysine in the S1^
pocket of the enzyme site.6,13 Ornithine is the unnatural amino acid similar to lysine but
with one less carbon on the side chain (9). The ornithine was acylated on the %-amino
group with thiophene or indole heterocylic moieties with varying chain lengths to give
analogs 9. These heterocycles were employed to interact with the Zn2+ ion located in the
enzyme active site. Biological results showed that the analogs containing three carbons
between the carboxylic acid and heterocyclic ring had poor activity because the alkyl
chain was too long to fit into the active site pocket. Likewise, analogs containing zero or
one carbons between the carboxylic acid and heterocyclic ring were able to fit into the
active site of ACE, but they exhibited poor activity because the side chains were too
short to bind strongly. On the other hand, analogs containing two carbons between the
carboxylic acid and heterocyclic ring showed the highest inhibition, suggesting these
substrates contain the appropriate number of carbons to form a tight fit in the active site,
with analog 10 being the most active. The two carbon chain length of the substituent is
consistent with the results from the Merck laboratories, where the phenethyl substituent
of the N-carboxyalkyl group was most active.
5Figure 4. Ornithine-based Tripeptidomimetic Analogs.
Many examples incorporating substituted prolines have appeared in literature
(Figure 5). Researchers from Schering-Plough Co. explored 4-substituted proline
derivatives of the commercial drug captopril (11).14 Monosubstituted and disubstituted
prolines were synthesized and tested for ACE inhibition. Their findings explained the
spatial requirements for the binding affinity of substituted prolines in the active site.
Cyclic acetals and thioacetals were also tested and gave the best activity. Researchers
from the Squibb Institute for Medical Research also explored 4-substituted proline
analogs, including analogs of N-carboxyalkyl dipeptides incorporating the phenethyl
substituent (12).15 Bhagwat et al. substituted the proline of captopril with a thiorphan
derivative in 13 to increase dual ACE and NEP activity, which acts as a diuretic and has
shown to significantly improve the efficacy of ACE inhibitors.16 Mencel et al. also
investigated 4-substituted prolines by incorporating an aryl sulfonamide diuretic moiety
into enalaprilat (14).17
Figure 5. Structures of 4-Substituted Proline Analogs.
Work has been done by substituting fused ring structures for the proline portion
of the ACE analogs to fit into the S2^ pocket of the active site.18-19 Wyvratt and Patchett
reported conformationally restricted analogs of captopril and enalaprilat in their review
6on ACE inhibitors.1 The benzo-fused analogs of captopril such as 15 greatly increased
the potency, while benzolactams 16 were also shown to be potent inhibitors. Bicyclic
lactam and benzolactam analogs of enalaprilat, such as 17 and 18, also showed high
inhibition of ACE.
Figure 6. Fused Ring Structures of ACE Inhibitor Analogs.
In summary, various analogs and structure-activity relationship studies of
captopril (5), enalapril (1) and lisinopril (2) have given insights into the structure of the
enzyme active site. The presence of the phenethyl substituent on the tripeptidomimetics
was of particular interest for the research reported in this thesis to make N-carboxyalkyl
amino acids. The introduction of this alkyl substituent has been synthetically derived in
various manners, as discussed below.
1.2. Examples of Solution-Phase Synthesis of N-Carboxyalkyl Dipeptides and Amino
Acids in the Chemical Literature: Introducing the N-Carboxyalkyl Group onto Nitrogen
When surveying the synthetic strategies for preparing the N-carboxyalkyl
dipeptides, the formation of the carbon-nitrogen bond on the amino acid has been the
focal point for synthesis. Typically, the two types of reactions commonly used are the N-
alkylation with %-haloesters and reductive amination with %-ketoesters (19 to 20, Figure
7). The esters 20 could then be hydrolyzed or hydrogenolyzed to give the diacid
products 21.
A comparison of the diastereoselectivity between these two synthetic routes
shows no diastereoselectivity when employing reductive amination methods. When
using an optically active %-haloester, however, various diastereoselectivity results have
been reported based on the reaction conditions. These results are discussed below.
7Figure 7. Synthetic Methods for Preparing N-Carboxyalkyl Amino Acids through the
Use of %-Haloesters or %-Ketoesters.
1.2.1. Solution-Phase Synthesis of ACE Inhibitor Analogs by N-Alkylation with
%-Halocarbonyl Compounds
Kaltenbronn et al. reported the synthesis of the major intermediate 24 by N-
alkylation of the t-butyl ester of (S)-alanine (23) with ethyl 2-bromo-4-phenylbutanoate
(22).20 The reaction was refluxed in acetonitrile in the presence of triethylamine for 40
hours to give an 88% yield of equal amounts of diastereomers of 24 (Scheme 1). This
intermediate has been important to make ACE inhibitor analogs by deprotecting and
coupling the carboxylic acid with various amino acids such as proline to afford enalapril.
Scheme 1. Synthesis of 24 as an Important Intermediate for the Synthesis of ACE
Inhibitors.
Iwasaki et al.21 also reported the synthesis of diastereomers 24 through a
diastereoselective synthesis involving the optically active enantiomer of ethyl 2-bromo-4-
phenylbutanoate (22). Various solvents and bases were evaluated to optimize the yield
and diastereoselectivity. The mixed solvent CH3NO2:H2O (1:4) and the base ammonium
carbonate [(NH4)2CO3] gave the highest yield and diastereoselectivity of 24 (Scheme 2).
8Scheme 2. Diastereoselective Synthesis of ACE Inhibitors.
Patchett et al.2 were the first to synthesize the ACE inhibitor enalapril (1).
Reductive amination with the %-ketoester was used to prepare enalapril, but they were
also interested in confirming the activity of the unsubstituted N-carboxyalkyl dipeptide.
To prepare this analog, they alkylated the dipeptide (S)-alanyl-(S)-proline 25 with
chloroacetic acid to give the unsubstituted analog 26 (Scheme 3).
Scheme 3. Synthesis of Unsubstituted N-Carboxyalkyl Dipeptides via N-Alkylation.
Jian-hong et al.8 used the N-alkylation method to generate N-[1-(S)-
ethoxycarbonyl-3-phenylpropyl]-(S)-alanine (ECPPA, 28), the intermediate generated by
the angiotensin-converting enzyme. (S)-Alanine (27) was alkylated with ethyl 2-bromo-4-
phenylbutanoate in the presence of potassium carbonate to form the carbon-nitrogen
bond in 28 (Scheme 4).
Scheme 4. Synthesis of ECPPA by N-Alkylation.
Barton et al.9 also used ethyl 2-bromo-4-phenylbutanoate to make analogs of
enalapril. One example involved alkylation of the amino acid N-Cbz-(S)-lysine (29) with
the %-bromoester 22 under anhydrous basic conditions in acetonitrile (Scheme 5). The
desired diastereomer was isolated by HPLC, and the amine was acylated before the
9ester was hydrolyzed with hydrochloric acid. The diacid product 30 was isolated in 28%
yield.
Scheme 5. Synthesis of ACE Inhibitor Analogs by N-Alkylation of Lysine.
Hayashi et al.10 used two synthetic methods involving the N-alkylation with %-
bromoesters to make 2-oxoimidazolidine analogs to test for ACE inhibition. The first
route (Scheme 6) involved N-acylation of the 2-oxoimidazolidine 31 with an %-bromoacyl
chloride to give intermediate 32, which was then used to alkylate the amine of various
benzyl protected amino acids to give diastereomers 33 and 34. The second route
involved initial alkylation of the nitrogen of various protected amino acids 35 with 2-
bromopropanoate esters to give diastereomers 36 and 37, followed by coupling with the
2-oxoimidazolidines to give diastereomers 33 and 34. The protected esters of 33 and 34
were deprotected to the carboxylic acids by hydrogenolysis or acid hydrolysis.
Scheme 6. The Synthesis of 2-Oxoimidazolidine Analogs by Two Synthetic Routes.
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Smith et al.11 focused their efforts on synthesizing spirapril related analogs of
enalapril and lisinopril. Their synthesis of the lisinopril derivative 39 involved N-alkylation
of t-butyl N-Cbz-(S)-lysine (29) with ethyl 2-bromo-4-phenylbutanoate 22 to give the
mixture of diastereomers 38. This mixture was then coupled with the spirapril proline
amino acid to give the target compounds 39 (Scheme 7).
Scheme 7. The Use of N-Alkylation to Make Spirapril Analogs of Lisinopril.
Ortiz et al.12 utilized ethyl 2-bromo-4-phenylbutanoate as an alkylating reagent to
synthesize pyrrole[1,2-b][1,1]diazepine derivatives 42 as bicyclic lactam analogs of
commercially available benazepril and cilazapril. The diazepine 40 was first N-alkylated
with ethyl bromoacetate to give intermediate 41. The Cbz-protecting group was removed
by hydrogenolysis and then alkylated with ethyl 2-bromo-4-phenylbutanoate, followed by
saponification of the ethyl ester to give the desired target 42 (Scheme 8).
Scheme 8. Synthesis of Pyrrole[1,2-b][1,1]diazepine Derivatives.
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1.2.2. Solution-Phase Synthesis of ACE Inhibitor Analogs by Reductive
Amination with %-Ketocarbonyl Compounds
Wyvratt et al.22 reported the first synthesis of the commercial drug enalapril by
reductive amination with ethyl 2-oxo-4-phenylbutanoate (43), using an excess of the %-
ketoester to avoid reduction to the %-hydroxyester. The dipeptide (S)-Alanyl-(S)-proline
(44) was coupled with the %-ketoester in the presence of sodium cyanoborohydride to
give a 90% yield of diastereomers 45 (Scheme 9).
Scheme 9. Synthesis of Enalapril by Reductive Amination.
Maycock et al.23 utilized the reductive amination method with an %-ketoacid to
produce thermolysins analogs, which had previously shown activity for the angiotensin-
converting enzyme. (S)-Leucyl-(S)-tryptophan 46 was condensed with 2-oxo-4-
phenylbutanoic acid (47) in the presence of sodium cyanoborohydride to give analog 48
(Scheme 10), which was shown to be the most active analog. The separate
diastereomers were tested with the more abundant diastereomers being the most active.
The exact configuration of this diastereomer was not determined but hypothesized to be
the S,S,S diastereomer from previous studies.
Scheme 10. Synthesis of Thermolysin Inhibitors as Compared to ACE Inhibitors.
Kori et al.24 designed ACE inhibitors by replacing the phenethyl side chain with a
4-piperidylpentyl group. In one example, the amino amide 49 was condensed with the
corresponding %-ketoester 50 in the presence of sodium cyanoborohydride to prepare
such analogs 51 in a 50:50 diastereomeric mixture (Scheme 11).
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Scheme 11. Synthesis of ACE Inhibitors Containing a 4-Piperidylpentyl Group.
Suh et al.25 made N-substituted glycine derivatives to explore ACE inhibition.
One route employed the amino amide 49, which was condensed with ethyl 2-oxo-4-
phenylbutanoate (43) with sodium cyanoborohydride to afford 52 (Scheme 12). The
esters could then be hydrolyzed to the carboxylic acids.
Scheme 12. Synthesis of N-Substituted Glycine Derivatives.
Ksander et al.26 were interested in incorporating dual ACE and TxS
(thromboxane synthase) inhibition into the same molecule. One set of analogs were the
5-oxy-substituted benazepines 54, which were prepared by reductive amination of 53
with ethyl 2-oxo-4-phenylbutanoate 43 (Scheme 13).
Scheme 13. Synthesis of Dual ACE/TxS Inhibitors by Reductive Amination.
Hagmann et al.27 prepared N-carboxyalkyl peptides as matrix metalloproteinase
(MMP) inhibitors. Synthetic routes commonly used to prepare ACE inhibitors were
employed by reductive amination of an amino acid ester 56 with %-ketoester 55 in the
early part of the synthetic sequence to afford 57 (Scheme 14).
Scheme 14. Synthesis of N-Carboxyalkyl Peptides as MMP Inhibitors.
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1.2.3 Solution-Phase Synthesis of Substituted Amines by N-Alkylation with
%-Halocarbonyl Compounds
Harfenist et al.28 were interested in making piperazinyl carbazoles for testing as
antipsychotic drugs. Structure-activity relationships were explored to minimize the side
effects commonly seen due to extended use of neuroleptic drugs. The enantioselective
synthesis of 60 was key in this synthesis. The same synthetic route was used for both
enantiomers of the alanine ethyl ester 58 (Scheme 15). The authors reported the
formation of the by-product meso compound of 60 by attack of bromide ion formed
during the reaction on the unreacted %-bromoester to give the other enantiomer of 59.
The meso by-product was separated by HPLC. The %-bromoester 59 was prepared from
the %-bromoacid of alanine through the diazotization and bromide displacement.
Scheme 15. N-Alkylation of Alanine Ethyl Ester with an %-Bromoester.
Brouoillette et al.29 made analogs of anti-influenza drugs for influenza A and B of
neuraminidase. Structure-activity relationship studies of benzoic acids of neuraminidase
inhibitors containing pyrrolidinone rings were investigated based on the previous lead
61. The first step in synthesizing a targeted analog involved the N-alkylation of methyl p-
aminobenzoate 62 with diethyl bromomalonate to afford intermediate 63 (Scheme 16).
Scheme 16. N-Alkylation with Diethyl Bromomalonate.
Zhu et al.30 reported the total synthesis of Ecteinascidin 743 that had been
isolated from the Caribbean tunicate Ecteinascidia turbinate. This was found to have
potent cytotoxicity against tumor cells and was in clinical trials for various cancer
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treatments. A variety of reaction conditions for the N-alkylation were tested including
solvents (CH3CN, trifluoroethanol, THF), bases (Et3N, pyridine, DBU, Ag2O), and
temperature (from -45 °C to rt). The optimal conditions were applied to the alkylation of
amine 65 with the %-bromoester 64 in acetonitrile with triethylamine at 0 °C (Scheme
17). The isolated diastereomers 66 showed a 75:25 diastereomeric ratio suggesting an
SN1 mechanism for the formation of the major diastereomer with absolute configuration
of R.
Scheme 17. Use of N-Alkylation in the Total Synthesis of Ecteinascidin 743.
Ou et al.31 reported the synthesis of 9H-carbazole-9-carboxylic acids using
microwave irradiation in solution-phase reactions. Previous work had reported the N-
alkylation of 9H-#!0" !8.+% 1  3-$ % 0  <$ 07= conditions in the absence of solvent. Some
previous analogs had been tested as potential immunodulating agents. Reactions were
conducted using %-bromoesters where the 9H-carbazole 67 was alkylated with ethyl
bromoacetate for 6 minutes to give compounds 68 (Scheme 18).
Scheme 18. Microwave Synthesis of N-Alkylated Carbazoles.
Kato and Kimura et al.32 prepared novel chelating agents for radiolabeling of
monoclonal antibodies for tumor imaging and cancer treatment. Kinetic and stability
studies were used to evaluate the complex formation of the bifunctional chelating agents
(BCAs), such as 71 with yttrium (III). The key intermediate 70 was made by N-alkylation
of p-nitrophenylalanine methyl ester 69 with methyl bromoacetate (Scheme 19).
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Scheme 19. The Synthesis of Bifunctional Chelating Agents by N-Alkylation.
Aladzheva et al.33 prepared N-3-chloropropyl amino acid esters as starting
materials for the synthesis of 1,2-azaphospholane-containing amino acid targets. 3-
Chloropropylamine was alkylated by %-bromoesters 72 to yield the N-3-
chloropropylglycine ethyl ester 73 or N-3-chloropropylalanine ethyl ester 74 for use as a
starting reagent in their synthesis (Scheme 20). These products were explored as novel
compounds for biological activity.
Scheme 20. Synthesis of N-3-Chloropropylglycine Ethyl Ester and N-3-Chloro-
propylalanine Ethyl Ester as Precursors to 1,2-Azaphospholanes.
Decroix et al.34 used diethyl %-bromohomophthalate 75 with various benzyl
amines to make compounds 76 as precursors to analogs of gilvocarcin (Scheme 21).
Gilvocarcin and related tetracyclic aromatic compounds are metabolites of some
Streptomyces species and were evaluated as a potential new class of antibiotics.
Scheme 21. Synthesis of Isoindolones as Precursors to Tetracyclic Gilvocarcin
Analogs.
Othman et al.35 used the N-alkylation reaction to synthesize various olefin-
containing phthalimidines 79. Diethyl bromohomophthalate 75 was coupled with
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allylamine to give isoindolones 77 (Scheme 22). The %-carbon of the ethyl ester was
then alkylated with allyl or propargyl bromide to introduce a second olefin in 78, which
could then react in one-pot Grubbs ring-closing metatheses to give phthalimidines 79.
Scheme 22. Synthesis of Olefin-Containing Phthalimidines as Precursors for Grubbs
Ring-Closing Metathesis Reactions.
Othman et al.36 synthesized the phthalimidines 80 from diethyl
bromohomophthalate 75 and various amines (Scheme 23) as intermediates to
spirolactones. These intermediates were converted to (-acetylenic carboxylic acids 81
that could be cyclized to the spirolactone compounds 82. Such spirolactones have been
shown to have cytotoxic, insecticidal, and antibiotic activity.
Scheme 23. Synthesis of Phthlamidine Compounds for Synthesis of Spirolactones.
Baldwin et al.37 synthesized azetidines as intermediates for the formation of (-
lactam analogs of carbapenicillanic acids to develop a new class of antibiotics. The %#%^-
dibromo diester 83 was reacted with benzylamine to give the four-membered ring
systems of 84 seen in penicillin analogs (Scheme 24). A diastereomeric ratio of 60:40
was observed with the trans isomer being more abundant. Further chemistry on the
esters gave carbapenicillanic acid analogs. Although the x-ray crystallographic studies
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showed the analogs closely resembled the carbapenicillanic acids, the targeted
compounds did not show any antibacterial or &-lactamase inhibitory activity.
Scheme 24. Synthesis of Azetidines as Precursors to Carbapenicillanic Acid Analogs.
Eastwood et al.38 prepared N-acylaziridines 86. The dibromoester 85 and
ammonia were coupled to form the three-membered ring system of 86 (Scheme 25).
These were then used to explore various reaction conditions for ring enlargements of the
three-membered rings to the 2,4-disubstituted oxazoles. Optimal conditions utilized a
nickel peroxide oxidation to give compounds 87. This chemistry was used to make
halichondramide scaffolds containing multiple 2,4-disubstituted oxazoles as potential
anti-fungal agents.
Scheme 25. Synthesis of 2,4-Disubstituted Oxazoles from N-Acylaziridines.
Kozikowski et al.39 explored the synthesis of azetidine-2,4-dicarboxylic acids for
stimulus of 45Ca2+ uptake in cerebellar granule cells. The N-methyl-D-aspartate (NMDA)
receptors have been linked to memory loss and degeneration after strokes and heart
attacks. The azetidine-2,4-dicarboxylic acids were made from 2,4-dibromoglutaric acid
diesters 88 with benzylamine to give diastereomers 89 and 90 (Scheme 26). These
targets were of interest to explore possible modulation of the NMDA receptors and their
impact on combating neurological degeneration.
Scheme 26. Synthesis of Azetidine-2,4-Diesters.
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1.3. Examples of Solid-Phase Synthesis of Substituted Amines
The above examples demonstrate the wide synthetic application of N-alkylation
with %-halocarbonyl compounds by solution-phase chemistry. The utilization of solid-
phase methods and combinatorial chemistry for the synthesis of amino acid derivatives
has become an important methodology since the beginnings of solid-phase peptide
synthesis by Merrifield in the 1960s.40 Considerable work in the field has involved the
synthesis of oligopeptides by coupling amines and carboxylic acids to form peptide
bonds. Various resins and linkers have been developed to produce the desired
functionalities after cleavage of the modified peptides or their derivatives. Only a few
examples have been reported for the alkylation of amines with %-halocarbonyl
compounds.41 In general, most involve reaction of a resin-bound %-bromocarbonyl
compound with excess amine in solution. This process of using excess amine in solution
capitalizes on solid-phase methodology to minimize dialkylation of the resin-bound
substrate. On the other hand, it cannot take advantage of the variety of resin-bound
amines accessible by solid-phase combinatorial chemistry. The route reported in this
thesis utilizes resin-bound amino acids as the nucleophile and excess %-bromoester as
the electrophile in solution. Few examples were found that used solid-phase synthesis to
produce ACE inhibitors,13,42 with only one targeting the N-carboxyalkyl dipeptides by
reductive amination.43 Thus, the utilization of solid-phase synthesis and combinatorial
chemistry is an area of potential utility for the synthesis of such analogs.
1.3.1. Solid-Phase Synthesis of ACE Inhibitors with %-Ketocarbonyl Compounds
Blackburn et al.43 synthesized a library of N-carboxyalkyl dipeptides as ACE
inhibitors using solid-phase synthesis. In order to avoid the premature cyclitative
cleavage of the dipeptide as the diketopiperazine from the resin when the starting resin-
bound amino acid was proline, a DHPP linker was employed. The resin-bound proline
(91) was coupled with 19 different amino acids to give the resin-bound dipeptides 92.
These were then condensed with ethyl 2-oxo-4-phenylbutanoate in the presence of
sodium cyanoborohydride, followed by TFA cleavage from the resin to afford a library of
19 compounds (Scheme 27, 93). Enalapril was made as a model compound for the
synthetic route. The mixture of cleaved products were analyzed by mass spectrometry
and screened for biological activity.
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Scheme 27. Solid-Phase Synthesis of ACE Inhibitors.
1.3.2. N-Alkylation of a Resin-Bound Nucleophile with %-Bromocarbonyl
Compounds
Brill et al.44 reported one of the few examples for N-alkylation of a resin-bound
nucleophilic nitrogen with %-bromocarbonyl compounds to synthesize cinnoline
derivatives 95. These compounds have shown a broad spectrum of activity in many
pharmaceutical, antibacterial and agricultural applications. A resin-bound cinnoline 94
was alkylated on the heterocylic nitrogen with alkyl halides, including bromomethyl
phenyl ketone, to give compound 95 (Scheme 28).
Scheme 28. N-Alkylation of Cinnoline Derivatives.
1.3.3. Resin-Bound Electrophilic %-Bromocarbonyl Compounds in Reaction with
Excess Amines in Solution
Many examples have been reported for coupling of a resin-bound alcohol with
bromoacetic acid to incorporate a resin-bound %-bromocarbonyl compound, which are
then reacted with excess amine (to avoid polyalkylation). Kihlberg et al.45 used this
chemistry to make fluorinated linkers for monitoring solid-phase synthesis by 19F NMR
spectroscopy. A resin-bound benzylic alcohol 96 was coupled to bromoacetic acid to
give the resin-bound %-bromoester 97, which was then used to alkylate n-butylamine to
give compound 98 (Scheme 29). The amine was then further acylated to give the final
targets that were monitored by 19F NMR.
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Scheme 29. Amine Alkylation by a Resin-Bound %-Bromoester.
Barany et al.46 used the BAL (Backbone Amide Linker) resin to develop a new
synthetic strategy for the synthesis of lidocaine and procainamide analogs. The resin-
bound amine 99 was acylated with bromoacetic acid to form the resin-bound %-
bromoamides 100. These intermediates were then reacted with secondary amines and
cleaved from the resin to afford target compounds 101 (Scheme 30).
Scheme 30. Synthesis of Lidocaine and Procainamide Analogs on BAL Resin.
Barn et al.47 explored methods to cleave resin-bound esters from Wang resin
with Lewis acids to produce amide functionalities. They used resin-bound %-bromoesters
to test different Lewis acids for cleavage from the Wang resin to afford the amide
products 105. The resin-bound alcohol 102 was coupled to a bromoacid to produce the
resin-bound bromide 103. These were then used to alkylate amines and thiols to give
intermediates 104. Secondary amines with various Lewis acids were then tested as a
route to the cleaved amide products 105 (Scheme 31).
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Scheme 31. Lewis Acid-Catalyzed Cleavage from Wang Resin to Afford Amides.
1.3.4. Synthesis of Peptoids from Resin-Bound %-Bromoesters and Amines
Zuckermann et al.48-49 pioneered the solid-phase synthesis of peptoids, N-
substituted glycine oligomers. A resin-bound amine 106 was acylated with bromoacetic
acid to give 107, which was reacted with excess amine in solution to give 108. The
alkylated amine 108 was then acylated again with bromoacetic acid and this two-step
cycle was repeated to give N-substituted glycine oligomers (Scheme 32).
Scheme 32. Synthesis of Peptoid Oligomers using Bromoacetic Acid and Primary
Amines.
The synthesis of peptoid oligomers has also been performed with the use of
microwave irradiation.50-51 The same synthetic route as described above (Scheme 32)
was carried out with each monomer addition step requiring less than one minute to
complete.
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1.4. The Mechanism of the N-Alkylation with %-Halocarbonyl Compounds
Markovnik et al.52 discuss the mechanism for reaction of nitrogen nucleophiles
with %-halocarbonyl compounds. Figure 8 shows the possible transition states (109-111)
for nucleophilic attack by the amine. The second order reaction of the N-acylalkylation is
frequently viewed as an SN2 nucleophilic substitution. However, a nucleophilic
substitution on the carbonyl followed by an elimination (SNAdE) mechanism was also
discussed. The electron-withdrawing effect of the carbonyl helps explain the stability of
the transition states. The SNAdE mechanism was indirectly confirmed by evidence that
the carbonyl is a competitive center for nucleophilic attack. As cited by Markovnik et al.,
a wide variety of nucleophiles have demonstrated this principle for the
haloalkylaminocarbinol intermediate 116. It was concluded that N-alkylation can occur by
either an SN2 mechanism with weaker nucleophiles or an SNAdE mechanism with
stronger nucleophiles.
Figure 8. Possible Transition States for N-Acylalkylation with Ammonia.52
The SNAdE mechanism, as outlined below (Scheme 33), has many possible
routes. The primary amine can first attack the carbonyl forming the tetrahedral
intermediate 114. Three routes can then be envisioned. The anionic oxygen of 115 could
deprotonate the cationic nitrogen to form 116. The neutral amine could then attack the
carbon alpha to the carbonyl with elimination of the halide and formation of the three-
membered ring intermediate 117. Loss of HX and subsequent ring-opening and
reformation of the carbonyl would afford product 119. In a second route from 114, the
anionic oxygen could attack the carbon alpha to the carbonyl with elimination of the
halide to form the epoxide intermediate 120. A second amine could attack the epoxide to
reform the carbonyl with loss of the protonated amine on the %-carbon to give product
119. In a third route, the nitrogen of the tetrahedral intermediate 114 could form a three-
membered ring transition state 12 with loss of the halide to form intermediate 121,
followed by subsequent loss of HX to give product 119.
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Scheme 33. SNAdE Mechanism of N-Acylalkylation.52
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CHAPTER 2. PLAN OF STUDY
This study will focus on the synthesis of N-carboxyalkyl unnatural amino acids
127 from the benzophenone imine of glycine on Wang resin 123    > .--% ++  !-$    # .2253-
55 reported the formation of unnatural amino acids 124 on resin by alkylation of the %-
carbon of glycine with alkyl halides. These resin-bound unnatural amino acids have been
used as key intermediates to many different combinatorial scaffolds. The overall purpose
of this study is to expand the use of resin-bound unnatural amino acids by establishing a
novel route for the N-alkylation of the amino acids with %-bromoesters 125 to prepare a
generic scaffold for potential ACE inhibitors 127 through intermediate 126. The
usefulness of the methodology will be demonstrated by the synthesis and isolation of a
combinatorial library of ACE analogs by varying the inputs R1 and R2 in 127 (Scheme
34).
Scheme 34. Proposed Synthesis of N-Carboxyalkyl Unnatural Amino Acids.
Initially, the reaction conditions (solvent, temperature and reagent stoichiometry)
for N-alkylation of the resin-bound amino acid with an %-bromoester will be studied. The
resin-bound natural amino acid Fmoc-Phe-Wang 128 will be deprotected, N-alkylated
and then cleaved from the resin to compare the crude yield of N-alkylated product 131 to
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the unalkylated phenylalanine 130 by LC/MS (Scheme 35). Any presence of dialkylated
product will be evaluated as well. Racemic ethyl 2-bromopropanoate [(±)-129], which is
commercially available, will be used as the generic %-bromoester. The crude products
will be used to establish a chromatographic purification procedure. Since a resin-bound,
optically active amino acid will be used, the isolation and characterization of the two
diastereomers formed during the alkylation will also be explored.
Scheme 35. Proposed Reaction Sequence to Find Optimal Conditions for N-Alkylation.
Following optimization of the N-alkylation of the resin-bound phenylalanine with
racemic ethyl 2-bromopropanoate, a synthetic route to prepare various %-bromoesters
will be investigated. Benzyl esters 125 will be prepared since these can be cleaved by
hydrogenolysis in the absence of aqueous base or acid to give the final products 127.
A convenient route for converting an optically active amino acid 132 to its %-
bromoacid 133 (Scheme 36) while retaining the chiral center was first described by
Izumiya and Nagamatsu56 and later refined by Karoyan et al.57 The double inversion of
this transformation was studied by Koch et al.58 and has been cited by many other
groups that have successfully used this method. This route will be used to prepare %-
bromoacids from the amino acids (S)-phenylalanine, (S)-homophenylalanine, and (S)-
leucine. These %-bromoacids (133b-d) and racemic ethyl 2-bromopropanoic acid (133a)
as the commercially available product will then be converted to their benzyl esters
(125a-d) in the presence of cesium carbonate and benzyl bromide (Scheme 36) adapted
from a procedure for the benzylation of %-hydroxyacids by Shin et al.59
Scheme 36. Synthesis of Benzyl %-Bromoesters by Diazotization of Naturally-Occurring
Amino Acids.
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The benzyl %-bromoesters 125a-d will be reacted with Phe-Wang, prepared from
Fmoc-Phe-Wang, to study the effects of steric hindrance on the benzyl %-bromoesters in
the N-alkylation reaction (Scheme 37). These compounds will also be used to establish
a standard procedure for the hydrogenolysis of the benzyl ester 134 to the diacid 135 in
order to isolate and characterize the amino diacids products.
Scheme 37. N-Alkylation of Phe-Wang and Hydrogenolysis to the Diacid.
Once the optimal reaction conditions for the N-alkylation with benzyl %-
bromoesters have been established, ten alkyl halides (141-150) will be used in the
alkylation of the resin-bound benzophenone imine of glycine (123, Scheme 38) to
prepare racemic, unnatural amino acids 124. These intermediates will then be reacted
with racemic benzyl 2-bromopropanoate (±)-125a to give 136.
Scheme 38. Proposed Scheme and Alkyl Halides to Rehearse on the BIG-Wang Resin.
Finally, the rehearsed alkyl halides will be used on an appropriate scale to make
10-20 mg of the N-carboxyalkyl amino acids analogs. A combinatorial approach will be
developed with the alkyl halides (141-150) as the input R1 and the benzyl %-bromoesters
as the input R2. The analogs will be made in a combinatorial fashion represented in
Scheme 39. Products 126 will be purified and fully characterized by LC/MS, 1H and 13C
NMR, and HRMS. Each compound 126 will be further hydrogenolyzed to give the
corresponding N-carboxyalkyl amino acids 127, which will also be fully characterized.
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Scheme 39. Final Combinatorial Synthesis of N-Carboxyalkyl Amino Acid Analogs.
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CHAPTER 3. RESULTS AND DISCUSSION
3.1. Experiments to Optimize the N-Alkylation Reaction
3.1.1. Optimization of the N-Alkylation of Phe-Wang with Ethyl 2-Bromo-
propanoate
In order to find optimal conditions for the N-alkylation of a resin-bound amino acid
with an %-bromoester, the literature background discussed in Chapter 1 was analyzed
and select reaction conditions were tested. Ethyl 2-bromopropanoate was found to be an
inexpensive, commercially available %-bromoester that could be used to first test these
literature conditions. Two common conditions found for the alkylation of an amine with
an %-bromoester were the use of potassium carbonate in acetonitrile and the use of
triethylamine in DMF (Scheme 40). These were tested on two side-by-side reactions for
each of the separate reaction conditions.
Resin-bound phenylalanine was treated with one equivalent of ethyl 2-
bromopropanoate and allowed to react for 3 days under both reaction conditions.
Following cleavage of the product from the resin, the potassium carbonate and
acetonitrile reactions showed a crude yield of 50 mg that was much higher than the
theoretical yield, likely due to the presence of the inorganic salt. It appeared that the
potassium carbonate did not dissolve well in the acetonitrile, and this poor solubility likely
led to poor conversion as evidenced by negligible product in the LC/MS. In contrast, the
triethylamine and DMF conditions led to crude yields comparable to the theoretical yield,
and the LC/MS showed 69% of the desired product 131. The diastereomeric ratio of the
products in this reaction and the subsequent optimization reactions covered in this
section was 52:48 to 55:45.
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Scheme 40. N-Alkylation using K2CO3/CH3CN or Et3N/DMF.
After observing a good conversion using triethylamine and DMF with only one
equivalent of the %-bromoester, a second reaction was performed using 2 equivalents of
the %-bromoester. A reaction vessel containing Fmoc-Phe-Wang was deprotected and
treated with the %-bromoester (2 equiv) and triethylamine (4 equiv) in 0.5 mL of DMF
(Scheme 41). In order to monitor the reactions, small aliquots were removed from the
reaction vessel and cleaved after one, two and four days to determine product yields.
The cleaved products at the three time points were analyzed by LC/MS. The LC/MS
results after one day showed that 21% of the product had formed, after two days 52% of
the product had formed, and after four days 51% of the product had formed. These
results suggested that the maximum amount of N-alkylated product was formed after two
days. The crude products were combined and purified to give 8 mg (30% yield) of
product 131.
Scheme 41. Monitoring the Reaction Time: One, Two and Four Days.
The above results were promising for these reaction conditions, but the removal
of sample aliquots may have been misleading since the exact amount of resin and
removed reagent solution may have been inconsistent. Another set of three separate
reactions was set up to analyze the time points of two, three and four days (Scheme 42).
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The three reactions were run simultaneously, and the equivalents of the %-bromoester
and triethylamine were increased to four and eight, respectively, while keeping the total
volume constant in order to double the concentration of reagents. The resin in each
reaction vessel was undisturbed until it was cleaved from the resin. The first reaction
vessel was washed and cleaved after two days, and the LC/MS results of the crude
product showed 59% product. The second reaction vessel was washed and cleaved
after three days, and the LC/MS results of the crude product showed 67% product.
Likewise, the third reaction vessel was washed and cleaved after four days, and the
LC/MS of the crude product showed 68% product. These results suggested that the
optimal reaction time at room temperature is two days, and an increase in the
concentration of reagents led to a higher yield of crude product by LC/MS from 52%
(Scheme 41) to 67%. Each of the three crude products was purified to give 5.5 mg (42%
yield) for the two-day reaction, 7.5 mg (58% yield) for the three-day reaction, and 7.0 mg
(54% yield) for the four-day reaction.
Scheme 42. Increased Concentration of %-Haloester and Base at Varying Reaction
Times.
Next, the same reaction was conducted using tetrabutylammonium iodide (TBAI)
through an in situ Finkelstein reaction in an attempt to increase the reactivity of the %-
bromoester. Two reactions, one for two days and one for three days, were run
simultaneously (Scheme 43). The LC/MS results showed poor UV detection, which were
commonly observed for these reactions due to the lack of chromophores present in the
target compound. The purified yields, however, were comparable to yields reported
above. The two-day reaction gave 8.5 mg (65%) and the three-day reaction gave 7.0 mg
(54%). It appeared the presence of TBAI did not have a measurable effect on the
reaction rate.
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Scheme 43. Addition of Tetrabutylammonium Iodide to Increase the Reaction Rate.
The next method tested to increase the overall conversion was to treat the resin-
bound phenylalanine with the %-bromoester and triethylamine at room temperature for
two days, wash the resin to remove all of the reagents, and then treat the resin again
with more %-bromoester and triethylamine for an additional two days (Scheme 44). This
technique is commonly used in solid-phase synthesis to decrease the reaction time by
continually supplying an excess amount of reagent to the resin. The LC/MS results of the
crude product showed 69% of the product formed. The crude material was purified to
afford 9.0 mg (66% yield). This method did slightly increase the isolated yield, but the
potential use of excess reagents that will require lengthy preparation may be
problematic.
Scheme 44. Introducing a Second Charge of Reagents to the Resin.
Next, as a final variable, the reaction temperature was explored. Two reactions
were set up simultaneously, one at 50 °C and one at 80 °C (Scheme 45). The LC/MS
results of the crude materials showed a 76% conversion for the reaction at 50 °C and a
70% conversion for the reaction at 80 °C. The crude products were purified to give 12.0
mg (91%) for the 50 °C reaction and 11.0 mg (82%) for the 80 °C reaction. Comparing
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the LC/MS yield of crude products to the isolated yield, the higher isolated yield is likely
due to the low UV absorbance of product 131.
Scheme 45. Results from Heating the N-Alkylation Reaction.
The optimal reaction conditions determined from these sets of experiments
(Schemes 40-45): reaction of 128 (50 )mol) with ethyl 2-bromopropanoate (4 equiv) and
triethylamine (8 equiv) in 0.5 mL of DMF at 50 °C for 2 days to give a conversion of 76%
(LC/MS) and a 91% purified yield of product 131 (Scheme 46).
Scheme 46. Optimized N-Alkylation of Phe-Wang with Ethyl 2-Bromopropanoate.
3.1.2. Synthesis of Benzyl %-Bromoesters as Reagents for the N-Alkylation Reaction
Benzyl %-bromoesters were prepared by diazotization of naturally-occurring
amino acids57 (S)-phenylalanine, (S)-homophenylalanine and (S)-leucine to give the %-
bromoacids 133a-d (Scheme 47). This transformation has been reported to occur with
retention of configuration by a double inversion previously discussed (Chapter 2).56,58,60-61
The prepared %-bromoacids (133b-d) and commercially available racemic 2-
bromopropanoic acid ((±)-133a) were converted to their benzyl esters (125a-d) in the
presence of cesium carbonate and benzyl bromide.59
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In order to confirm the stereochemistry of the %-bromoesters 125b-d, the optical
rotations of these starting reagents was measured. The optical rotations of 125b and
125c were +0.2° and -0.3°, respectively. Literature values were not available and, unless
the optical rotations of both pure compounds were near zero, this result suggests
possible racemization during preparation. The measured optical rotation of (R)-125d,
however, was previously reported in literature (+31.8°, c = 1.0, methanol).62 The optical
rotation of (S)-125d was -22.5° (c = 1.0, methanol), suggesting partial racemization of
the starting chiral center. Since the optical rotations of the %-bromoacids 133a-d were
not measured, it cannot be determined whether the racemization occurred during the
diazotization step or the benzyl ester formation step. Given the literature precedence for
the retention of configuration for the diazotization step (Chapter 2), it is speculated the
racemization occurs during the benzylation step due to the presence of cesium
carbonate. Since the exact stereochemistry for 125b and 125c is unknown based on
these results, the side chain R is drawn with a straight bond throughout the rest of this
thesis.63 Since the optical rotation for 125d appears to have been partially preserved, it
is given as the S enantiomer.
Scheme 47. Preparation of Benzyl %-Bromoesters.
3.1.3. N-Alkylation of Phe-Wang with Benzyl 2-Bromo-3-phenylpropanoate
Following the optimized synthesis of benzyl %-bromoesters 125a-d (Section
3.1.2), these prepared reagents were used to alkylate the resin-bound phenylalanine to
further optimize the reaction conditions. (S)-Benzyl 2-bromo-3-phenylpropanoate (125b)
was first subjected to the optimal reaction conditions described above preparing 131
(Section 3.1.1). Fmoc-Phe-Wang was deprotected and treated with the %-bromoester (4
equiv) and triethylamine (9 equiv) in DMF at 50 °C (Scheme 48). A sample was removed
and cleaved after 2 days (19%, LC/MS), and the remaining resin was cleaved after 3
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days (36%, LC/MS). The amount of product observed by LC/MS was much lower than
the amount observed with ethyl 2-bromopropanoate (Scheme 46).
Scheme 48. N-Alkylation of Phe-Wang with Benzyl 2-Bromo-3-phenylpropanoate.
The reduced yield of product 137 was likely due to &-elimination of the %-
bromoester to the conjugated %#&-unsaturated carbonyl compound due to the large
excess of base present and acidity of the benzylic proton. As a control, a sample of the
%-bromoester was allowed to react under identical reaction conditions in the absence of
the resin-bound phenylalanine overnight. The reaction mixture was extracted with ether
and concentrated. 1H NMR analysis of the product showed 67% of the %-bromoester had
undergone elimination. It is noted that the other %-bromoesters 125a and 125c showed
negligible elimination. This competing reaction consumed the starting reagent, resulting
in the lower yield of N-alkylated product. The results from the additional studies
described below are reported in Table 1.
Table 1. Results from the N-Alkylation of Phe-Wang with Benzyl 2-Bromo-3-phenyl-
propanoate.
Entry Equiv of 125b Base (equiv) TBAI (equiv) Solvent Temp. (°C) LC/MS (%)a
1 4 Et3N (9) ---- DMF 50 36
2 4 Pyr (8) ---- DMF 70 22
3 4 Pyr (8) 0.2 DMF 50 26
4 6 Pyr (10.5) ---- DMF 55 39
5 6 Pyr (10.5) 2.0 DMF 55 28
6 4 Pyr (8.5) 2.0 DMF rt 16
7 4 Pyr (8.8) ---- NMP 50 30
a % Product in the reaction mixture. Diastereomeric ratios ranged from 56:44 to 46:54.
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Due to the possible elimination of the %-bromoester, the subsequent reactions
were repeated in the presence of the weaker base pyridine. Phe-Wang was treated with
benzyl 2-bromo-3-phenylpropanoate (4 equiv) and pyridine (8 equiv) in DMF and
allowed to react at 70 °C (Table 1, entry 2). This higher temperature was used in an
attempt to increase the amount of alkylation; however, the rate of elimination may have
also increased. After cleaving the product from the resin, the LC/MS results showed 22%
of the desired product. It appeared the pyridine also led to elimination of the starting %-
bromoester because of the presence of such a large amount of unalkylated
phenylalanine observed by LC/MS.
Next, the addition of tetrabutylammonium iodide (TBAI) was tested. The N-
alkylation of Phe-Wang was conducted with benzyl 2-bromo-3-phenylpropanoate (4
equiv) and pyridine (8 equiv) at 50 °C in the presence of TBAI (0.2 equiv). LC/MS results
showed 26% product (Table 1, entry 3). Thus, as observed earlier with ethyl 2-
bromopropanoate, TBAI did not lead to an increased yield of product.
Because of the competing elimination reaction and consumption of the %-
bromoester, Phe-Wang resin was next treated with six equivalents of benzyl 2-bromo-3-
phenylpropanoate (Table 1, entry 4). The amount of pyridine was also increased slightly,
but not in the 2:1 ratio of base to %-bromoester used before. LC/MS results of the
reaction mixture showed 39% of the product had formed. The use of more equivalents of
the %-bromoester only slightly increased the amount of product observed by LC/MS.
Next, Phe-Wang was treated again benzyl 2-bromo-3-phenylpropanoate (6
equiv), but also in the presence of 2 equivalents of TBAI (Table 1, entry 5). LC/MS
results indicated 28% of the product had formed, and this result again confirmed that the
use of TBAI did not increase the N-alkylation.
Since the use of six equivalents of benzyl 2-bromo-3-phenylpropanoate seemed
to only slightly increase the amount of N-alkylation observed by LC/MS and considering
several steps were needed to prepare this starting material (Section 3.1.2), the benzyl 2-
bromo-3-phenylpropanoate was used in 4 equivalents for subsequent reactions. The
reaction had been conducted with 0.2 equivalents of TBAI with 4 equivalents of the %-
bromoester, thus the reaction was repeated in the presence of 2.0 equivalents of TBAI at
room temperature to possibly avoid elimination of the starting reagent. The 16% of the
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product seen by the LC/MS analysis ultimately confirmed that the use of TBAI, even in
greater than stoichiometric amounts, did not increase N-alkylation (Table 1, entry 6).
Finally, N-methylpyrrolidone (NMP) was used as a solvent in place of
dimethylformamide (DMF). Although the competing elimination reaction with the starting
%-bromoester would still occur, NMP was tested with the other %-bromoesters and this
reaction was conducted for comparison. Fmoc-Phe-Wang was deprotected and treated
with benzyl 2-bromo-3-phenylpropanoate (4 equiv) and pyridine (8.8 equiv) in NMP at 50
°C. The LC/MS results showed 30% of the product had formed (Table 1, entry 7).
After analyzing the results from these reactions with benzyl 2-bromo-3-
phenylpropanoate, it appeared that the competing elimination reaction could not readily
be overcome to produce a reasonable yield of alkylated material. Considering the 50-
100 )mol scale of these reactions, isolating enough material when only 30-35% of the
resin-bound phenylalanine was being alkylated was not practical and this electrophile
was not used further.
3.1.4 N-Alkylation of Phe-Wang with Benzyl 2-Bromo-4-phenylbutanoate
Incorporation of the phenethyl substituent into the N-carboxyalkyl amino acid
scaffold was of considerable interest due to the known inhibitory activity of similar
compounds against the angiotensin-converting enzyme (for example, see 1, 12, 14, 17,
18, Figures 1, 5 and 6). The reagent benzyl (S)-2-bromo-4-phenylbutanoate (125c) was
synthesized as described previously (Scheme 48). Elimination of the bromide from this
%-bromoester was not expected to be a competing reaction because an acidic &-proton
was no longer present.
Initially, the optimal reaction conditions determined earlier for ethyl 2-
bromopropanoate (Scheme 46) were tested. Fmoc-Phe-Wang was deprotected and
treated with benzyl 2-bromo-4-phenylbutanoate (4.5 equiv) and triethylamine (7.5 equiv)
in DMF at 50 °C for 2-3 days (Scheme 49, Table 2, entry 1). A sample aliquot was
removed after 2 days, washed and cleaved to give 63% of the desired product by
LC/MS. There was also a small amount of dialkylated material 139 (<5%) in which one of
the benzyl esters had been converted to the carboxylic acid that was only visible by the
mass spectrum and not by UV absorption. The resin was heated an additional day and
cleaved after 3 days to give 79% of product by LC/MS. These initial results suggested
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that the %-bromoester was not being consumed in the elimination side reaction with
triethylamine. The results for the following optimization experiments are shown in Table
2.
Scheme 49. N-Alkylation of Phe-Wang with Benzyl 2-Bromo-4-phenylbutanoate.
Table 2. Results from the N-Alkylation of Phe-Wang with Benzyl 2-Bromo-4-phenyl-
butanoate.
Entry Equiv of 125c Base (equiv) TBAI Solvent Temp (°C) LC/MS %a
1 4.5 Et3N (7.5) ---- DMF 50 79
2 3 Et3N (7) ---- DMF 70 44
3 6 Et3N (11) ---- DMF 55 54
4 6 Et3N (10.5) 2.0 DMF 55 49
5 4 Et3N (7.5) 2.0 DMF rt 33
6 4 Et3N (7.5) ---- NMP 50 34
7 4 Et3N (8) 2.0 CH2Cl2 rt 0
8 4 Et3N (8) 2.0 CH3CN rt 0
9 4 Et3N (8) 2.0 THF/MeOH (2:1) rt 0
10 4 Et3N (8) ---- DMSO 50 59
11 4 Et3N (4) ---- DMF 50 62
12 4 Et3N (4) ---- DMSO 50 63
13 4 Et3N (2.5) ---- DMF 50 67
14 4 Et3N (1.5) ---- DMF 50 69
15 4 Et3N (1.5) ---- DMF 70 73
a % Product in the reaction mixture. Diastereomeric ratio 56:44.
Next, the above reaction was repeated with benzyl 2-bromo-4-phenylbutanoate
(3 equiv) and triethylamine (7 equiv) in DMF at 70 °C. After 3 days, LC/MS analysis
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showed 44% of the product had formed (Table 2, entry 2). There also appeared to be a
negligible amount of the dialkylated material 139 apparent in the mass spectrum. From
these results, the increase in temperature appeared to give a lower percentage of
alkylated product.
The number of equivalents of the %-bromoester and triethylamine were increased
to 6 and 11 equivalents, respectively, in an effort to increase the amount of alkylated
product in the absence of and presence of TBAI (Table 2, entries 3-4). The LC/MS
results showed 54% of the product had formed for the reaction in the absence of TBAI,
while the reaction containing TBAI gave 49% of the desired product. It appeared an
increase in the %-bromoester and triethylamine did not significantly increase the amount
alkylated product, and similar conversions were seen with or without the presence of
TBAI. Due to the several steps required to make this starting %-bromoester, four
equivalents of the %-bromoester were used in all further studies.
Next, the same reaction was repeated with TBAI at room temperature with 4
equivalents of the %-bromoester (Table 2, entry 5). The results from this reaction would
indicate whether TBAI could achieve the same conversion as the reaction at 50-55 °C.
LC/MS results showed only 33% of the product formed, confirming that elevated
temperatures were necessary to achieve the optimal amount of alkylated product.
A solvent study was conducted next by running the reaction in NMP, methylene
chloride, acetonitrile, THF/methanol, and DMSO (Table 2, entries 6-10). The reactions in
methylene chloride, acetonitrile, and THF/methanol were conducted at room
temperature for three days due to the relatively low boiling points of these solvents. TBAI
was added to these reactions (entries 7-9) in an attempt to increase the N-alkylation.
The reactions in NMP and DMSO were conducted at 50 °C for three days. All of these
reactions involved 4 equivalents of the %-bromoester and 8 equivalents of triethylamine.
LC/MS results showed only 34% of the resin-bound phenylalanine was alkylated for the
reaction in NMP (entry 6) and 59% of the product for the reaction in DMF (entry 10). The
reactions conducted in the other three solvents (entries 7-9) showed no conversion of
the starting material to product. The results for the reaction in DMSO were comparable
to the yields seen using DMF; however, NMR analysis of the crude material showed the
presence of DMSO. Numerous washes prior to cleavage of the product from the resin
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did not eliminate all of the DMSO from the alkylation reaction. Because of this
contamination problem, DMF still appeared to be the best solvent for the N-alkylation.
Next, the number of equivalents of triethylamine was examined in the two best
solvents, DMF and DMSO (Table 2, entries 11-14). Although complete removal of the
DMSO had been problematic, reactions were still tested in DMSO to compare the overall
yield observable by LC/MS. Phe-Wang was treated with the %-bromoester (4 equiv) and
triethylamine (4, 2.5 or 1.5 equiv) in DMF and DMSO at 50 °C for 3 days (entries 11-13).
LC/MS results (62-69%) again showed comparable results for the corresponding
reactions in DMF and DMSO with a decrease in the amount of triethylamine having no
effect on the amount of product observed by LC/MS. The fewer equivalents of
triethylamine seemed to be sufficient for the neutralization of the HBr produced in the
alkylation step.
The reaction temperature was explored as a final variable by repeating the
reaction with %-bromoester (4 equiv) and triethylamine (1.5 equiv) at 70 °C for three days
(Table 2, entry 15). Previous reactions conducted at 70 °C had given slightly lower
yields, and LC/MS results showed 73% of the product had been formed (entry 15).
These results were comparable to the reaction conducted at 50 °C (entry 14), and the
increase in temperature did not seem to substantially increase the conversion.
The optimal reaction conditions with benzyl 2-bromo-4-phenylbutanoate used the
%-bromoester (4 equiv) and triethylamine (1.5 equiv) in DMF at 50& for 3 days. In order to
obtain at least the desirable amount of 10 mg of purified product, the reaction was
scaled up to 150 )mol of the starting Fmoc-Phe-Wang (Scheme 50). LC/MS results
indicated 69% of the product was formed and 25.8 mg (41% yield) was isolated.
Scheme 50. Optimized N-Alkylation of Phe-Wang with Benzyl 2-Bromo-4-phenyl-
butanoate.
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3.1.5. N-Alkylation of Fmoc-Phe-Wang with Benzyl 2-Bromopropanoate
The use of benzyl 2-bromopropanoate as an alkylating reagent was of interest in
order to evaluate the steric demands between the side chain on the amino acid and the
side chain introduced through the N-alkylation with the %-bromoesters. The methyl side
chain used earlier (Section 3.1.1) is the least hindered alkyl side chain, which mimics the
alanine residues seen in many of the ACE analogs previously discussed (Section 1.1-
1.2). Racemic benzyl 2-bromopropanoate ((±)-125a) was synthesized from commercially
available 2-bromopropanoic acid (Scheme 48, (±)-133a). It is noted that, as a control,
these experiments were conducted simultaneously alongside those with benzyl 2-bromo-
4-phenylbutanoate (125c).
First, the optimized reaction conditions from the studies involving ethyl 2-bromo-
propanoate were used. Fmoc-Phe Wang was deprotected and treated with the %-
bromoester (4 equiv) and triethylamine (8 equiv) in DMF at 50 °C for 3 days (Scheme
51). The crude LC/MS results showed 76% of crude product (Table 3, entry 1). These
results were similar to those from the N-alkylation with ethyl 2-bromopropanoate
(Scheme 46). The complete list of results from this set of optimization experiments is
given in Table 3.
Scheme 51. N-Alkylation of Phe-Wang with Benzyl 2-Bromopropanoate.
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Table 3. Results from the N-Alkylation of Phe-Wang with Benzyl 2-Bromopropanoate.
Entry Equiv of 125a Base (equiv) TBAI Solvent Temp. (°C) LC/MS (%)a
1 4 Et3N (8) ---- DMF 50 76
2 4 Et3N (7.5) 2.0 DMF rt 66
3 4 Et3N (7.5) ---- NMP 50 82
4 4 Et3N (8) 2.0 CH2Cl2 rt 15
5 4 Et3N (8) 2.0 CH3CN rt 0
6 4 Et3N (8) 2.0 THF/MeOH (2:1) rt 0
7 4 Et3N (8) ---- DMSO 50 62
8 4 Et3N (4) ---- DMF 50 81
9 4 Et3N (4) ---- DMSO 50 64
10 4 Et3N (2.5) ---- DMF 50 82
11 4 Et3N (1.5) ---- DMF 50 83
12 4 Et3N (1.5) ---- DMF 70 84
a % Product in the reaction mixture. Diastereomeric ratio ranged from 52:48 to 45:54.
The reaction was repeated in the presence of TBAI at room temperature to see if
the reaction could be run at ambient temperature (Table 3, entry 2). The resin was
treated with benzyl 2-bromopropanoate (4 equiv), triethylamine (7.5 equiv) and TBAI (2
equiv) in DMF. LC/MS results showed 66% product. It is unclear whether the presence
of TBAI increased the reaction rate since a reaction at room temperature without TBAI
was not conducted; however, the reaction at 50 °C in the absence of TBAI gave a higher
conversion of alkylated product.
Next, a solvent study was conducted by running the reaction in NMP, methylene
chloride, acetonitrile, THF/methanol, and DMSO (Table 3, entries 3-7). As before, the
reactions in methylene chloride, acetonitrile, and THF/methanol were conducted at room
temperature for three days due to their relatively low boiling points of these solvents. In
addition, TBAI was added to these reactions in an attempt to increase the N-alkylation.
The reactions in NMP and DMSO were conducted at 50 °C for three days. All of these
reactions used the %-bromoester (4 equiv) and triethylamine (8 equiv). LC/MS results
showed a high conversion (82%) for the reaction in NMP (entry 3). The reaction in
methylene chloride only gave 15% of the desired product, while those run in acetonitrile
and THF/methanol did not give any product (entry 4-6). The reaction in DMSO also gave
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a reasonable yield of 62% (entry 7). Although NMP gave the highest conversion for
benzyl 2-bromopropanoate (entry 3), reactions with the other %-bromoesters worked
best in DMF. Thus, DMF was chosen as the best overall solvent. DMSO was also
considered a possible solvent for conducting these reactions; however, the
contamination discussed earlier was still problematic.
Next, the stoichiometry of triethylamine was explored with DMF and DMSO. The
number of equivalents of triethylamine was reduced to 4, 2.5 and 1.5 equivalents, and
the reactions were conducted in DMF and in DMSO for 3 days at 50 °C (Table 3, entries
8-11). LC/MS results indicated that reactions run in DMF gave higher conversion than
DMSO, and the decrease in the number of equivalents of triethylamine did not affect the
yield, confirming only 1.5 equivalents of triethylamine are required for the N-alkylation.
The reaction temperature was explored as a final variable by conducting the
reaction at 70 °C. Phe-Wang was deprotected and treated with benzyl 2-
bromopropanoate (4 equiv) and triethylamine (1.5 equiv) in DMF (Table 3, entry 12) at
70 °C for 3 days. LC/MS results showed 84% of crude products. Since this conversion
was almost identical to the same reaction conducted at 50 °C, it appeared the increase
in temperature did not increase the rate of N-alkylation.
The optimal reaction conditions for the N-alkylation were benzyl 2-
bromopropanoate (4 equiv) and triethylamine (1.5 equiv) in DMF at 50 °C for 3 days
(Scheme 52). The reaction was scaled-up to 150 )mol of Fmoc-Phe-Wang to determine
the amount of isolable product possible after purification. The LC/MS results showed
79% of crude product, which was purified to give 31.0 mg (63% yield) of 140.
Scheme 52. Optimized N-Alkylation of Phe-Wang with Benzyl 2-Bromopropanoate.
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3.2 Evaluation of Alkyl Halides in the Synthesis of Unnatural Amino Acids
Once the N-alkylation of a resin-bound amino acid had been optimized, the
application of this step to unnatural amino aci$ 1  5 !1  % 6/+.0% $     > .--% ++  !-$    # .22  et
al.54-55,64 have reported the C-alkylation of the resin-bound benzophenone imine of
glycine to generate unnatural amino acid side chains. Since this methodology utilizes
alkyl halides that are commercially available, a combinatorial approach is easily
accessible. A range of alkylating reagents (141-150) of varying types was tested in
conjunction with the N-alkylation of the resulting resin-bound, unnatural amino acid with
racemic benzyl 2-bromopropanoate ((±)-125a, Scheme 53). Good overall conversions
for this four-step reaction sequence were seen by LC/MS analysis of the crude products
(49-71%). LC/MS analysis also showed a diastereomeric mixture of each benzyl ester
136. Isolation of these products was accomplished by cyano-silica chromatography to
give 7.5-22.4 mg of product (14-47% purified yield, Table 4).
Scheme 53. Synthesis of Unnatural Amino Acids by C-Alkylation of Glycine.
Table 4. Results of C-Alkylation with Alkylating Reagents Followed by N-Alkylation.
R1X Conversion by LC/MS Purified Yield of 126 (%)
141 60% 16.3 mg (33%)
142 71% 18.7 mg (37%)
143 63% 7.5 mg (14%)
144 48% 10.9 mg (18%)
145 67% 13.5 mg (24%)
146 55% 15.1 mg (25%)
147 49% 8.2 mg (15%)
148 70% 17.5 mg (34%)
149 67% 22.4 mg (47%)
150 56% 13.8 mg (31%)
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Compared to the percent conversion observed by LC/MS, the isolated yields are
much lower. It was difficult to analyze the crude samples for the presence of the
trifluoroacetic acid salt of products 136 due to the known presence of the trifluoracetic
acid salt of the unalkylated amino acid. 19F NMR of the crude samples showed the
presence of fluorine due to this trifluoroacetic acid salt, while a 19F NMR of the purified
samples confirmed the isolated material was not the trifluoroacetic acid salt form of
product 136.
3.3. Combinatorial Synthesis of N-Carboxyalkyl Amino Acid Analogs
Next, the combinatorial synthesis of N-carboxyalkyl amino acid analogs 126 was
performed using the alkylating reagents (141-150, Scheme 53) as the input for R1 and
the benzyl %-bromoesters 125a, 125c and 125d (Scheme 47) as the input for R2
(Scheme 54). Two samples of each analog were prepared to ensure the reproducibility
of the synthetic sequence and to provide an additional sample for biological testing.
Three 4 x 6 combinatorial reaction boards, one for each of the benzyl %-bromoesters
(Scheme 55), with 20 reactions per board (the 10 alkylating reagents in duplicate)
afforded two samples of each of the 30 analogs. The benzophenone imine of glycine on
Wang resin was alkylated with 2 equivalents of the alkyating reagents 141-147 and 150
and 2 equivalents of BTPP. For the less-activated alkylating reagents 148-149, 10
equivalents each of R1X and BTPP were used following the procedure previously
0% /.02% $   " 7   > .--% ++  et al.64 The benzophenone imine activating group was then
hydrolyzed with hydrochloric acid, and the hydrochloride salt of the unnatural amino acid
was neutralized with N,N-diisopropylethylamine (DIEA). The free amine was alkylated
with the corresponding %-bromoester (4 equiv) and triethylamine (1.5 equiv) in DMF at
55 °C. After 3 days the reagents and solvents were removed by filtration and the resin
was washed. The crude products were cleaved from the resin with trifluoroacetic acid,
and the results are shown in Table 5.
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Scheme 54. Combinatorial Synthesis of N-Carboxyalkyl Amino Acid Analogs 126.
Scheme 55. Combinatorial Set-Up for Synthesizing N-Carboxyalkyl Amino Acid
Analogs 126.
46
Table 5. Results of the Combinatorial Synthesis of N-Carboxyalkyl Amino Acid Analogs.
Entry Structure LC/MS %(Crude)a
Crude Yield
(mg)
Purified Yield (mg)
(% Yield)
LC/MS %
Purity
1
72%
66%
53.6
52.0
25.8 (53%)
25.1 (51%)
98%
98%
2 68%76%
55.0
58.8
22.5 (44%)
20.3 (40%)
98%
100%
3 67%72%
58.6
58.8
14.6 (27%)
7.0 (13%)
95%
92%
4 64%59%
64.4
64.4
18.5 (31%)
21.6 (36%)
99%
99%
5 67%67%
64.5
63.0
20.0 (35%)
13.5 (24%)
89%
98%
6 34%32%
46.8
52.1
6.0 (10%)
10.0 (17%)
90%
90%
7 55%60%
62.2
62.0
11.9 (22%)
15.2 (28%)
100%
100%
8 69%75%
49.8
48.5
11.1 (22%)
19.4 (38%)
100%
100%
9 65%65%
45.0
42.3
10.0 (21%)
7.6 (16%)
100%
100%
10 59%63%
43.4
44.1
6.2 (14%)
18.9 (43%)
100%
95%
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Entry Structure LC/MS %(Crude)a
Crude Yield
(mg)
Purified Yield (mg)
(% Yield)
LC/MS %
Purity
11 39%39%
43.5
44.1
16.9 (30%)
11.0 (20%)
90%
96%
12 41%41%
46.0
45.1
12.2 (21%)
15.2 (26%)
98%
96%
13 33%34%
46.5
46.6
13.4 (22%)
15.6 (26%)
87%
93%
14 29%28%
49.3
49.4
13.8 (21%)
7.5 (11%)
93%
93%
15 40%37%
45.5
51.2
15.0 (24%)
15.0 (24%)
96%
92%
16 20%23%
47.6
48.3
4.7 (8%)
5.7 (9%)
96%
95%
17 21%19%
49.8
50.0
9.4 (15%)
8.4 (14%)
87%
87%
18 35%35%
32.7
34.0
4.2 (7%)
12.6 (22%)
94%
90%
19 34%37%
29.6
29.3
18.0 (33%)
2.6 (5%)
93%
93%
20 40%38%
34.7
33.0
14.4 (29%)
14.2 (29%)
91%
95%
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Entry Structure LC/MS %(Crude)a
Crude Yield
(mg)
Purified Yield (mg)
(% Yield)
LC/MS %
Purity
21 51%45%
61.5
60.8 4.6 (7%) 100%
22 55%52%
65.5
69.0
8.4 (13%)
12.6 (19%)
100%
100%
23 49%54%
67.1
73.7
12.9 (19%)
8.7 (13%)
100%
100%
24 43%48%
76.1
72.3
3.0 (4%)
5.7 (8%)
100%
100%
25 47%44%
81.8
73.3
9.8 (14%)
8.0 (11%)
100%
100%
26 28%27%
50.0
47.3
3.8 (5%)
2.6 (4%)
100%
100%
27 30%28%
80.1
72.5
4.0 (6%)
5.0 (7%)
100%
100%
28 56%56%
46.5
50.7
8.2 (13%)
8.8 (14%)
100%
100%
29 72%72%
41.6
46.1
8.6 (14%)
7.2 (12%)
100%
100%
30 68%67%
47.3
43.8
7.3 (13%)
9.4 (16%)
100%
100%
a Diastereomeric ratios ranged from 68:33 to 44:56. See Experimental Section for
individual values.
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In general, the unnatural amino acids that were N-alkylated with benzyl 2-
bromopropanoate ((±)-125a) gave the highest conversions to products 151-160 (Table 5,
entries 1-10) by LC/MS analysis. The analogs 161-170 (Table 5, entries 11-20) prepared
using benzyl 2-bromo-4-methylpentanoate ((S)-125d) gave the lowest conversions of the
three %-bromoesters, rationalized by the disubstituted branching on the (-carbon. Benzyl
2-bromo-4-phenylbutanoate ((±)-125c) gave reasonable conversions to the N-alkylated
products 171-180 (Table 5, entries 21-30), but not as high as (±)-125a, likely due to the
increased steric hindrance by the phenethyl side chain on the %-bromoester. Overall, the
LC/MS yields indicated in Table 5 were much higher than the isolated yields.
Quantitative NMR of the crude mixture of 157 gave a 34% yield, much closer to the
purified yield. This result suggests the LC/MS results are higher than the actual yield due
to higher UV absorption of the products versus the unalkylated amino acids. This
indicates all of the N-alkylated product was eluted from the column and no trifluoroacetic
acid salt of the product formed, contrary to the discussion in Section 3.2.
The more sterically demanding alkylating reagents 2-(bromomethyl)naphthalene
145 (product entries 5, 15 and 25) and bromodiphenylmethane 146 (product entries 6,
16 and 26) gave poorer yields of products, likely due to the increased steric hindrance
employed by these unnatural side chains on the resin-bound amino acid. 4-Chlorobenzyl
bromide 143 (product entries 3, 13 and 23) and 2-chloro-5-(chloromethyl)pyridine 147
(product entries 7, 17 and 27) alkylating reagents gave comparable conversion (LC/MS)
to the analogs prepared with the same %-bromoester; however, the isolated yields after
column chromatography were consistently lower for these alkylating reagents. These
analogs were more insoluble in organic solvents seen by their salt-like character after
purification, likely making it more difficult for all of the product to elute from the column
resulting in the lower yields.
For most cases the duplicate samples gave consistent results for crude LC/MS
results, crude yields and purified yields. These results confirm the reproducibility and
robust synthetic sequence for isolating compounds 126. A few cases, however, showed
similar results for the crude LC/MS and crude yield but gave very different purified yields
(Table 1, entries 8, 10, 18, and 19). These inconsistencies are likely a result of
conducting the purifications in a combinatorial fashion by purifying multiple samples at
once, usually 5 or 10 samples at a time. The lower isolated yields for one sample may
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have been due to contaminated fractions during the column chromatography, ultimately
determined by how evenly the sample was loaded on the prepacked cyano-silica gel
cartridges. Some crude samples were insoluble and required more solvent to transfer
the crude material to the column. This would create a larger bandwidth for the loaded
material, causing a poorer separation.
The analogs made with the %-bromoesters (±)-125a and (S)-125d were easily
isolated using cyano-silica gel chromatography. However, the LC/MS results for the
purified analogs alkylated with the %-bromoester (S)-125c showed a large amount of
dialkylated material 139 (~10-25%) that had also been debenzylated by an
intramolecular loss of one equivalent of benzyl alcohol, likely through the anhydride 182
(Scheme 56). Cyano-silica gel and silica gel chromatography did not give separation of
the desired monoalkylated product 138 from the dialkylated by-product 139. These
analogs (entries 21-30) were first purified on cyano-silica gel to remove impurities, and
then the mixture of the monoalkylated and dialkylated products were separated by
preparative liquid chromatography using reverse-phase conditions. This purification
method also allowed separation of the diastereomers for most analogs, and each of the
diastereomers were isolated and characterized. The purified yields of these analogs
(entries 21-30) reflect the combined yields of the two diastereomers and are slightly
lower due to the requirement of two purifications to isolate the desired products from the
by-product of the dialkylated material.
Scheme 56. Mechanism of the Formation of the Dialkylated By-Product 136.
The analogs alkylated with the %-bromoester containing the isobutyl group [(S)-
125d, entries 11-20] showed <5% of the corresponding dialkylated products by LC/MS.
The identification of this contaminant was not determined until after complete purification
and analysis of each analog and the large amount of this by-product had been observed
in the synthesis of analogs prepared with (S)-125c (entries 21-30). The isobutyl analogs
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(entries 11-20) were not purified a second time by preparative liquid chromatography to
remove the dialkylated material, and the LC/MS results of the purified compounds reflect
this in Table 5. The analogs made with the %-bromoester containing the methyl group
[(±)-125a, entries 1-10] did not show the presence of dialkylated material. Taken
together, these results indicate that there is more dialkylation with the larger side chain
on the %-bromoester. All of the purified samples were analyzed by LC/MS, 1H NMR, 13C
NMR, and HRMS. The NMR spectra for the products alkylated with the %-bromoester
(S)-125d (entries 11-20) show contaminant peaks for the dialkylated by-product.
3.4 Deprotection of Benzyl-Protected N-Carboxyalkyl Amino Acids to the Diacid
The conversion of the benzyl ester intermediates 140 and 151-160 (where R2 =
CH3) to the N-carboxyalkyl amino acids was explored using hydrogenolysis conditions
(Scheme 57). The benzyl ester was dissolved in ethanol and Pd/C (10%, 20-35 mg) was
added depending on the amount of starting material (5[25 mg). 1,4-Cyclohexadiene (20
equiv) was then added by a syringe. The reaction temperature (room temperature to 55
°C) and length of the reaction (6-24 h) were evaluated. Reactions conducted at room
temperature did not always show complete conversion to the carboxylic acid, and many
of the benzyl esters were not soluble in ethanol unless heated at elevated temperatures.
Thus, a reaction temperature of 55 °C was used for optimal conversion. Reactions
conducted for 6-12 hours did not always show complete conversion by LC/MS either,
and reactions were allowed to proceed for 24 hours to ensure complete deprotection.
Scheme 57. Hydrogenolysis of Benzyl Ester Intermediates to the N-Carboxyalkyl Amino
Acids.
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The crude reaction mixtures were filtered through celite with ethanol and
concentrated under a stream of nitrogen or under vacuum. LC/MS analyses of these
reactions often showed the desired products 183 and 184 streaking on the column with
poor ionization through the mass spectrometer. However, the disappearance of the
starting benzyl ester was observed. Initial attempts to obtain NMR data showed these
compounds were very hygroscopic and lyophilization was required to remove all water
from the samples. After lyophilization, it was still difficult to obtain clean spectra because
the hygroscopic character of these compounds due to the presence of a small amount of
water interfering with the proton shifts. Attempts to obtain 13C NMR of 183 and 184 also
gave inconsistent results. Some samples gave clear carbon signals while others gave no
carbon signals at all. Indications that the presence of palladium in the samples was a
potential problem became apparent when palladium was observed settling out of the
DMSO-d6 solution of one compound in its NMR tube. It was hypothesized that the
presence of palladium in the samples was interfering with the ability to acquire NMR
spectra.
Micron syringe filters (0.2-0.5 micron) were used in an attempt to remove the
palladium, but the quality of the 13C NMR spectra was not improved. SciFinder searches
of the N-carboxyalkylamino acids show a large number of these scaffolds as ligands to
metals, suggesting the amine and two carboxylic acids were complexing with palladium.
An elemental analysis was performed on a sample that had been hydrogenolyzed under
the conditions described above, and the results showed 12.6% palladium present in the
sample.
The metal scavengers Smopex-234 and DARKO were used in an attempt to remove
the palladium from the reaction mixture,65 but without success. One sample was heated
with Smopex-234, but NMR analysis showed no evidence of the desired product
present. Other samples were stirred in DARKO at room temperature, and NMR analyses
did not show any improvement in the acquisition of carbon signals. An elemental
analysis was obtained for one of the samples stirred with DARKO for four days, and the
presence of palladium was confirmed at 17.2%. It appeared the interaction between the
carboxylic acids and amine of the N-carboxyalkylamino acid compounds and palladium
was too strong to completely remove the palladium from the samples that had been
hydrogenolyzed.
53
Therefore, hydrolysis conditions were used for deprotection of the benzyl ester
intermediates. Initial tests were performed on analogs 161-170 and then the hydrolysis
was carried out on the remaining analogs (Scheme 58). Heating the benzyl esters in 6 N
HCl (2 mL) at 95 °C in an oil bath or oven for 24 hours gave complete debenzylation by
LC/MS. Initially hydrolysis was carried out in a 1:1 mixture of 6 N HCl/dioxane; however,
the dioxane also hydrolyzed to side products as observed by the high yield and 1H NMR.
The dioxane was removed and hydrolysis was carried out in 6 N HCl at 95 °C.
Scheme 58. Hydrolysis of Benzyl Ester Intermediates to the N-Carboxyalkyl Amino
Acids.
Hydrolysis of intermediates 157 and 161-170 showed complete conversion of the
starting benzyl esters by LC/MS, and the corresponding ions for the diacids were
observed in the mass spectra. After evidence of complete hydrolysis, the reaction
mixtures were concentrated under vacuum and lyophilized to afford white or yellow
solids as the hydrochloride salt products. The isolated yields were consistently higher
than those that were previously observed under the hydrogenolysis conditions (186-196,
Table 6).
Since the diastereomers of the benzyl esters 171-180 were separated by
preparative liquid chromatography, the duplicate samples of each separate diastereomer
(171-180) were combined and hydrolyzed to the diacids 197-206. In some cases
complete separation of the benzyl ester diastereomers was not possible with the
reverse-phase conditions used, and these samples were hydrolyzed as mixtures
(indicated in Table 6). For the diacids 186-196 (Table 6, entries 1-11), hydrolysis was
performed on the mixture of diastereomers. For 189 (entry 4), the initial purity of the
benzyl ester starting material was only 87%, giving a lower purity for the isolated
product. A few examples (198-200, entry 13-15) were insoluble in the 6 N HCl solution
and showed incomplete hydrolysis after 24 hours. A small amount of DMSO was added
to these samples to assist in solubilizing the benzyl ester. Even after the addition of
DMSO, these samples still did not completely dissolve in solution, resulting in incomplete
hydrolysis. These samples were not further characterized. All other samples were
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analyzed by 1H and 13C NMR, when quantities permitted (>6 mg), and high-resolution
mass spectrometry.
. Table 6. Results from the Hydrolysis of the Benzyl Ester Intermediates to the Diacids.
Entry Structure Overall IsolatedYield mg (% Yield) LCMS %
1 12.4 (27%) 100%
2 12.4 (26%) 100%
3 6.0 (12%) 99%
4 10.0 (19%) 88%a
5 5.0 (9%) 97%
6 11.8 (22%) 100%
7 4.0 (7%) 100%
8 7.8 (15%) 100%
9 11.0 (22%) 95%
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Entry Structure
Overall Isolated
Yield
mg (% Yield)
LCMS %
10 ------b 100%
11 8.9 (21%) 100%
12 4.5 (8%)3.7 (7%)
Diast. 1: 100%
Diast. 2: 100%
13 Insoluble12.0 (21%)
Diast. 1:
Incomplete
Diast. 2: 100%
14 Insoluble8.4 (14%)
Diast. 1:
Incomplete
Diast. 2: 100%
15 Insoluble Mixture:Incomplete
16 5.0 (8%)6.0 (10%)
Diast. 1:
Incomplete
Diast. 1: 100%
17 3.6 (5%)4.3 (7%)
Diast. 1: 100%
Diast. 2: 100%
18 3.5 (6%)4.1 (7%)
Diast. 1: 100%
Diast. 2: 100%
19 5.5 (10%)8.5 (15%)
Diast. 1: 100%
Mixture: 100%
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Entry Structure Isolated Yield (mg)(Overall % Yield) LCMS %
20 6.8 (13%)4.6 (9%)
Diast. 1: 100%
Diast. 2: 100%
21 10.8 (22%)4.4 (9%)
Mixture:100%
Diast. 2: 100%
a Initial sample purity [ 87%.
b Tare lost during hydrolysis.
3.5. Synthesis of an Ethyl Ester Analog and Subsequent Hydrolysis to the Amino Diacid
Since hydrogenolysis conditions were not successful for conversion of the benzyl
ester intermediates 126 to the amino diacids 185 (Section 3.4) and hydrolysis conditions
were successful, methyl or ethyl %-bromoesters 207 could be used to prepare alkyl ester
intermediates 208 (Scheme 59). The benzophenone imine of glycine 123 could be
alkylated with various alkylating reagents to give the resin-bound unnatural amino acid
124. N-Alkylation could then be performed using a methyl or ethyl %-bromoester 207,
and cleavage from the resin would give the alkyl ester intermediate 208. Hydrolysis of
this intermediate would then give the amino diacids 185.
Scheme 59. Use of Alkyl %-Bromoesters to Prepare Amino Diacids 185.
Analog 186 was made through the ethyl ester intermediate 209 using racemic
ethyl 2-bromopropanoate 129. The benzophenone imine of glycine 123 was alkylated
with 2-chloro-5-(chloromethyl)pyridine 147 to give the unnatural amino acid 124, which
was then N-alkylated with 129 and cleaved from the resin. The crude ethyl ester
intermediate 209 was purified over cyano-silica gel to give 14 mg (31% yield). The ester
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was then hydrolyzed under acidic conditions to give 15.7 mg of amino diacid 186 (34%
overall yield, Scheme 60).
Scheme 60. Synthesis of Amino Diacid 186 through Ethyl Ester 209.
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CHAPTER 4. CONCLUSIONS
The solid-phase synthesis of N-carboxyalkyl unnatural amino acids was
accomplished through the N-alkylation of resin-bound unnatural amino acids with %-
bromoesters. The unnatural amino acids were obtained by C-alkylation of resin-bound
glycine. The N-alkylation step with %-bromoesters to give N-carboxyalkyl unnatural
amino acids that mimic commercially available drugs for ACE inhibitors, especially those
incorporating the phenethyl side chain, was optimized. The preparation of the benzyl %-
bromoester starting reagents for the N-alkylation was carried out in order to permit
hydrogenolysis conditions for the debenzylation step. However, the complexation of
palladium catalyst was problematic and was overcome by acidic hydrolysis of the benzyl
esters to the carboxylic acids. Since it was demonstrated that the benzyl ester
hydrogenolysis was unsuccessful, other alkyl %-bromoesters would likely be preferable
to the benzyl %-bromoesters for future experiments. The synthesis of analog 186 with the
ethyl %-bromoester was completed; however, if the synthetic route to prepare the %-
bromoesters would be used, control experiments would need to be conducted to
determine the stereochemical fate of the %-carbon on the starting amino acid. The
combinatorial synthesis of the thirty analogs was shown to be a powerful tool for
synthesizing many analogs at one time. Considering the stereospecificity of the ACE
active site, separation of the diastereomers was possible in order to test each racemic
diastereomer separately in biological assays, but the relative configuration of these
diastereomers would need to be determined in the future.
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CHAPTER 5. EXPERIMENTAL SECTION
5.1 General Methods
All chemicals and organic solvents were reagent grade and used directly without
further purification. Acetone, 2-(bromoethyl)benzene, chloroform-d1, 5-(chloromethyl)-2-
chloropyridine, cyclohexyl iodide, triethylamine, 4-trifluoromethylbenzyl bromide,
hexanes, N,N-dimethylformamide (DMF), and dimethylsulfoxide-d6 were purchased from
Acros Organics. Benzyl bromide, 2-(bromomethyl)naphthalene, n-butyl iodide, 4-
chlorobenzyl bromide, trifluoroacetic acid (TFA), N,N-diisopropylethylamine (DIEA), 4-
methylbenzyl bromide, diphenylbromomethane, and piperidine were purchased from
Aldrich Chemical Co. Acetonitrile, hydrochloric acid, methanol, and 1-methyl-2-
pyrrolidone (NMP) were purchased from Fisher Scientific. Dichloromethane, absolute
ethanol and tetrahydrofuran (THF) were purchased from Pharmco-Aaper. tert-
Butylimino-tri(pyrrolidino)phosphorane (BTPP) was purchased from Fluka. Fmoc-
Phenylalanine on Wang resin (Fmoc-Phe-W, 0.70 mmol/g, 75[150 )m) and
benzophenone imine of glycine Wang resin (PL-BIG-W, 0.83 mmol/g, 75[150 )m) were
purchased from Polymer Laboratories. DARKO (20-40 mesh) was purchased from EM
Science. SMOPEX-234 was purchased from Johnson Matthey. Solution- and solid-
phase organic transformations and resin washes were carried out at ambient
temperatures unless otherwise indicated. Ratios in all solvents and reagent mixtures
prepared are volume to volume unless otherwise noted.
Manual solid-phase organic syntheses were carried out in two types of reaction
vessels. Small scale reactions (50 )mol) were performed in 3.5 mL fritted glass reaction
vessels (Chemglass, IUP-0305-270H) equipped with polypropylene screw caps
(Chemglass, IUP-0305-280H) with Teflon-faced silicon septa (Chemglass, IUP-0305-
281H) on the Bill-Board set. Small scale reactions (150 )mol) were performed in 5.0 mL
fritted glass reaction vessels (Chemglass, IUP-0905-210PS) equipped with
polypropylene screw caps (Chemglass, IUP-0305-280H) with Teflon-faced silicon septa
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(Chemglass, IUP-0305-281H) on the Bill-Board set. The Bill-Board set was designed by
Professor Scott as inexpensive equipment to simplify and expedite multiple, manual
solid-phase syntheses.66 Motor rotators were used as rotation apparatus for small scale
reactions.
Depending on the number of reactions performed, the starting resin was
distrib32% $   % )2( % 0  " 7  5 % )' ( 2   96 reactions) or as aliquots from an isopycnic suspension
(>6 reactions). The resin for the optimization reactions, performing one to six reactions at
a time, was distributed by weight, typically 50 )mol (with a known loading) unless
otherwise noted, and the resin was swelled for 30 min to 1 h in 2:1 CH2Cl2/DMF (or
CH2Cl2/NMP). The resin for the combinatorial syntheses of N-carboxyalkyl amino acid
analogs in the 6 x 4 Bill-Board set was distributed as aliquots from an isopycnic
suspension from a neutral buoyancy suspension in CH2Cl2/NMP, distributing 150 )mol of
the starting resin (with a known loading) by repeated aliquots (1[2 mL) to each of the
reaction vessels in the Bill-Board. During the distribution of the resin, the isopycnic
solvent was allowed to drain through the frit in the reaction vessels. When distribution
5 !1  #.,/+% 2%    0% 1)$ 3!+  1.+4 % -2  5 !1  0% ,.4 % $   5 )2(   !-  <!)0-/31( =  &0.,   !  $ )1/.1!" +%   /+!12)#  
pipet (Fisher, 13-711-23) fitted with a pierced septum (Aldrich, Z12743-4). The bottom of
each reaction vessel was then capped, and a new calibrated pipet (Fisher, 13-711-24)
was used for adding each reagent in the following step. The tops of all reaction vessels
were capped and the Bill-Board was placed on an appropriate rotation apparatus.
Following the reaction, the reagents and solvents were drained and the resin product
was washed with the indicated solvents. For washing of small scale reactions, at least
30 sec was normally used after addition of solvents to the reaction vessels (with bottom
% -$   ./% -  &.0  $ 0!)-)-'    &.++.5 % $   " 7  !-  <!)0-/31(  =   .+)$ -phase reactions at elevated
temperatures were carried out in an Isotemp® Oven Model 280A (Fisher Scientific) with
the reaction vessels capped to finger tightness.
Analytical thin layer chromatography (TLC) was performed on EM Science silica
gel 60 F254, 0.25 mm pre-coated glass plates (EMD Chemical Inc., 5715-7) or EM
Science cyano-silica gel F254, 0.15-0.20 pre-coated glass plates (EMD Chemical Inc.,
16464-5). TLC plates were visualized using UV254. Column chromatography was
performed on HyperSep Cyano-Silica 3 mL cartridges (60108-748) pre-loaded with 500
mg of silica gel 60 (irregular particles 40 [ 63 )m) from ThermoScientific for 50 )mol
small scales reactions. For 150 )mol small scale reactions, the cyano-silica gel from two
61
of the HyperSep Cyano-Silica® 3 mL cartridges were combined to form 1 g columns in
one of the 3 mL cartridges. Reverse-phase chromatography was performed on a Waters
PrepLC 400 System with ISCO Absorbance Detector and an Agilent Eclipse XDB-C18
columns (5 )m, 9.4 x 250 mm, PN 990967-202). The isocratic mobile phase used for
these purifications was 1:1 0.1% TFA/CH3CN:H2O. Yields of the final compounds, after
chromatographic purification, were calculated on the basis of the initial loading of the
starting resins and are the overall yields for all reaction steps starting from these resins.
LC/MS analyses were conducted using an Agilent system, consisting of a 1100
series HPLC connected to a diode array detector and a 1946D mass spectrometer
configured for positive-ion electrospray ionization. The LC/MS samples were analyzed
as solutions in CH3CN or a mixture of CH3CN:CH3OH. The LC/MS samples analyzed for
the hydrolysis reactions were run as aliquots from the aqueous reaction mixture. The
LC/MS-derived composition of mixtures was determined based on UV integration at 210
nm. The LC/MS chromatography was carried out on an Agilent Eclipse XDB-C18 column
(5 )m, 4.6 x 250 mm, PN 990967-902) eluting with 1:1 acetonitrile/methanol containing 5
mM NH4OAc as the organic mobile phase and water containing 5 mM aqueous NH4OAc
as the aqueous mobile phase. This system was used for all compounds except those
purified by PrepLC, which were eluted with an Agilent Eclipse C18 column (5 )m, 4.6 x
150 mm, PN 993967-902) eluting with 0.1% TFA/CH3CN solvent system.
1H NMR and 13C NMR spectra were recorded at 500 MHz (Bruker Advance III
500 spectrometer) using TMS (0.00 ppm) and chloroform-d1 or dimethylsulfoxide-d6. 13C
NMR were run with broadband decoupling, and the carbon signals for the carbonyl
carbons were not always visible in the spectra. Copies of the NMR spectra reported in
this experimental are located in Appendix A. High-resolution mass spectrometry results
were obtained on a MAT 95XP (Thermo Electron Corp.) with electron impact (EI) or
chemical ionization (CI) methods at Indiana University, Bloomington, IN. Optical
rotations were performed using a PerkinElmer Model 343 Polarimeter with a polarimeter
cell (1-mL capacity and 100-mm pathlength) at Indiana University, Bloomington, IN.
Concentrations are reported in g per 100 mL. Elemental analyses were performed by
Midwest Microlabs, Indianapolis, IN.
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5.2 General Procedure for the Optimization of N-Alkylation of Resin-Bound Amino
Acids with Ethyl 2-Bromopropanoate: N-[1-Methyl-2-oxo-2-(ethoxy)ethyl]phenylalanine
Fmoc-Phe-Wang resin 128 (72 mg, 0.70 mmol/g, 50 )mol) was added to a solid-
phase reaction vessel (3 mL) and swelled in 2:1 CH2Cl2/NMP for 1 h. The resin was
filtered, a solution of 20% piperidine/DMF (2 mL) was added and the vessel was rotated
at room temperature for 30 min. The resin was filtered and washed with DMF (3 x 2 mL).
A mixture of the ethyl 2-bromopropanoate (200 or 400 )mol, 2 or 4 equiv) and
triethylamine (400 or 800 )mol, 4 or 8 equiv) in DMF (0.5 mL) was added. If
tetrabutylammonium iodide (TBAI) was used, it was then added to the vessel as a solid.
The resin was heated at 50 °C for the indicated time (1-4 d) referenced in Chapter 3.1.1.
The vessels were allowed to cool to room temperature and the resin was washed with
DMF (3 x 2 mL), MeOH (3 x 2 mL), THF (3 x 2 mL), and MeOH (3 x 2 mL). A solution of
95% TFA/H2O (2 mL) was added to each vessel followed by rotation for 1 h. The filtrate-
containing product was collected in tared vials and the cleavage solution was
evaporated with a stream of nitrogen. Each sample was analyzed by LC/MS and cyano-
silica TLC plates (30% acetone/hexanes). The products were purified by loading the
crude product (13-19 mg) onto a dry 500 mg cyano-silica cartridge with 200-300 )L of
acetone and allowing the column to dry with a stream of nitrogen. The column was then
washed with hexanes (2 x 2 mL) and eluted with 30% acetone/hexanes (8 x 1 mL).
Fractions were analyzed by cyano-silica TLC plates (30% acetone/hexanes) and pooled
to afford the product as a white solid. For the reaction under optimal conditions
(Scheme 47), 131 was obtained as a white solid (12.0 mg, 91% isolated yield). Crude
LC/MS purity 76%, tR = 3.8, 4.0 min (dr 52:48 [ 55:45); 1H NMR (500 MHz, CDCl3): '
1.24 (t, J = 14.3 Hz, 3H), 1.33 (d, J = 7.2 Hz, 1.5H), 1.42 (d, J = 7.2 Hz, 1.5H), 3.17 (m,
1H), 3.34 [ 3.48 (m, 2H), 3.68 (m, 1H), 4.15 (m, 2H), 7.30 [ 7.35 (m, 5H).
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5.3 General Procedure for the Conversion of Amino Acids to %-Bromoacids (133b-d)
To the amino acid (S)-132b-d (2.4-13.8 mmol) in a 100 [ 250 mL round-bottom
flask equipped with a magnetic stirrer was added 2.5 M H2SO4 (1.3[1.5 mL/mmol) at
room temperature. Sodium bromide (3.5 equiv) was added with stirring and the mixture
was placed in an ice bath (0 °C), where it rapidly became a thick solution. Sodium nitrite
(1.2 equiv) in water (2[5 mL) was added in small portions (about 5 drops every 5 min),
with each releasing a yellow gas. If the solution had not changed from a heterogeneous,
white mixture to a clear solution after 1 h, additional sodium nitrite was added as a solid
until no color change was observed. Stirring was continued for 6-24 h. Experimentation
with the reaction conditions showed that over time a polymer-like solid formed,
especially when the reaction was allowed to continue overnight. (This solid may be a
polymer-like compound due to alkylation on the nitrogen of the starting amino acid with
the %-bromoacid product.) Also, when colder reaction conditions were maintained (-10
°C to 0 °C), higher yields were observed, particularly for converting (S)-132c to (S)-133c.
The reaction was quenched with brine and extracted three times with ethyl acetate. The
organic layers were washed with brine and dried over Na2SO4. The crude material was
loaded on a silica column and eluted with 0[5% CH3OH/CH2Cl2 (0.2% TFA). The purified
products were obtained as oils.
(S)-2-bromo-3-phenylpropanoic acid (133b)
Compound 133b was obtained from 132b (2.00 g, 12.1 mmol) as a yellow oil (1.90 g,
69% isolated yield) following chromatographic purification over silica gel with 0.2%
TFA/CH2Cl2. 1H NMR (500 MHz, CDCl3): ' 3.23 [ 3.27 (m, 1H), 3.44 [ 3.49 (m, 1H),
4.42 (t, J = 8.0 Hz, 1H), 7.22 [ 7.32 (m, 5H).56
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(S)-2-bromo-4-phenylbutanoic acid (133c)
Compound 133c was obtained from 132c (2.00 g, 11.2 mmol) as a pale yellow oil
(1.464 g, 54% isolated yield) following chromatographic purification over silica gel with
0.2-0.3% TFA/CH2Cl2. 1H NMR (500 MHz, CDCl3): ' 2.31 [ 2.39 (m, 2H), 2.77 [ 2.85 (m,
2H), 4.19 (t, J = 6.2 Hz, 1H), 7.21 [ 7.31 (m, 5H).65
(S)-2-bromo-4-methylpentanoic acid (133d)
Compound 133d was obtained from 132d (10.15 g, 77.4 mmol) as a clear oil (5.075
g, 34% isolated yield) following chromatographic purification over silica gel with 0.2%
TFA/CH2Cl2. 1H NMR (500 MHz, CDCl3):    0.93 (d, J = 6.6 Hz, 3H), 0.98 (d, J = 6.7 Hz,
3H), 1.82 (m, 1H), 1.92 (t, J = 7.3 Hz, 2H), 4.30 (t, J = 7.7 Hz, 1H).56
5.4 General Procedure for Conversion of %-Bromoacids to Benzyl %-Bromoesters
(125a-d)
The %-bromoacid 133a-d (0.96[65.6 mmol) in a round-bottom flask was
dissolved in H2O:MeOH (1.5:0.15 mL/mmol) and stirred at room temperature. A solution
of 20% aq Cs2CO3 was added until the pH was ~8[9 as measured by indicator paper.
The solution was concentrated and benzyl bromide (1.25 equiv) in DMF (1 mL/mmol)
was added. The solution was stirred at room temperature for 5-24 h. The reaction was
quenched with brine and extracted three times with ether. The organic layers were
washed three times with excess water to remove any remaining DMF and dried over
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Na2SO4 and concentrated. The crude product was purified on silica gel chromatography
with 1[3% ethyl acetate/hexanes to give pure product 125a-d as an oil (R = CH3, 42%;
R = CH2Ph, 48%; R = CH2CH2Ph, 60%; R = CH2CH(CH3)2, 78%).
Benzyl (±)-2-bromopropanoate (125a)
Compound (±)-125a was obtained from (±)-133a (10.03 g, 65.6 mmol) as an oil (6.77
g, 42% isolated yield) following chromatographic purification over silica gel with 1% ethyl
acetate/hexanes. 1H NMR (500 MHz, CDCl3): ' 1.70 (d, J = 7.0 Hz, 3H), 4.27 [ 4.31 (m,
1H), 5.05 [ 5.11 (m, 2H), 7.21 [ 7.27 (m, 5H). 13C NMR (500 MHz, CDCl3): ' 21.7, 40.2,
67.6, 128.2, 128.4, 128.5, 128.7, 135.4, 170.0.
Benzyl 2-bromo-3-phenylpropanoate (125b)
Compound 125b was obtained from 133b (1.685 g, 8.09 mmol) as an oil (1.235 g,
48% isolated yield) following chromatographic purification over silica gel with 3% ethyl
acetate/hexanes. [%]27D +0.2° (c = 1.0, MeOH); 1H NMR (500 MHz, CDCl3): ' 3.24 [ 3.28
(m, 1H), 3.45 [ 3.49 (m, 1H), 4.44 (t, J = 7.0 Hz, 1H), 5.14 (s, 2H), 7.16 [ 7.18 (m, 2H),
7.24 [ 7.28 (m, 5H), 7.32 [ 7.34 (m, 3H). 13C NMR (500 MHz, CDCl3): ' 41.2, 45.3, 67.6,
127.4, 128.3, 128.5, 128.7, 128.8, 129.3, 135.1, 136.7, 169.3.
Benzyl 2-bromo-4-phenylbutanoate (125c)
Compound 125c was obtained from (S)-133c (3.140 g, 12.9 mmol) as an oil (2.585
g, 60% isolated yield) following chromatographic purification over silica gel with 1% ethyl
acetate/hexanes. [%]27D -0.3° (c = 1.0, MeOH); 1H NMR (500 MHz, CDCl3): ' 2.28 [ 2.42
(m, 2H), 2.67 [ 2.81 (m, 2H), 4.20 (t, J = 6.4 Hz, 1H), 5.19 (s, 2H), 7.14 [ 7.16 (m, 2H),
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7.19 [ 7.22 (m, 1H), 7.26 [ 7.29 (m, 3H), 7.30 [ 7.38 (m, 5H). 13C NMR (500 MHz,
CDCl3): ' 32.1, 35.2, 44.1, 66.5, 125.4, 127.2, 127.5, 127.5, 127.6, 134.1, 138.7, 168.4.
(S)-Benzyl 2-bromo-4-methylpentanoate (125d)
Compound 125d was obtained from (S)-133d (5.075 g, 26.0 mmol) as an oil (5.760
g, 78% isolated yield) following chromatographic purification with 1-2% ethyl
acetate/hexanes. [%]27D -22.5° (c = 1.0, MeOH); 1H NMR (500 MHz, CDCl3):    0.92 (d, J
= 6.6 Hz, 3H), 0.97 (d, J = 6.6 Hz, 3H), 1.78 (m, 1H), 1.90 [ 1.94 (m, 2H), 4.34 (t, J = 7.3
Hz, 1H), 5.23 (s, 2H), 7.40 (m, 5H). 13C NMR (500 MHz, CDCl3): ' 21.5, 22.3, 26.3, 43.4,
44.5, 67.5, 128.2, 128.4, 128.6, 135.2, 169.8.
Anal. Calcd. for C13H17Br: C, 54.75%; H, 6.01%; Br, 28.02%. Found: C, 54.81%; H,
5.92%; Br, 28.06%.
5.5 General Procedure for the Optimization of the N-Alkylation of Resin-Bound Amino
Acids with Benzyl %-Bromoesters
Fmoc-Phe-Wang resin 128 (72 mg, 0.70 mmol/g, 50 )mol) was added to a solid-
phase reaction vessel (3 mL) and swelled in 2:1 CH2Cl2/DMF for 1 h. The resin was
filtered, a solution of 20% piperidine/DMF (2 mL) was added, and the vessel was rotated
at room temperature for 30 min. The resin was filtered and washed with DMF (3 x 2 mL).
A mixture of the %-bromoester (125a-c) and triethylamine in DMF (0.5 mL) was added at
the equivalents indicated (Section 3.1.3-4). If the presence of tetrabutylammonium iodide
(TBAI) was being tested, it was then added to the vessel as a solid. The resin was
heated at 50 °C for the indicated time (2-4 d). The vessels were allowed to cool to room
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temperature and the resin was washed with DMF (3 x 2 mL), MeOH (2 x 2 mL), THF (2 x
2 mL), and MeOH (3 x 2 mL). A solution of 95% TFA/H2O (2 mL) was added to each
vessel followed by rotation for 30 min to 1 h. The filtrate-containing product was
collected in tared vials and the cleavage solution was evaporated with a stream of
nitrogen. Each sample was analyzed by LC/MS and cyano-silica TLC plates (30%
acetone/hexanes). The products were purified by loading the crude product (12[18 mg)
onto a dry 500 mg cyano-silica cartridge with 200[300 )L of acetone and allowing the
column to dry with a stream of nitrogen. The column was washed with hexanes (2 x 2
mL) and eluted with 30% acetone/hexanes (8 x 1 mL). Fractions were analyzed by
cyano-silica TLC (30% acetone/hexanes) and pooled to afford the product as a white
solid upon evaporation.
N-[1-Phenylmethyl-2-oxo-2-(phenylmethoxy)ethyl]phenylalanine (137)
Compound 137 was obtained by N-alkylation with 125b (for conditions, see Table 1,
entry 1). Crude LC/MS purity 36%, tR = 7.8, 8.2 (dr 56:44 to 46:54); 1H NMR (500 MHz,
CDCl3): ' 2.64 [ 2.78 (m, 1H), 2.87 [ 3.06 (m, 3H), 3.18 [ 3.51 (m, 2H), 5.00 [ 5.15 (m,
2H), 6.75 (d, J = 7.6 Hz, 1H), 6.95 (d, J = 7.5 Hz, 1.5H), 7.04 (d, J = 7.2 Hz, 1.5H), 7.11
[ 7.19 (m, 4H), 7.28 [ 7.31 (m, 4H), 7.36 [ 7.38 (m, 3H).
Mono(phenylmethyl) -[(1-carboxy-2-phenylethyl)amino]benzenebutanoate (138)
Compound 138 was obtained by N-alkylation with 125c (for optimal conditions, see
Scheme 50 and Table 2, entry 15). Crude LC/MS purity 63%, tR = 9.6, 10.1 (dr 56:44);
1H NMR (500 MHz, CDCl3): ' 1.97 [ 2.04 (m, 2H), 2.24 [ 2.50 (m, 2H), 3.08 [ 38 (m,
2.5H), 3.71 [ 3.72 (m, 1.5H), 4.94 [ 5.06 (m, 2H), 6.85 (d, J = 6.9 Hz, 1H), 6.90 (d, J =
7.0 Hz, 1H), 7.06 [ 7.23 (m, 13H).
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N-[1-Methyl-2-oxo-2-(phenylmethoxy)ethyl]phenylalanine (140)
Compound 140 was obtained by N-alkylation with (±)-125a (for optimal conditions,
see Scheme 52 and Table 3, entry 12). Crude LC/MS purity 81%, tR = 6.5, 6.8 (dr 52:48
to 45:54); 1H NMR (500 MHz, CDCl3): ' 1.37 (d, J = 7.0 Hz, 1.2H), 1.41 (d, J = 7.1 Hz,
1.7H), 3.13 [ 3.20 (m, 1H), 3.32 [ 3.48 (m, 1.5H), 3.80 [ 3.89 (m, 1.5H), 5.01 [ 5.06 (m,
2H), 7.21 [ 7.33 (m, 10H).
5.6 General Procedure for the Evaluation of Alkylating Agents in the Synthesis of
Unnatural Amino Acids
An isopycnic solution of the benzophenone imine of glycine resin (BIG-Wang,
0.84 mmol/g) was prepared by mixing the resin in a solution of NMP/CH2Cl2 (13:7). The
isopycnic solution was distributed evenly (150 )mol each) to six solid-phase reaction
vessels (5 mL) by equally repeated dispenses using an autopipetter. The solvent was
drained from the resin. For the reactions involving 2 equivalents of the alkylating reagent
and BTPP, a solution of 0.2 M BTPP (1.5 mL, 300 )mol) was added to the resin and
allowed to mix with the resin for 5 min. A solution of 0.2 M of each alkylating reagent
(R1X, 1.5 mL, 300 )mol) was then added to its corresponding reaction vessel. For the
reactions involving 10 equivalents of the alkylating reagent and BTPP, 0.375 mL of NMP
was added to the resin followed by 0.75 mL of 2.0 M BTPP (1.5 mmol, 10 equiv) and
mixed for 5 min. A solution of 1.33 M of each alkylating reagent (R1X, 1.2 mL, 1.5 mmol,
10 equiv) was added to its corresponding reaction vessel. The reactions were rotated at
room temperature for 24 hrs.
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The reagents were filtered off, and the resin was washed with NMP (2 x 2 mL)
and THF (2 x 2 mL). The benzophenone imine was hydrolyzed by adding 1 N HCl/THF
(2 mL, 1:2) to each reaction vessel and rotating the resin for 20 min. The reagents were
filtered off, and the resin was washed with THF (2 x 2 mL), 10% DIEA/CH2Cl2 (3 x 2 mL),
and DMF (3 x 2 mL). To each reaction vessel was added a solution of benzyl 2-
bromopropanoate (0.4 M, 1.5 mL, 600 )mol, 4 equiv) followed by triethylamine (31 )L,
225 )mol. 1.5 equiv). The reactions were heated in an oven at 55 °C for 3 d.
The reagents were filtered off, and the resin was washed with DMF (2 x 2 mL),
THF (2 x 2 mL), and CH2Cl2 (3 x 2 mL). The products were cleaved from the resin by
95% TFA/H2O (2 mL) to each reaction vessel and rotating at room temperature for 1 h.
The cleavage solutions were collected in tared vials, washed with CH2Cl2 (1 x 2 mL), and
evaporated down under a stream of nitrogen. The crude yield was recorded and the
purity was analyzed by LC/MS.
The crude products were analyzed by cyano-silica gel TLC (30%
acetone/hexanes). Each sample was purified by loading the crude product (29[74 mg)
onto a dry 500 mg cyano-silica cartridge with 200[300 )L of acetone and allowing the
column to dry with a stream of nitrogen or by standing overnight. The column was
equilibrated with hexanes (2 x 2 mL) and eluted with a gradient of 10[40%
acetone/hexanes based on the TLC profile. Fractions were analyzed by cyano-silica TLC
(30% acetone/hexanes) and pooled to afford products 138. Analytical data for these
products is given following their combinatorial preparation (see Section 5.7).
5.7 General Procedure for the Synthesis of N-Carboxyalkyl Amino Acid Analogs
For each of the 3 Bill-Boards depicted in Scheme 56, an isopycnic solution of the
benzophenone imine of glycine resin (BIG-Wang, 0.84 mmol/g) was prepared by mixing
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the resin (3.61 g, 3.03 mmol) in a solution of NMP/CH2Cl2 (13:7). The isopycnic solution
was distributed evenly (150 )mol) to the twenty solid-phase reaction vessels (5 mL) by
equally repeated dispenses using an autopipetter. The solvent was drained and the resin
for each reaction vessel was washed with CH2Cl2 (1 mL). For the reactions involving 2
equivalents of the alkylating reagent and BTPP, a solution of 0.2 M BTPP in NMP (1.5
mL, 300 )mol) was added to the resin and allowed to mix with the resin for 5 min. A
solution of 0.2 M of each alkylating reagent in NMP (R1X, 1.5 mL, 300 )mol) was then
added to its corresponding reaction vessel. For the reactions involving 10 equivalents of
the alkylating reagent and BTPP, 0.375 mL of NMP was added to the resin followed by
2.0 M BTPP in NMP (0.75 mL, 1.5 mmol, 10 equiv) and mixed for 5 min. A solution of
1.33 M of each alkylating reagent in NMP (R1X, 1.2 mL, 1.5 mmol, 10 equiv) was added
to its corresponding reaction vessel. The reactions were rotated at room temperature for
24 hrs.
The reagents were filtered off, and the resin was washed with NMP (2 x 2 mL)
and THF (2 x 2 mL). The benzophenone imine was hydrolyzed by the addition of 1 N
HCl/THF (2 mL, 1:2) to each reaction vessel and rotating the resin for 20 min. The
hydrolysis solution was filtered off, and the resin was washed with THF (2 x 2 mL), 10%
DIEA/CH2Cl2 (3 x 2 mL), and DMF (3 x 2 mL). To each reaction vessel was added a 0.4
M solution of the %-bromoester in DMF (1.5 mL, 600 )mol, 4 equiv [ Bill-Board #1:
benzyl 2-bromopropanoate; Bill-Board #2: benzyl 2-bromo-4-methylpentanoate; Bill-
Board #3: benzyl 2-bromo-4-phenylbutanoate), followed by triethylamine (31 )L, 225
)mol. 1.5 equiv). The reactions were heated in an oven at 55 °C for 3 d.
The reagents were filtered off, and the resin was washed with DMF (2 x 2 mL),
THF (2 x 2 mL), and CH2Cl2 (3 x 2 mL). The products were cleaved from the resin by
adding 95% TFA/H2O (2 mL) to each reaction vessel and rotating at room temperature
for 1 h. The cleavage solutions were collected in tared vials, washed with CH2Cl2 (1 x 2
mL), and evaporated under a stream of nitrogen. The crude yield was recorded and the
purity of each sample was analyzed by LC/MS.
The crude products were analyzed by cyano-silica gel TLC with acetone-hexanes
(1:2). Each sample was purified by loading the crude product (29 [ 82 mg) onto a dry 1 g
cyano-silica cartridge with acetone (300-400 )L) and allowing the column to dry with a
stream of nitrogen or by standing overnight. The column was equilibrated with hexanes
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(2 x 2 mL) and eluted with a gradient of 10-40% acetone/hexanes based on the TLC
profile. Fractions were analyzed by cyano-silica TLC (30% acetone/hexanes) and pooled
to afford products 126 as a mixture of diastereomers. For Bill-Board #3 where the %-
bromoester was benzyl 2-bromo-4-phenylbutanoate and the dialkylated by-product was
observed, the samples, following purification on the cyano-silica cartridges, were further
purified on reverse-phase PrepLC using an isocratic system of 30:70 organic/aqueous
for more polar analogs, 50:50 organic/aqueous for most of the analogs, and 70:30
organic/aqueous for the more lipophilic analogs. The dialkylated material was eluted with
80:20 organic/aqueous and the column washed with 100:0 organic/aqueous. The
diastereomers were separated by this method for most of the analogs from Bill-Board
#3. Results for each of the 30 analogs, produced in duplicate, are shown in Table 1
(page 69). The diastereomeric ratios in the LC/MS results below are reported in the
order of elution from the column. The identification of the diastereomers in the 1H NMR
data below is designated as diastereomer A being the more abundant diastereomer and
diastereomer B being the least abundant diastereomer based on integration areas. The
more abundant diastereomer in the 1H NMR spectra does not necessarily correspond to
the more prevalent diastereomer indicated by LC/MS, since the purification of the crude
material may have altered this ratio due to possible salt formation of the diastereomers
that did not elute from the column (see discussion on page 46). Analog 157 was also
analyzed by 2D NMR experiments (COSY, DEPT-90, DEPT-135, HSQC, and HMBC) to
try and separate the diastereomer signals in the 1H and 13C NMR. A table correlating the
proton and carbon signals can be seen in Appendix B. For analogs 169-178 where
diastereomers were separated, the HRMS data is reported for both diastereomers in
which diastereomer 1 corresponds to the diastereomer that eluted first from the column
and first on the LC/MS and diastereomer 2 corresponds to the diastereomer that eluted
second from the column and second on the LC/MS.
N-[1-Methyl-2-oxo-2-(phenylmethoxy)ethyl]phenylalanine (151)
Compound 151 was obtained with benzyl bromide and benzyl (±)-2-
bromopropanoate as a white solid (sample 1: 25.8 mg, 53% isolated yield; sample 2:
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25.1 mg, 51% isolated yield) following chromatographic purification over cyano-silica gel
with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 72% (sample 1) and 66%
(sample 2), tR = 6.3, 6.6 min (dr 50:50); 1H NMR (500 MHz, CDCl3):    1.37 (diastereomer
B, d, J = 7.2 Hz, 1.5 H), 1.41 (diastereomer A, d, J = 7.2 Hz, 1.5 H), 3.12 [ 3.21 (m, 1H),
3.31 (diastereomer A, dd, J = 14.4 Hz, J = 5.4 Hz, 0.59 H), 3.42 (diastereomer B, dd, J =
14.5 Hz, 5.2 Hz, 0.48 H), 3.52 (diastereomer B, q, J = 7.2 Hz, 0.47H), 3.80
(diastereomer A, q, J = 7.1 Hz, 0.56H), 3.82 [ 3.87 (m, 1H), 5.04 [ 5.11 (m, 2H), 7.23 [
7.35 (m, 10H), 7.95 (s). 13C NMR (500 MHz, CDCl3): ' 15.4, 16.7, 36.4, 37.0, 55.7, 55.9,
61.9, 68.0, 127.5, 127.6, 128.4, 128.4, 128.7, 128.7, 128.8, 129.0, 129.0, 129.2, 129.4,
134.5, 134.5, 134.9, 135.8. HRMS calcd for (M + H)+: C19H21NO4 328.1549, found
328.1545.
N-[1-Methyl-2-oxo-2-(phenylmethoxy)ethyl]-4-methylphenylalanine (152)
Compound 152 was obtained with 4-methylbenzyl bromide and benzyl (±)-2-
bromopropanoate as a white solid (sample 1: 22.5 mg, 44% isolated yield; sample 2:
20.3 mg, 40% isolated yield) following chromatographic purification over cyano-silica gel
with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 68% (sample 1) and 76%
(sample 2), tR = 7.3, 7.6 min (dr 54:46); 1H NMR (500 MHz, CDCl3): ' 1.32 (diastereomer
B, d, J = 7.1 Hz, 2H), 1.38 (diastereomer A, d, J = 7.1 Hz, 1H), 2.29 (diastereomer B, s,
2H), 2.30 (diastereomer A, s, 1H), 3.06 [ 3.10 (m, 1H), 3.22 (diastereomer A, dd, J =
14.3 Hz, J = 10.4 Hz, 0.3H), 3.35 (diastereomer B, dd, J = 14.5 Hz, J = 4.9 Hz, 0.7H),
3.45 (diastereomer B, q, J = 7.1 Hz, 0.7H), 3.63 [ 3.70 (m, 0.7H), 3.74 [ 3.76 (m, 0.6H),
5.13 [ 5.05 (m, 2H), 7.09 [ 7.15 (m, 4H), 7.25 [ 7.38 (m, 5H). 13C NMR (500 MHz,
CDCl3): ' 21.0, 21.1, 36.3, 55.9, 56.0, 61.8, 61.9, 67.8, 67.9, 128.4, 128.7, 128.7, 128.8,
129.0, 129.2, 129.7, 129.8, 131.0, 131.7, 132.5, 134.6, 134.7, 137.2, 137.3, 172.3.
HRMS calcd for (M + H)+: C20H23NO4 342.1705, found 342.1721.
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N-[1-Methyl-2-oxo-2-(phenylmethoxy)ethyl]-4-chlorophenylalanine (153)
Compound 153 was obtained with 4-chlorobenzyl bromide and benzyl (±)-2-
bromopropanoate as a white solid (sample 1: 14.6 mg, 27% isolated yield; sample 2: 7.0
mg, 13% isolated yield) following chromatographic purification over cyano-silica gel with
acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 67% (sample 1) and 72% (sample
2), tR = 7.6, 7.9 min (dr 51:49); 1H NMR (500 MHz, DMSO): ' 1.14 (diastereomer B, d, J
= 6.9 Hz, 1.4H), 1.17 (diastereomer A, d, J = 6.9 Hz, 1.5H), 2.77 [ 2.91 (m, 2H), 3.31 [
3.35 (m, 0.5 H), 3.38 [ 3.46 (m, 1.5H), 5.05 [ 5.12 (m, 2H), 7.19 [ 7.23 (m, 2H), 7.28 [
7.39 (m, 7H). 13C NMR (500 MHz, DMSO): ' 18.3, 18.4, 37.7, 37.8, 54.2, 59.7, 60.0,
65.5, 65.6, 127.7, 127.7, 127.8, 127.9, 128.3, 130.8, 130.8, 130.9, 131.1, 135.9, 136.0,
136.8, 137.0. HRMS calcd for (M + H)+: C19H20ClNO4 362.1159, found 362.1176.
N-[1-Methyl-2-oxo-2-(phenylmethoxy)ethyl]-4-trifluoromethylphenyl-alanine (154)
Compound 154 was obtained with 4-trifluoromethylbenzyl bromide and benzyl
(±)-2-bromopropanoate as a white solid (sample 1: 18.5 mg, 31% isolated yield; sample
2: 21.6 mg, 36% isolated yield) following chromatographic purification over cyano-silica
gel with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 64% (sample 1) and 59%
(sample 2), tR = 8.0, 8.3 min (dr 49:51); 1H NMR (500 MHz, DMSO): ' 1.15
(diastereomer B, d, J = 6.9 Hz, 1.4H), 1.19 (diastereomer A, d, J = 6.9 Hz, 1.6H), 2.89 [
3.02 (m, 2H), 3.38 (diastereomer A, q, J = 6.8 Hz, 0.6H), 3.45 (diastereomer B, q, J = 6.9
Hz, 0.6H), 3.51 [ 3.56 (m, 1H), 5.05 [ 5.13 (m, 2H), 7.32 [ 7.38 (m, 5H), 7.41 [ 7.45 (m,
2H), 7.58 [ 7.62 (m, 2H). 13C NMR (500 MHz, DMSO): ' 18.3, 18.3, 38.0, 38.1, 54.1,
54.2, 59.5, 59.7, 65.5, 65.7, 123.3, 124.6, 124.6, 124.7, 124.7, 124.7, 125.4, 126.5,
126.7, 127.0, 127.8, 127.8, 127.9, 128.3, 129.9, 130.1, 135.9, 135.9, 142.7, 143.0.
HRMS calcd for (M + H)+: C20H20F3NO4 396.1423, found 396.1441.
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-[[2-Oxo-2-(phenylmethoxy)-1-(methyl)ethyl]amino]-&$%+-naphthylpropanoic acid
(155)
Compound 155 was obtained with 2-(bromomethyl)naphthalene and benzyl (±)-
2-bromopropanoate as a yellow oil (sample 1: 20.0 mg,35% isolated yield; sample 2:
13.5 mg, 24% isolated yield) following chromatographic purification over cyano-silica gel
with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 67% (sample 1) and 67%
(sample 2), tR= 8.1, 8.3 (dr unavailable due to overlapping peaks); 1H NMR (500 MHz,
CDCl3): ' 1.15 (diastereomer B, d, J = 7.0 Hz, 1.9H), 1.30 (diastereomer A, d, J = 7.0
Hz, 0.9H), 3.14 [ 3.19 (m, 0.7H), 3.20 [ 3.25 (m, 0.5H), 3.30 (diastereomer B, q, J = 7.2
Hz, 0.8H), 3.33 [ 3.37 (m, 0.5H), 3.44 [ 3.45 (m, 0.6H), 3.47 [ 3.51 (m, 0.5H), 3,61 [
3.65 (m, 1H), 3.68 [ 3.71 (m, 1H), 5.01 [ 5.11 (m, 1H), 7.21 [ 7.24 (m, 2H), 7.32 [ 7.36
(m, 4H), 7.46 [ 7.52 (m, 2H), 7.68 (s, 1H), 7.77 [ 7.82 (m, 3H). 13C NMR (500MHz,
CDCl3) : ' 15.7, 29.3, 31.7, 36.6, 53.8, 55.8, 56.0, 51.8, 68.0, 68.0, 126.1, 126.4, 126.5,
126.6, 126.8, 127.7, 127.8, 127.8, 128.3, 128.4, 128.7, 128.7, 128.8, 129.0, 132.2,
132.5, 133.1, 133.4, 133.5, 134.3, 172.0. HRMS calcd for (M + H)+: C23H23NO4
378.1705, found 378.1712.
-[[2-Oxo-2-(phenylmethoxy)-1-(methyl)ethyl]amino]-3-diphenylpropanoic acid
(156)
Compound 156 was obtained with bromodiphenylmethane and benzyl (±)-2-
bromopropanoate as a yellow oil (sample 1: 6.0 mg, 10% isolated yield; sample 2: 10.0
mg, 17% isolated yield) following chromatographic purification over cyano-silica gel with
acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 82% (sample 1) and 89% (sample
2), tR = 5.5, 6.0 min (dr 55:45); 1H NMR (500 MHz, CDCl3): ' 1.30 (diastereomer B, d, J
= 7.1 Hz, 1.4H), 1.32 (diastereomer A, d, J = 7.1 Hz, 1.6H), 3.48 [ 3.52 (diastereomer
B, m, 0.4H), 3.85 [ 3.90 (diastereomer A, m, 0.6H), 4.34 (d, J = 9.0 Hz, 0.5H), 4.42 [
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4.47 (m, 1H), 4.58 (d, J = 9.1 Hz, 0.5H), 5.02 (diastereomer B, d, J = 12.2 Hz, 0.45H),
5.08 (diastereomer B, d, J = 12.2 Hz, 0.45H), 5.16 (diastereomer A, d, J = 12.1 Hz,
0.8H), 5.23 (diastereomer A, d, J = 12.0 Hz, 0.6H), 7.21 [ 7.38 (m,15H), 8.56 (s). HRMS
calcd for (M + H)+: C25H25NO4 404.1862, found 404.1871.
-[[2-Oxo-2-(phenylmethoxy)-1-(methyl)ethyl]amino]-3$'+-(2-chloro-pyridinyl)-
propanoic acid (157)
Compound 157 was obtained with 5-(chloromethyl)-2-chloropyridine and benzyl
(±)-2-bromopropanoate as a yellow, oily solid (sample 1: 11.9 mg, 22% isolated yield;
sample 2: 15.2 mg, 28% isolated yield) following chromatographic purification over
cyano-silica gel with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 55% (sample
1) and 60% (sample 2), tR = 5.6, 5.9 (dr 53:47); 1H NMR (500 MHz, DMSO): ' 1.14
(diastereomer B, d, J = 7.0 Hz, 1.1H), 1.18 (diastereomer A, d, J = 6.9 Hz, 1.8H), 2.79 [
2.95 (m, 2H), 3.38 [ 3.49 (m, 2H), 5.05 [ 5.13 (m, 2H), 7.30 [ 7.42 (m, 6H), 7.69 [ 7.72
(m, 1H), 8.24 (s, 1H). 13C NMR (500 MHz, DMSO): ' 18.3, 18.4, 34.2, 34.5, 54.1, 54.1,
59.2, 59.4, 65.5, 65.7, 123.3, 123.4, 127.7, 127.8, 127.9, 127.9, 128.3, 133.0, 133.1,
135.9, 135.9, 140.4, 140.6, 148.1, 148.1, 150.3, 150.4, 173.6, 174.1, 174.3. HRMS calcd
for (M + H)+: C18H19ClN2O4 363.1111, found 363.1130.
-[[2-Oxo-2-(phenylmethoxy)-1-(methyl)ethyl]amino]-4-phenylbutanoic acid (158)
Compound 158 was obtained with (2-bromoethyl)benzene and benzyl (±)-2-
bromopropanoate as a yellow oil (sample 1: 11.1 mg, 22% isolated yield; sample 2: 19.4
mg, 38% isolated yield) following chromatographic purification over cyano-silica gel with
acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 69% (sample 1) and 75% (sample
2), tR = 7.2, 7.4 (dr 45:55); 1H NMR (500 MHz, DMSO): ' 1.25 (diastereomer B, d, J =
6.9 Hz, 0.7H), 1.29 (diastereomer A, d, J = 6.9 Hz, 2.2H), 1.81 [ 1.91 (m, 2H), 2.57 [
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2.71 (m, 2H), 3.27 (diastereomer B, t, J = 5.9 Hz, 0.3H), 3.35 (diastereomer A, s, 0.8H),
3.50 [ 3.52 (diastereomer B, m, 0.3H), 3.59 [ 3.60 (diastereomer A, m, 0.8H), 5.07 [
5.16 (m, 2H), 7.16 [ 7.19 (m, 3H), 7.26 [ 7.29 (m, 2H), 7.32 [ 7.35 (m, 1H), 7.36 [ 7.38
(m, 4H). 13C NMR (500 MHz, DMSO): ' 17.8, 31.0, 31.1, 33.7, 33.9, 54.3, 54.2, 57.9,
58.3, 65.8, 125.8, 127.8, 128.0, 128.2, 128.2, 128.2 128.3, 135.8, 141.2, 172.9, 174.3.
HRMS calcd for (M + H)+: C20H23NO4 342.1705, found 342.1718.
Mono(phenylmethyl) -[[(1-carboxy-1-methyl)ethyl]amino]-2-cyclohexylethanoate
(159)
Compound 159 was obtained with cyclohexyl iodide and benzyl (±)-2-
bromopropanoate as a yellow oil (sample 1: 10.0 mg, 21% isolated yield; sample 2: 7.6
mg, 16% isolated yield) following chromatographic purification over cyano-silica gel with
acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 65% (sample 1) and 65% (sample
2), tR = 6.9, 7.3 (dr 56:44); 1H NMR (500 MHz, DMSO): ' 1.05 [ 1.21 (m, 5H), 1.34 [
1.36 (m, 3H), 1.61 (s, 3H), 1.67 [ 1.69 (m, 3H), 3.37 (s, 1H), 3.71 (s, 1H), 5.11 [ 5.20
(m, 2H), 7.34 [ 7.39 (m, 5H). 13C NMR (500 MHz, DMSO): ' 25.4, 25.4, 25.6, 28.3, 54.9,
64.0, 128.0, 128.1, 128.3, 135.6. HRMS calcd for (M + H)+: C18H25NO4 320.1862, found
320.1864.
-[[2-Oxo-2(phenylmethoxy)-1-(methyl)ethyl]amino]hexanoic acid (160)
Compound 160 was obtained with n-butyl iodide and benzyl (±)-2-
bromopropanoate as a yellow oil (sample 1: 6.2 mg, 14% isolated yield; sample 2: 18.9
mg, 43% isolated yield) following chromatographic purification over cyano-silica gel with
acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 59% (sample 1) and 63% (sample
2), tR = 6.1, 6.2 (dr unavailable due to overlapping peaks); 1H NMR (500 MHz, DMSO): '
0.84 (t, J = 6.9 Hz, 3H), 1.25 [ 1.28 (m, 4H), 1.32 (d, J = 6.9 Hz, 3H), 1.57 [ 1.65 (m,
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2H), 3.45 (s, 1H), 3.69 (s, 1H), 5.12 [ 5.19 (m, 2H), 7.33 [ 7.36 (m, 1H), 7.38 [ 7.39 (m,
4H). 13C NMR (500 MHz, DMSO): ' 13.7, 17.2, 21.7, 27.0, 54.2, 58.6, 66.1, 127.9,
128.1, 128.4, 135.6. HRMS calcd for (M + H)+: C16H23NO4 294.1705, found 294.1731.
N-[1-Isobutyl-2-oxo-2-(phenylmethoxy)ethyl]phenylalanine (161)
Compound 161 was obtained with benzyl bromide and benzyl (S)-2-bromo-4-
methylpentaoate as a yellow oil (sample 1: 16.9 mg, 30% isolated yield; sample 2: 11.0
mg, 20% isolated yield) following chromatographic purification over cyano-silica gel with
acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 39% (sample 1) and 39% (sample
2), tR = 8.4, 9.3 min (dr 62:38); 1H NMR (500 MHz, CDCl3):    0.66 (d, J = 6.5 Hz, 1.1H),
0.71 (d, J = 6.5 Hz, 1.2H), 0.81 [ 0.84 (diastereomer A, m, 3.4H), 1.40 (diastereomer B,
m, 0.4H), 1.62 [ 1.68 (m, 2H), 1.70 [ 1.77 (diastereomer A, m, 0.6H), 3.19 [ 3.27 (m,
1H), 3.34 (diastereomer B, t, J = 7.1 Hz, 0.4H), 3.43 (diastereomer A, dd, J = 14.6 Hz, J
= 4.9 Hz, 0.6H), 3.52 (diastereomer B, dd, J = 14.8 Hz, J = 4.2 Hz, 0.4H), 3.79 [ 3.82
(diastereomer B, m, 0.4H), 3.85 [ 3.88 (diastereomer A, 0.6H), 3.93 (diastereomer A, t, J
= 6.7 Hz, 0.6H), 5.08 [ 5.15 (m, 2H), 7.26 [ 7.37 (m, 10H), 8.94 (s). 13C NMR (500 MHz,
CDCl3): ' 21.1, 21.7, 22.2, 22.6, 24.6, 24.6, 35.5, 36.4, 39.0, 39.6, 59.3, 59.5, 62.2, 62.8,
68.4, 68.5, 127.9, 128.0, 128.6, 128.6, 128.8, 129.0, 129.0, 129.1, 129.2, 129.3, 129.4,
134.1, 134.1, 135.2, 169.3, 169.4, 170.3, 170.9. HRMS calcd for (M + H)+: C22H27NO4
370.2018, found 370.2010.
N-[1-Isobutyl-2-oxo-2-(phenylmethoxy)ethyl]-4-methylphenylalanine (162)
Compound 162 was obtained with 4-methylbenzyl bromide and benzyl (S)-2-
bromo-4-methylpentaoate as a yellow oil (sample 1: 12.2 mg, 21% isolated yield; sample
2: 15.2 mg, 26% isolated yield) following chromatographic purification over cyano-silica
gel with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 41% (sample 1) and 41%
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(sample 2), tR = 9.2, 10.0 min (dr 62:38); 1H NMR (500 MHz, CDCl3):    0.66 (d, J = 6.5
Hz, 1.2H), 0.71 (d, J = 6.5 Hz, 1.3H), 0.81 [ 0.83 (diastereomer A, m, 3.5H), 1.40
(diastereomer B, septet, J = 6.7 Hz, 0.4H), 1.61 [ 1.68 (m, 2H), 1.70 [ 1.76
(diastereomer A, m, 0.6H), 2.28 (diastereomer B, s, 1.3H), 2.32 (diastereomer A, s,
1.7H), 3.16 [ 3.24 (m, 1H), 3.35 (diastereomer B, t, J = 7.1 Hz, 0.4H), 3.39
(diastereomer A, dd, J = 14.8 Hz, J = 4.9 Hz, 0.6H), 3.49 (diastereomer B, dd, J = 14.8
Hz, J = 4.1 Hz, 0.4H), 3.81 (diastereomer B, dd, J = 9.8 Hz, J = 4.2 Hz, 0.4H), 3.89
(diastereomer A, dd, J = 9.2 Hz, J = 4.9 Hz, 0.6H), 3.98 (diastereomer A, t, J = 6.7 Hz,
0.6H), 5.10 [ 5.16 (m, 2H), 7.09 [ 7.12 (m, 1H), 7.14 (s, 2H), 7.19 [ 7.21 (m, 1H), 7.25 [
7.29 (2H), 7.34 [ 7.38 (m, 3H), 9.29 (s). 13C NMR (500 MHz, CDCl3):    21.0, 21.0, 21.1,
21.7, 22.2, 22.5, 24.6, 24.7, 35.1, 35.9, 38.9, 39.4, 59.3, 59.5, 62.2, 62.9, 68.5, 68.6,
114.8, 117.1, 128.6, 128.6, 128.8, 129.0, 129.0, 129.3, 129.9, 130.0, 130.7, 131.8,
134.1, 137.7, 137.8, 169.1, 169.1, 170.2, 170.8. HRMS calcd for (M + H)+: C23H29NO4
384.2175, found 384.2171.
N-[1-Isobutyl-2-oxo-2-(phenylmethoxy)ethyl]-4-chlorophenylalanine (163)
Compound 163 was obtained with 4-chlorobenzyl bromide and benzyl (S)-2-
bromo-4-methylpentaoate as a yellow oil (sample 1: 13.4 mg, 22% isolated yield; sample
2: 15.6 mg, 26% isolated yield) following chromatographic purification over cyano-silica
gel with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 33% (sample 1) and 34%
(sample 2); tR = 9.3, 10.0 min (dr 61:39); 1H NMR (500 MHz, CDCl3):    0.70 (d, J = 6.6
Hz, 1.2H), 0.74 (d, J = 6.5 Hz, 1.2H), 0.82 [ 0.84 (diastereomer A, m, 3.5H), 1.44
(diastereomer B, septet, J = 6.8 Hz, 0.4H), 1.62 [ 1.73 (m, 2.6H), 3.18 [ 3.26 (m, 1H),
3.36 [ 3.40 (m, 1H), 3.46 (diastereomer B, dd, J = 14.9 Hz, 4.6 Hz, 0.4H), 3.77 [ 3.80
(diastereomer B, m, 0.4H), 3.85 [ 3.88 (diastereomer A, m, 0.6H), 3.97 (Diastereomer A,
t, J = 6.5 Hz, 0.6H), 5.12 [ 5.17 (m, 2H), 7.18 [ 7.19 (m, 1H), 7.23 [ 7.25 (m, 1H), 7.26 [
7.31 (m, 4H), 7.35 [ 7.39 (m, 3H), 9.40 (s). 13C NMR (500 MHz, CDCl3): ' 21.0, 21.7,
22.1, 22.5, 24.6, 24.7, 34.7, 35.6, 38.9, 39.4, 59.4, 59.4, 61.9, 62.5, 68.7, 68.8, 128.6,
128.7, 128.8, 128.9, 129.1, 129.2, 129.4, 129.5, 129.8, 130.1, 130.8, 132.4, 132.5,
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133.6, 133.9, 133.9, 134.1, 169.0, 169.2, 170.0, 170.6. HRMS calcd for (M + H)+:
C22H26ClNO4 404.1629, found 404.1614.
N-[1-Isobutyl-2-oxo-2-(phenylmethoxy)ethyl]-4-trifluoromethylphenylalanine (164)
Compound 164 was obtained with 4-trifluoromethylbenzyl bromide and benzyl
(S)-2-bromo-4-methylpentaoate as a yellow oil (sample 1: 13.8 mg, 21% isolated yield;
sample 2: 7.5 mg, 11% isolated yield) following chromatographic purification over cyano-
silica gel with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 29% (sample 1) and
28% (sample 2), tR = 9.5, 10.2 (dr 62:38); 1H NMR (500 MHz, CDCl3):    0.66 (d, J = 6.5
Hz, 1.1H), 0.71 (d, J = 6.6 Hz, 1.2H), 0.82 [ 0.84 (diastereomer A, m, 3.6H), 1.40
(diastereomer B, m, 0.4H), 1.60 [ 1.72 (m, 2.6H), 3.27 [ 3.33 (m, 1.4H), 3.43
(diastereomer A, dd, J = 14.7 Hz, J = 5.6 Hz, 0.6H), 3.54 (diastereomer B, dd, J = 14.7
Hz, J = 4.4 Hz, 0.4H), 3.77 [ 3.80 (diastereomer B, m, 0.4H), 3.86 [ 3.88 (diastereomer
A, m, 0.6H), 3.92 (diastereomer A, t, J = 6.4 Hz, 0.6H), 5.15 (m, 2H), 7.25 [ 7.31 (m,
2H), 7.35 [ 7.38 (m, 4H), 7.42 [ 7.44 (m, 1H), 7.55 [ 7.60 (m, 2H), 9.00 (s). 13C NMR
(500 MHz, CDCl3):    21.0, 21.8, 22.1, 22.5, 24.6, 24.7, 35.5, 36.3, 39.2, 39.9, 59.3, 61.7,
62.4, 68.5, 68.5, 114.8, 117.1, 122.9, 125.0, 125.1, 126.0, 126.0, 126.1, 128.6, 128.6,
128.8, 128.8, 129.1, 129.1, 129.6, 129.8, 130.0, 130.3, 131.1, 134.0, 134.1, 138.6,
139.7, 161.6, 161.9, 169.6, 170.0, 170.7, 171.0. HRMS cald for (M + H)+ C23H26F3NO4
438.1892, found 438.1881.
Mono(phenylmethyl) -[[(1-Carboxy-%$%+-naphthyl)ethyl]amino]-4-methyl-
pentanoate (165)
Compound 165 was obtained with 2-(bromomethyl)naphthalene and benzyl (S)-
2-bromo-4-methylpentaoate as a yellow oil (sample 1: 15.0 mg, 24% isolated yield;
sample 2: 15.0 mg, 24% isolated yield) following chromatographic purification over
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cyano-silica gel with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 40% (sample
1) and 37% (sample 2), tR = 9.6, 10.2 (dr 59:41); 1H NMR (500 MHz, CDCl3): ' 0.41 (d, J
= 6.5 Hz, 1.2H), 0.51 (d, J = 6.5 Hz, 1.2H), 0.77 [ 0.80 (diastereomer A, m, 3.5H), 1.24 [
1.30 (diastereomer B, m, 0.4H), 1.55 [ 1.68 (m, 2.6H), 3.25 (diastereomer B, t, J = 7.2
Hz, 0.4H), 3.35 [ 3.42 (m, 1.H), 3.54 (diastereomer B, dd, J = 14.6 Hz, J = 4.9 Hz, 0.6H),
3.67 (diastereomer B, dd, J = 14.7 Hz, J = 3.8 Hz, 0.4H), 3.87 [ 3.94 (m, 1.6H), 4.95 [
5.10 (m, 2H), 7.16 [ 7.20 (m, 2H), 7.30 [ 7.37 (m, 4H), 7.45 [ 7.49 (m, 2H), 7.77 [ 7.83
(m, 3.6H), 7.89 (Diastereomer B, s, 0.4H), 9.13 (s). 13C NMR (500 MHz, CDCl3):    20.9,
21.8, 22.1, 22.2, 24.5, 24.6, 36.0, 36.9, 39.2, 40.0, 53.4, 59.4, 59.5, 61.9, 62.7, 68.2,
68.2, 126.2, 126.3, 126.5 126.6, 126.7, 127.6, 127.7, 127.8, 127.9, 128.5, 128.7, 128.7,
128.8, 128.9, 128.9, 129.1, 129.2, 131.8, 132.7, 132.7, 132.8, 133.5, 133.6, 134.1,
134.2, 169.7, 170.0, 171.0, 171.3. HRMS calcd for (M + H)+ C26H29NO4 420.2175, found
420.2172.
Mono(phenylmethyl) -[[(1-Carboxy-2-diphenyl)ethyl]amino]-4-methylpentanoate
(166)
Compound 166 was obtained with bromodiphenylmethane and benzyl (S)-2-
bromo-4-methylpentaoate as a yellow oil (sample 1: 4.7 mg, 7% isolated yield; sample 2:
5.7 mg, 9% isolated yield) following chromatographic purification over cyano-silica gel
with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 20% (sample 1) and 23%
(sample 2), tR = 9.9, 10.9 min (dr 55:45); 1H NMR (500 MHz, CDCl3):    0.63 (d, J =
6.5Hz, 1.4H), 0.66 (d, J = 6.5 Hz, 1.3H), 0.74 [ 0.76 (diastereomer A, m, 3.3H), 1.26
(diastereomer B, m, 0.45H), 1.45 [ 1.57 (m, 2H), 1.62 [ 1.68 (diastereomer A, m,
0.55H), 3.51 (diastereomer B, t, J = 7.1 Hz, 0.45H), 4.02 [ 4.04 (diastereomer A, 0.55H),
4.37 [ 4.41 (m, 1H), 4.52 [ 4.55 (m, 1H), 5.11 (diastereomer B, d, J = 12.0 Hz, 0.4H),
5.13 (diastereomer B, d, J = 12.0 Hz, 0.5H), 5.23 (diastereomer A, d, J = 12.0 Hz, 0.6H),
5.29 (diastereomer A, d, J = 12.0 Hz, 0.5H), 7.17 [ 7.42 (m, 15H), 9.32 (s). 13C NMR
(500 MHz, CDCl3): ' 21.6, 22.2, 22.3, 24.5, 24.7, 39.8, 29.9, 52.3, 53.0, 59.1, 59.8, 64.5,
64.9, 68.2, 68.7, 127.7, 127.8, 128.0, 128.1, 128.1, 128.4, 128.5, 128.6, 128.7, 128.7,
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128.8, 128.9, 128.9, 129.0, 129.4, 129.7, 134.2, 134.4, 136.9, 138.2, 138.4, 138.7,
169.0, 169.9, 171.7. HRMS calcd for (M + H)+: C28H31NO4 446.2331, found 446.2309.
Mono(phenylmethyl) -[[(1-Carboxy-%$'+-(2-chloropyridine))ethyl]-amino]-4-methyl-
pentanoate (167)
Compound 167 was obtained with 5-(chloromethyl)-2-chloropyridine and benzyl
(S)-2-bromo-4-methylpentaoate as a yellow oil (sample 1: 9.4 mg, 15% isolated yield;
sample 2: 8.4 mg, 14% isolated yield) following chromatographic purification over cyano-
silica gel with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 21% (sample 1) and
19% (sample 2), tR = 7.6, 8.5 min (dr 67:33); 1H NMR (500 MHz, CDCl3): ' 0.81 (d, J =
3.1 Hz, 1.1H), 0.83 (d, J = 3.1 Hz, 1.2H), 0.85 [ 0.86 (diastereomer A, m, 3.4H), 1.58
(diastereomer B, m, 0.4H), 1.66 [ 1.80 (m, 2.6H), 3.32 [ 3.34 (m, 2H), 3.67 [ 3.71
(diastereomer B, m, 0.4H), 3.91 [ 3.93 (m, 1.6H), 5.13 [ 5.25 (m, 2H), 7.28 [ 7.38 (m,
6H), 7.68 [ 7.72 (m, 1H), 8.33 (s, 1H), 10.3 (s). 13C NMR (500 MHz, CDCl3):    21.4,
21.9, 22.0, 22.4, 24.7, 24.8, 32.5, 33.0, 39.2, 39.7, 59.5, 61.1, 68.5, 68.6, 124.9, 125.0,
128.6, 128.7, 128.8, 128.8, 129.0, 129.0, 130.0, 130.6, 134.1, 141.2, 141.4, 150.0,
150.0, 169.8, 170.0, 170.4. HRMS calcd for (M + H)+: C21H25ClN2O4 405.1581, found
405.1574.
Mono(phenylmethyl) -[[(1-Carboxy-3-phenyl)propyl]amino]-4-methylpentanoate
(168)
Compound 168 was obtained with (2-bromoethyl)benzene and benzyl (S)-2-
bromo-4-methylpentaoate as a yellow oil (sample 1: 4.2 mg, 7% isolated yield; sample 2:
12.6 mg, 22% isolated yield) following chromatographic purification over cyano-silica gel
with acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 35% (sample 1) and 35%
(sample 2), tR = 8.9, 9.9 min (dr 65:35); 1H NMR (500 MHz, CDCl3): ' 0.82 [ 0.84 (m,
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6H), 1.68 [ 1.69 (m, 3H), 2.11 [ 2.17 (m, 1H), 2.22 [ 2.28 (m, 1H), 2.71 [ 2.84 (m, 2H),
3.52 (t, J = 6.0 Hz, 1H), 3.79 (t, J = 6.0 Hz, 1H), 5.13 [ 5.22 (m, 2H), 7.12 [ 7.13 (m,
2H), 7.16 [ 7.19 (m, 1H), 7.22 [ 7.25 (m, 2H), 7.30 [ 7.33 (m, 2H), 7.34 [ 7.36 (m, 3H),
9.10 (s). 13C NMR (500 MHz, CDCl3):    21.9, 22.2, 24.6, 31.5, 32.6, 39.7, 59.4, 60.6,
68.5, 126.5, 128.5, 128.6, 128.7, 128.8, 128.9, 129.0, 134.1, 139.5, 169.5, 171.9. HRMS
calcd for (M + H)+: C23H29NO4 found 384.2165.
Mono(phenylmethyl) -[[(1-Carboxy-1-cyclohexyl)methyl]amino]-4-methyl-
pentanoate (169)
Compound 169 was obtained with cyclohexyl iodide and benzyl (S)-2-bromo-4-
methylpentaoate as a yellow oil (sample 1: 18.0 mg, 33% isolated yield; sample 2: 2.6
mg, 5% isolated yield) following chromatographic purification over cyano-silica gel with
acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 34% (sample 1) and 37% (sample
2), tR = 9.2, 10.8 min (dr 66:34); 1H NMR (500 MHz, DMSO):    0.84 [ 0.88 (m, 6H), 1.03
[ 1.23 (m, 5H), 1.55 [ 1.69 (m, 8H), 1.75 [ 1.80 (m, 1H), 3.53 (s, 1H), 3.77 (s, 1H), 5.13
[ 5.24 (m, 2H), 7.35 [ 7.41 (m, 5H). 13C NMR (500 MHz, DMSO):    21.7, 22.1, 22.3,
24.2, 24.2, 25.4, 25.6, 28.4, 28.5, 58.2, 64.4, 128.1, 128.2, 128.2, 128.3, 135.2, 157.7,
157.9. HRMS calcd for (M + H)+: C21H31NO4 362.2331, found 362.2327.
-[[2-Oxo-2-(phenylmethoxy)-1-(isobutyl)ethyl]amino]hexanoic acid (170)
Compound 170 was obtained with n-butyl iodide and benzyl (±)-2-
bromopropanoate as a yellow oil (sample 1: 14.4 mg, 29% isolated yield; sample 2: 14.2
mg, 28% isolated yield) following chromatographic purification over cyano-silica gel with
acetone-hexanes (1:4 to 2:5). Crude LC/MS purities 40% (sample 1) and 38% (sample
2), tR = 8.3, 9.4 min (dr 60:40); 1H NMR (500 MHz, CDCl3): ' 0.84 [ 0.95 (m, 2H), 1.25 [
1.33 (m, 2H), 1.35 [ 1.45 (m, 2H), 1.60 [ 1.66 (m, 0.5H), 1.71 [ 1.81 (m, 2H), 1.82 [
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1.96 (m, 2.5H), 3.58 (diastereomer A, t, J = 6.1 Hz, 0.6H), 3.65 (diastereomer B, t, J =
6.2 Hz, 0.4H), 3.88 [ 3.92 (m, 1H), 5.16 [ 5.30 (m, 2H), 7.31 [ 7.33 (m, 1H), 7.34 [ 7.39
(m, 4H), 10.2 (s). 13C NMR (500 MHz, CDCl3):    13.5, 13.5, 19.0, 21.3, 21.8, 22.1, 22.2,
22.2, 22.8, 24.6, 24.9, 27.3, 27.5, 29.5, 30.4, 38.6, 39.5, 58.9, 59.4, 60.8, 61.4, 68.6,
68.6, 128.7, 128.8, 128.8, 129.1, 134.1, 168.9, 169.0, 171.7, 171.9. HMRS calcd for (M
+ H)+: C19H29NO4 336.2175, found 336.2181.
Mono(phenylmethyl) 1-carboxy-2-(phenyl)ethyl]amino]benzenebutanoate (171)
Compound 171 was obtained with benzyl bromide and (S)-benzyl 2-bromo-4-
phenylbutanoate as a white solid (5.6 mg, 9% isolated yield [ 2.3 mg and 2.2 mg of
separate diastereomers and 1.1 mg of a mixture of diastereomers) following
chromatographic purification over cyano-silica gel with acetone-hexanes (1:4 to 2:5) and
over C18-silica gel with 0.1% TFA/CH3CN and H2O (50:50) by preparative liquid
chromatography. Crude LC/MS purities 51% (sample 1) and 45% (sample 2), tR = 9.3,
9.9 min (dr 56:44); Diastereomer 1 [ 1H NMR (500 MHz, CDCl3): ' 1.92 [ 1.94 (m, 1H),
1.99 [ 2.03 (m, 1H), 1.57 (t, J = 7.2 Hz, 2H), 3.04 [ 3.08 (m, 1H), 3.14 [ 3.16 (m, 1H),
3.37 (s, 1H), 3.50 (s, 1H), 5.08 (d, J 12.0 Hz, 1H), 5.11 (d, J = 12.0 Hz, 1H), 7.05 (d, J =
14.6 Hz, 2H), 7.20 [ 7.22 (m, 3H), 7.25 [ 7.27 (m, 2H), 7.30 [ 7.34 (m, 5H), 7.38 [ 7.41
(m, 3H). 13C NMR (500 MHz, CDCl3): ' 31.7, 34.8, 38.0, 60.6, 61.7, 67.2, 126.3, 127.5,
128.3, 128.6, 128.6, 128.7, 129.0, 129.4, 135.1, 135.3, 140.1, 173.0, 173.5.
Diastereomer 2 [ 1H NMR (500 MHz, CDCl3): ' 1.82 [ 1.88 (m, 2H), 2.31 [ 2.34 (m, 2H),
2.91 [ 2.96 (m, 1H), 3.19 [ 3.22 (m, 1H), 3.29 [ 3.32 (m, 1H), 3.5 (s, 1H), 5.09 (d, J =
11.8 Hz, 1H), 5.16 (d, J = 12.0 Hz, 1H), 6.93 (d, J = 14.6 Hz, 2H), 7.17 [ 7.20 (m, 1H),
7.23 [ 7.26 (m, 4H), 7.32 [ 7.35 (m, 4H), 7.36 [ 7.40 (m, 3H). 13C NMR (500 MHz,
CDCl3): ' 29.7, 31.2, 33.9, 38.4, 60.4, 67.4, 126.2, 127.4, 128.2, 128.5, 128.6, 128.7,
129.0, 129.3, 135.0, 136.4, 173.2. HRMS calcd for (M + H)+: C26H27NO4 418.2018, found
418.2017.
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Mono(phenylmethyl) -[[1-carboxy-2-(4-methylphenyl)ethyl]amino]benzene-
butanoate (172)
Compound 172 was obtained with 4-methylbenzyl bromide and (S)-benzyl 2-
bromo-4-phenylbutanoate as a white solid (sample 1: 8.4 mg, 13% isolated yield [ 5.4
mg and 3.0 mg of separate diastereomers; sample 2: 12.6 mg, 19% isolated yield [ 7.2
mg and 5.4 mg of separate diastereomers ) following chromatographic purification over
cyano-silica gel with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1%
TFA/CH3CN and H2O (50:50 organic/aqueous) by preparative liquid chromatography.
Crude LC/MS purities 55% (sample 1) and 52% (sample 2), tR = 9.9, 10.4 min (dr 56:44);
Diastereomer 1 [ 1H NMR (500 MHz, CDCl3): ' 1.90 [ 1.97 (m, 1H), 1.99 [ 2.07 (m, 1H),
2.34 (s, 3H), 2.47 [ 2.59 (m, 2H), 2.98 [ 3.04 (m, 1H), 3.09- 3.15 (m, 1H), 3.49 [ 3.50
(m, 1H), 3.56 [ 3.58 (m, 1H), 5.09 (d, J = 12.6 Hz, 1H), 5.11 (d, J = 12.6 Hz, 1H), 7.02
(d, J = 14.7 Hz, 2H), 7.08 [ 7.14 (m, 4H), 7.17 [ 7.20 (m, 1H), 7.23 [ 7.26 (m, 2H), 7.32
[ 7.34 (m, 2H), 7.36 [ 7.42 (m, 3H). 13C NMR (500 MHz, CDCl3): ' 21.1, 31.3, 33.6,
37.0, 60.0, 61.6, 67.6, 126.4, 128.3, 128.6, 128.6, 128.8, 128.8, 129.2, 129.2, 129.7,
129.9, 132.0, 134.8, 137.2, 139.8, 171.8, 173.2. Diastereomer 2 [ 1H NMR (500 MHz,
CDCl3):    1.89 (s, 2H), 2.29 (s, 3H), 2.33 [ 2.37 (m, 2H), 2.92 [ 2.97 (m, 1H), 3.27 [
3.29 (m, 2H), 3.56 (s, 1H), 5.06 (d, J = 12.0 Hz, 1H), 5.14 (d, J = 12.0 Hz, 1H), 6.91 (d, J
= 7.3 Hz, 2H), 7.10 (s, 4H), 7.15 [ 7.18 (m, 1H), 7.20 [ 7.23 (m, 2H), 7.30 [ 7.32 (m,
2H), 7.34 [ 7.37 (m, 3H). 13C NMR (500 MHz, CDCl3):    21.1, 29.7, 31.1, 33.5, 37.4,
60.2, 62.1, 67.5, 126.2, 128.2, 128.5, 128.6, 128.7, 129.1, 129.7, 133.2, 134.9, 137.1,
140.1, 172.4, 174.0. HRMS calcd for (M + H)+: C27H29NO4 432.2175, found 432.2189
(diastereomer 1) and 432.2168 (diastereomer 2).
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Mono(phenylmethyl) -[[1-carboxy-2-(4-chlorophenyl)ethyl]amino]benzene-
butanoate (173)
Compound 173 was obtained with 4-chlorobenzyl bromide and (S)-benzyl 2-
bromo-4-phenylbutanoate as a white solid (sample 1: 11.8 mg, 17% isolated yield [ 5.8
mg and 6.0 mg of separate diastereomers; sample 2: 7.0 mg, 10% isolated yield [ 3.0
mg and 4.0 mg of separate diastereomers) following chromatographic purification over
cyano-silica gel with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1%
TFA/CH3CN and H2O (50:50) by preparative liquid chromatography. Crude LC/MS
purities 55% (sample 1) and 52% (sample 2), tR = 9.9, 10.4 min (dr 59:41); Diastereomer
1 [ 1H NMR (500 MHz, CDCl3): ' 1.99 [ 2.07 (m, 2H), 2.58 (s, 2H), 3.08 [ 3.14 (m, 2H),
3.53 [ 3.56 (m, 2H), 5.12 (d, J = 13.0 Hz, 1H), 5.13 (d, J = 13.0 Hz, 1H), 6.28 (s), 7.03
(d, J = 3.4 Hz, 2H), 7.13 (d, J = 4.0 Hz, 2H), 7.17 [ 7.20 (m, 1H), 7.23 [ 7.26 (m, 2H),
7.28 [ 7.29 (m, 2H), 7.33 [ 7.35 (m, 2H), 7.39 [ 7.43 (m, 3H). 13C NMR (500 MHz,
CDCl3): ' 31.5, 34.7, 38.6, 59.3, 60.4, 66.2, 125.7, 128.1, 128.2, 128.2, 128.2, 128.4,
130.6, 132.1, 135.5, 135.6, 141.0, 173.6, 174.8. Diastereomer 2 [ 1H NMR (500 MHz,
CDCl3): ' 2.13 (s, 2H), 2.39 [ 2.41 (m, 1H), 2.55 [ 2.58 (m, 1H), 3.03 [ 3.04 (m, 1H),
3.36 [ 3.38 (m, 1H), 3.45 (s, 1H), 3.80 (s, 1H), 5.06 (d, J = 11.8 Hz, 1H), 5.17 (d, J =
11.8 Hz, 1H), 6.95 (d, J= 7.1 Hz, 2H), 7.12 [ 7.14 (m, 2H), 7.19 [ 7.26 (m, 5H), 7.30 [
7.32 (m, 2H), 7.39 [ 7.40 (m, 3H), 7.53 (s). 13C NMR (500 MHz, CDCl3): ' 29.7, 30.9,
32.4, 35.8, 59.6, 68.2, 126.5, 127.0, 128.3, 128.6, 128.8, 128.8, 129.0, 129.2, 130.5,
133.5, 134.4, 139.3, 170.4, 172.5. HRMS calcd for (M + H)+: C26H26ClNO4 452.1629,
found 452.1635 (diastereomer 1) and 452.1650 (diastereomer 2).
Mono(phenylmethyl) -[[1-carboxy-2-(4-trifluoromethylphenyl)ethyl]amino]-
benzenebutanoate (174)
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Compound 174 was obtained with 4-trifluoromethylbenzyl bromide and (S)-
benzyl 2-bromo-4-phenylbutanoate as a white solid (sample 1: 3.0 mg, 4% isolated yield
as a mixture of diastereomers; sample 2: 5.7 mg, 8% isolated yield [ 3.0 mg and 5.7 mg
of separate diastereomers) following chromatographic purification over cyano-silica gel
with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1% TFA/CH3CN and H2O
(50:50) by preparative liquid chromatography. Crude LC/MS purities 43% (sample 1) and
48% (sample 2), tR = 10.2, 10.6 min (dr 58:42); 1H NMR (500 MHz, CDCl3): ' 1.97 [ 2.05
(m, 2H), 2.59 (s, 2H), 3.16 (s, 2H), 3.42 [ 3.44 (m, 1H), 3.55 (s, 1H), 5.10 [ 5.16 (m,
2H), 7.04 [ 7.07 (m, 2H), 7.18 [ 7.21 (m, 1H), 7.25 [ 7.27 (m, 2H), 7.31 [ 7.36 (m, 4H),
7.38 [ 7.41 (m, 3H), 7.58 (d, J = 7.0 Hz, 2H). 13C NMR (500 MHz, CDCl3):    29.7, 31.7,
34.7, 37.8, 60.6, 61.3, 67.4, 125.8, 126.4, 128.2, 128.6, 128.8, 128.8, 129.8, 135.0,
139.6, 140.0, 173.2, 173.3. HRMS calcd for (M + H)+: C27H26F3NO4 486.1892, found
486.1912.
Mono(phenylmethyl) -[[(1-Carboxy-%$%+-naphthyl)ethyl]amino]benzenebutanoate
(175)
Compound 175 was obtained with 2-(bromomethyl)naphthalene and (S)-benzyl
2-bromo-4-phenylbutanoate as a yellow-white solid (sample 1: 9.0 mg,13% isolated yield
[ 2.8 mg and 6.2 mg of separate diastereomers; sample 2: 7.7 mg, 11% isolated yield [
2.5 mg and 5.2 mg of separate diastereomers) following chromatographic purification
over cyano-silica gel with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1%
TFA/CH3CN and H2O (50:50) by preparative liquid chromatography. Crude LC/MS
purities 47% (sample 1) and 44% (sample 2), tR = 10.2, 10.6 min (dr 55:45);
Diastereomer 1 [ 1H NMR (500 MHz, CDCl3):    1.89 [ 2.03 (m, 2H), 2.53 (s, 2H), 3.19 [
3.46 (m, 2H), 3.61 (s, 2H), 4.96 [ 5.03 (m, 2H), 6.99 (s, 2H), 7.15 [ 7.25 (m, 5H), 7.32 [
7.36 (m, 4H), 7.49 [ 7.52 (m, 2H), 7.69 (s, 1H), 7.82 [ 7.86 (m, 3H). Diastereomer 2 [ 1H
NMR (500 MHz, CDCl3):    1.97 (s, 2H), 2.25 [ 2.29 (m, 2H), 2.34 [ 2.37 (m, 1H), 3.26 [
3.29 (m, 1H), 3.37 (s, 1H), 3.56 [ 3.59 (m, 1H), 3.86 (s, 1H), 4.94 (d, J = 11.9 Hz, 1H),
5.11 (d, J = 11.99 Hz, 1H), 6.77 [ 6.78 (m, 2H), 7.11 [ 7.12 (m, 3H), 7.21 [ 7.22 (m, 2H),
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7.32 [ 7.37 (m, 4H), 7.48 [ 7.52 (m, 2H), 7.76 [ 7.83 (m, 4H). 13C NMR (500 MHz,
CDCl3): ' 31.0, 32.8, 37.3, 60.0, 62.2, 67.8, 126.1, 126.2, 126.5, 126.7, 127.0, 127.7,
127.7, 128.1, 128.2, 128.4, 128.6, 128.6, 128.7, 128.8, 129.0, 132.6, 133.5, 133.6,
134.6, 139.6, 171.2, 172.2. HRMS calcd for (M + H)+: C30H29NO4 found 468.2175
(diastereomer 1) and 468.2195 (diastereomer 2).
Mono(phenylmethyl) -[[(1-Carboxy-2-diphenyl)ethyl]amino]benzenebutanoate
(176)
Compound 176 was obtained with bromodiphenylmethane and (S)-benzyl 2-
bromo-4-phenylbutanoate as a clear oil (sample 1: 3.8 mg, 5% isolated yield [ 2.0 mg
and 1.8 mg of separate diastereomers; sample 2: 2.6 mg, 4% isolated yield [ 1.2 mg
and 1.4 mg of separate diastereomers) following chromatographic purification over
cyano-silica gel with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1%
TFA/CH3CN and H2O (70:30 to 100:0) by preparative liquid chromatography. Crude
LC/MS purities 28% (sample 1) and 27% (sample 2), tR = 10.5, 10.9 min (dr 54:46);
Diastereomer 1 [ 1H NMR (500 MHz, CDCl3):    1.93 [ 2.03 (m, 2H), 2.49 (t, J = 15.8 Hz,
2H), 3.65 (s, 1H), 4.24 (d, J = 9.9 Hz, 1H), 4.41 (d, J = 10.0 Hz, 1H), 5.16 (d, J = 12.0
Hz, 1H), 5.22 (d, J = 11.9 Hz, 1H), 6.96 (d, J = 7.3 Hz, 2H), 7.13 [ 7.40 (m, 18 H).
Diastereomer 2 [ 1H NMR (500 MHz, CDCl3):    1.75 [ 1.88 (m, 2H), 2.27 (t, J = 7.9 Hz,
2H), 3.24 (t, J = 5.7 Hz, 1H), 3.99 (d, J = 8.7 Hz, 1H), 4.43 (d, J = 8.7 Hz, 1H), 5.07 (d, J
= 12.0 Hz, 1H), 5.14 (d, J = 12.0 Hz, 1H), 6.90 (d, J = 14.3 Hz, 2H), 7.15 [ 7.38 (m,
18H). HRMS calcd for (M + H)+: C32H31NO4 494.2331, found 494.2314 (diastereomer 1)
and 494.2321 (diastereomer 2).
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Mono(phenylmethyl) -[[(1-Carboxy-%$'+-(2-chloropyridine))ethyl]-amino]benzene-
butanoate (177)
Compound 177 was obtained with 5-(chloromethyl)-2-chloropyridine and (S)-
benzyl 2-bromo-4-phenylbutanoate as a white solid (sample 1: 4.0 mg, 6% isolated yield
as a mixture of diastereomers; sample 2: 5.0 mg, 7% isolated yield [ 2.2 mg and 2.8 mg
of separate diastereomers) following chromatographic purification over cyano-silica gel
with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1% TFA/CH3CN and H2O
(30:70 to 50:50) by preparative liquid chromatography. Crude LC/MS purities 30%
(sample 1) and 28% (sample 2), tR = 8.6, 9.2 min (dr 61:39); Diastereomer 1 [ 1H NMR
(500 MHz, CDCl3): ' 1.95 - 1.96 (m, 1H), 2.05 (s, 1H), 2.59 [ 2.62 (m, 2H), 3.05 (s, 2H),
3.45 (s, 1H), 3.52 (s, 1H), 5.11 (d, J = 12.0 Hz, 1H), 5.16 (d, J = 12.0 Hz, 1H), 7.05 (d, J
= 7.4 Hz, 2H), 7.16 [ 7.19 (m, 1H), 7.23 [ 7.24 (m, 2H), 7.33 [ 7.40 (m, 5H), 7.50 (d, J =
7.3 Hz, 1H), 8.24 (s, 1H). Diastereomer 2 [ 1H NMR (500 MHz, CDCl3):    2.09 [ 2.17
(m, 2H), 2.50 [ 2.52 (m, 1H), 2.70 (s, 1H), 3.10 [ 3.21 (m, 2H), 3.55 (s, 1H), 3.76 (s,
1H), 5.08 (d, J = 11.9 Hz, 1H), 5.20 (d, J = 11.9 Hz, 1H), 6.99 (d, J = 7.2 Hz, 2H), 7.17 [
7.20 (m, 1H), 7.22 [ 7.25 (m, 3H), 7.32 [ 7.33 (m, 2H), 7.36 [ 7.37 (m, 3H), 7.54 (d, J =
7.3 Hz, 1H), 8.25 (s, 1H). HRMS calcd for (M + H)+: C25H25ClN2O4 453.1581, found
453.1571 (diastereomer 1) and 453.1566 (diastereomer 2).
Mono(phenylmethyl) -[[(1-Carboxy-3-phenyl)propyl]amino]benzenebutanoate
(178)
Compound 178 was obtained with (2-bromoethyl)benzene and (S)-benzyl 2-
bromo-4-phenylbutanoate as a white solid (sample 1: 8.2 mg, 13% isolated yield [ 5.3
mg and 2.9 mg of separate diastereomers; sample 2: 8.8 mg, 14% isolated yield [5.6
mg and 3.2 mg of separate diastereomers) following chromatographic purification over
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cyano-silica gel with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1%
TFA/CH3CN and H2O (50:50) by preparative liquid chromatography. Crude LC/MS
purities 56% (sample 1) and 56% (sample 2), tR = 9.7, 10.4 min (dr 58:42); Diastereomer
1 [ 1H NMR (500 MHz, CDCl3): 2.11 [ 2.19 (m, 4H), 2.53 [ 2.57 (m, 2H), 2.73 (s, 2H),
3.57 (s, 1H), 3.77 (s, 1H), 5.08 (d, J = 11.9 Hz, 1H), 5.19 (d, J = 11.9 Hz, 1H), 6.96 (d, J
= 7.3 Hz, 2H), 7.09 [ 7.23 (m, 8H), 7.27 [ 7.34 (m, 2H), 7.35 [ 7.36 (m, 3H). 13C NMR
(500 MHz, CDCl3): ' 30.8, 31.4, 32.2, 32.3, 60.0, 60.6, 68.5, 126.5, 126.6, 128.2, 128.5,
128.6, 128.8, 128.9, 129.1, 134.2, 139.1, 139.5, 169.4, 172.2. Diastereomer 2 [ 1H NMR
(500 MHz, CDCl3): ' 2.05 [ 2.13 (m, 1H), 2.18 [ 2.19 (m, 2H), 2.24 [ 2.29 (m, 1H), 2.47
[ 2.53 (m, 1H), 2.56 [ 2.69 (m, 1H), 2.70 [ 2.79 (m, 2H), 3.45 (t, J = 5.9 Hz, 1H), 3.64 (t,
J = 5.8 Hz, 1H), 4.99 (d, J = 12.0 Hz, 1H), 5.13 (d, J = 11.9 Hz, 1H), 6.99 (d, J = 7.3 Hz,
2H), 7.08 (d, J = 7.3 Hz, 7.14 [ 7.24 (m, 6H), 7.27 [ 7.28 (m, 2H), 7.32 [ 7.37 (m, 3H).
HRMS calcd for (M + H)+: C27H29NO4 432.2175, found 432.2166.
Mono(phenylmethyl) -[[(1-Carboxy-1-cyclohexyl)methyl]amino]benzenebutanoate
(179)
Compound 179 was obtained with cyclohexyl iodide and (S)-benzyl 2-bromo-4-
phenylbutanoate as a clear oil (sample 1: 7.5 mg, 12% isolated yield [ 4.4 mg and 3.1
mg of separate diastereomers; sample 2: 7.2 mg, 12% isolated yield [1.2 mg and 6.0
mg of separate diastereomers) following chromatographic purification over cyano-silica
gel with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1% TFA/CH3CN and
H2O (50:50) by preparative liquid chromatography. Crude LC/MS purities 72% (sample
1) and 72% (sample 2), tR = 10.1, 11.1 min (dr 60:40); Diastereomer 1 [ 1H NMR (500
MHz, CDCl3):    1.02 [ 1.27 (m, 5H), 1.58 [ 1.68 (m, 5H), 1.94 [ 1.99 (m, 1H), 2.09 [
2.12 (m, 2H), 2.49 (t, J = 7.9 Hz, 2H), 3.45 [ 3.46 (m, 1H), 3.61 [ 3.63 (m, 1H), 5.12 (d, J
= 11.8 Hz, 1H), 5.27 (d, J = 11.8, 1H), 6.94 (d, J = 7.4 Hz, 2H), 7.07 [ 7.10 (m, 1H), 7.16
[ 7.19 (m, 2H), 7.35 [ 7.40 (m, 5H). 13C NMR (500 MHz, CDCl3): ' 25.4, 25.6, 25.9,
28.5, 28.7, 30.7, 31.9, 39.6, 61.0, 67.2, 68.8, 126.7, 128.1, 128.7, 128.9, 129.1, 129.2,
134.0, 139.1, 168.6, 171.3. Diastereomer 2 [ 1H NMR (500 MHz, CDCl3): ' 1.03 [ 1.10
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(m, 2H), 1.14 [ 1.23 (m, 3H), 1.61 [ 1.71 (m, 5H), 1.87 [ 1.91 (m, 1H), 2.15 [ 2.22 (m,
2H), 2.54 [ 2.60 (m, 1H), 2.65 [ 2.71 (m, 1H), 3.31 [ 3.32 (m, 1H), 3.68 (t, J = 5.8 Hz,
1H), 5.05 (d, J = 11.9 Hz, 1H), 5.18 (d, J = 12.0 Hz, 1H), 7.04 (d, J = 7.2 Hz, 2H), 7.16 [
7.19 (m, 1H), 7.22 [ 7.26 (m, 2H), 7.32 [ 7.37 (m, 5H). 13C NMR (500 MHz, CDCl3): '
25.6, 25.8, 26.0, 28.8, 31.4, 32.2, 39.8, 60.5, 65.8, 68.1, 126.5, 128.3, 128.7, 128.8,
128.8, 128.9, 134.6, 139.6, 170.5, 172.6. HRMS calcd for (M + H)+: C25H31NO4
410.2331, found 410.2344 (diastereomer 1) and 410.2318 (diastereomer 2).
-[[2-Oxo-2(phenylmethoxy)-1-(2-phenylethyl)ethyl]amino]hexanoic acid (180)
Compound 180 was obtained with n-butyl iodide and (S)-benzyl 2-bromo-4-
phenylbutanoate as a white, oily solid (sample 1: 7.3 mg, 13% isolated yield [ 1.3 mg
and 6.0 mg of separate diastereomers; sample 2: 9.4 mg, 16% isolated yield [ 5.0 mg
and 4.4 mg of separate diastereomers) following chromatographic purification over
cyano-silica gel with acetone-hexanes (1:4 to 2:5) and over C18-silica gel with 0.1%
TFA/CH3CN and H2O (30:70 to 50:50) by preparative liquid chromatography. Crude
LC/MS purities 68% (sample 1) and 67% (sample 2), tR = 9.2, 10.0 min (dr 58:42);
Diastereomer 1 [ 1H NMR (500 MHz, CDCl3): ' 0.86 (t, J = 6.5 Hz, 3H), 1.25 [ 1.35 (m,
4H), 1.82 [ 1.84 (m, 2H), 2.17 [ 2.18 (m, 2H), 2.63 (s, 2H), 3.47 (s, 1H), 3.72 (s, 1H),
5.14 (d, J = 12.3 Hz, 1H), 5.25 (d, J = 11.8 Hz, 7.03 [ 7.05 (m, 2H), 7.15 [ 7.18 (m, 1H),
7.21 [ 7.24 (m, 2H), 7.34 [ 7.39 (m, 5H). Diastereomer 2 [ 1H NMR (500 MHz, CDCl3): '
0.84 (t, J = 7.3 Hz, 3H), 1.23 (sextet, J = 7.4 Hz, 2H), 1.31 [ 1.39 (m, 2H), 1.73 [ 1.87
(m, 2H), 2.09 [ 2.17 (m, 2H), 2.54 [ 2.65 (m, 2H), 3.45 (t, J = 6.1 Hz, 1H), 3.69 (t, J =
5.9 Hz, 1H), 5.12 (d, J = 11.9 Hz,12H), 5.23 (d, J = 11.9 Hz, 1H), 6.99 (d, J = 7.3 Hz,
2H), 7.13 [ 7.15 (m, 1H), 7.19 [ 7.21 (m, 2H), 7.34 [ 7.39 (m, 5H). 13C NMR (500 MHz,
CDCl3): ' 13.6, 22.2, 27.3, 30.9, 31.0, 32.8, 60.2, 61.5, 68.3, 126.5, 128.3, 128.6, 128.8,
128.9, 129.0, 134.3, 139.4, 170.0, 172.6. HRMS calcd for (M + H)+: C23H29NO4
384.2175, found 384.2162 (diastereomer 1) and 384.2185 (diastereomer 2).
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5.8 General Procedure for the Hydrolysis of the Benzyl Ester Intermediates
To the benzyl ester intermediate 126 was added to 6 N HCl (2 mL) and the
mixture was heated at 95 °C in an oil bath (Y 4 samples) or in an oven (>4 samples).
After 24 hrs the samples were cooled to room temperature and an aliquot was removed
for analysis by LC/MS. If the hydrolysis was complete, the reaction mixture was
concentrated under vacuum, frozen in water (1[2 mL) and then lyophilized to give
products 127 as a white or yellow solid. If the hydrolysis was not complete, heating of
the reaction mixture was continued for an additional 48[72 hrs until the reaction was
complete by LC/MS.
-[[(1-Carboxy-1-methyl)ethyl]amino]-&$'+-(2-chloropyridinyl)propanoic acid
hydrochloride (186)
Compound 186 was obtained from 155 as a solid (12.4 mg, 27% overall yield).
LC/MS purity 100%, tR = 2.8, 3.1 (dr unavailable due to overlapping peaks); 1H NMR
(500 MHz, DMSO): ' 1.51 [ 1.54 (m, 3H), 3.23 [ 3.27 (m, 1H), 3.41 (diastereomer A, dd,
J = 14.5 Hz, J = 5.8 Hz, 0.7H), 3.51 (diastereomer B, dd, J = 14.3 Hz, J = 5.1 Hz, 0.4H),
4.07 [ 4.13 (m, 1H), 4.29 [ 4.32 (m, 0.5H), 4.35 [ 4.38 (m, 0.7H), 7.50 [ 7.53 (m, 1H),
7.86 [ 7.90 (m, 1H), 8.36 [ 8.37 (m, 1H). 13C NMR (500 MHz, DMSO):    14.2, 14.9,
31.1, 31.2, 53.7, 54.1, 58.1, 58.2, 128.9, 130.4, 131.0, 140.6, 140.8, 148.9, 149.0, 150.5,
150.6, 168.9, 169.0, 170.4. HRMS calcd for (M + H)+: C11H13ClN2O4 273.0642, found
273.0652.
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N-[(1-Isobutyl-2-carboxy)ethyl]phenylalanine hydrochloride (187)
Compound 187 was obtained from 159 as a solid (12.4 mg, 26% overall yield).
LC/MS purity 100%, tR = 4.3, 5.5 (dr 60:40); 1H NMR (500 MHz, DMSO): ' 0.47 (d, J =
6.5 Hz, 0.3H), 0.54 (d, J = 6.6 Hz, 0.3H), -.65 [ 0.71 (m, 0.3H), 0.79 [ 0.81 (m, 1.3H),
0.86 [ 0.89 (m, 2.6H), 1.28 [ 1.34 (m, 0.2H), 1.41 [ 1.46 (m, 0.2H), 1.51 [ 1.56 (m,
0.5H), 1.59 [ 1.66 (m, 1H), 1.80 (m, 0.5H), 3.04 [ 3.18 (m, 2H), 3.62 (s, 1H), 3.79 (s,
0.4H), 3.93 (s, 0.6H), 7.22 [ 7.45 (m, 5H). 13C NMR (500 MHz, DMSO): ' 21.1, 21.8,
22.1, 22.4, 24.1, 24.2, 57.3, 57.5, 59.9, 126.8, 128.2, 128.3, 128.5, 129.1, 129.2, 135.9,
136.0. HRMS calcd for (M + Na)+: C15H21NO4 302.1368, found 302.1369.
N-[(1-Isobutyl-2-carboxy)ethyl]-4-methylphenylalanine hydrochloride (188)
Compound 188 was obtained from 160 as a solid (6.0 mg, 12% overall yield).
LC/MS purity 99%, tR = 5.3, 6.4 (dr 60:40); 1H NMR (500 MHz, DMSO): ' 0.47 (d, J = 6.5
Hz, 0.2H), 0.51 (d, J = 6.6 Hz, 0.2H), 0.63 [ 0.72 (m, 0.2H), 0.78 [ 0.81 (m, 2H), 0.86 [
0.88 (m, 3.5H), 1.48 [ 1.50 (m, 1H), 1.55 [ 1.57 (m, 1H), 1.62 (m, 0.4H), 1.78 (m, 0.6H),
2.26 (s, 3H), 2.97 [ 3.08 (m, 2H), 3.30 (s, 0.5H), 3.54 (s, 0.8H), 3.68 (s, 0.5H), 3.82 (s,
0.6H), 7.09 [ 7.14 (m, 4H). 13C NMR (500 MHz, DMSO): ' 20.5, 21.9, 21.9, 22.1, 22.4,
24.1, 24.1, 36.4, 57.3, 57.5, 60.1, 60.3, 128.7, 128.8, 129.0, 129.1, 132.9, 135.5, 135.7,
171.5, 172.7. HRMS calcd for (M + Na)+: C16H23NO4 316.1525, found 316.1522.
N-[(1-Isobutyl-2-carboxy)ethyl]-4-chlorophenylalanine hydrochloride (189)
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Compound 189 was obtained from 161 as a solid (10.0 mg, 19% overall yield).
LC/MS purity 88%, tR = 5.6, 6.6 (dr 60:40; 1H NMR (500 MHz, DMSO): ' 0.78 [ 0.82
(diastereomer B, m, 2.3H), 0.86 [ 0.89 (diastereomer A, m, 3.7H), 1.48 [ 1.51 (m, 1H),
1.57 [ 1.60 (m, 1H), 1.52 [ 1.66 (diastereomer B, m, 0.4H), 1.77 [ 1.82 (diastereomer A,
m, 0.6H), 3.02 [ 3.15 (m, 2H), 3.32 (s), 3.61 (s), 3.90 (s), 7.29 [ 7.30 (m, 2H), 7.35 [
7.39 (m, 2H). 13C NMR (500 MHz, DMSO): ' 21.9, 22.1, 22.3, 24.1, 24.1, 57.4, 57.5,
59.8, 60.0, 128.0, 128.2, 131.1, 131.2, 131.3, 131.5. HRMS calcd for (M + Na)+:
C15H20ClNO4 336.0979, found 336.0992.
N-[(1-Isobutyl-2-carboxy)ethyl]-4-trifluoromethylphenylalanine hydrochloride (190)
Compound 190 was obtained from 162 as a solid (5.0 mg, 9% overall yield).
LC/MS purity 97%, tR = 6.3, 7.3 (dr 70:30); 1H NMR (500 MHz, DMSO): ' 0.44 (d, J = 6.4
Hz, 0.4H), 0.52 (d, J = 6.5 Hz, 0.4H), 0.66 [ 0.70 (m, 0.5H), 0.74 (d, J = 6.5 Hz, 0.6H),
0.78 (d, J = 6.5 Hz, 0.6H), 0.86 [ 0.89 (m, 3.6H), 1.26 [ 1.45 (m, 0.8H), 1.50 [ 1.57 (m,
1.4H), 1.79 (m, 0.6H), 7.50 [ 7.52 (m, 2H), 7.65 [ 7.69 (m, 2H). 13C NMR (500 MHz,
DMSO): ' 20.9, 21.7, 22.0, 22.1, 23.5, 24.1, 57.4, 57.6, 59.6, 125.0, 125.3, 130.1, 130.2,
130.2, 130.3. HRMS calcd for (M + Na)+: C16H20F3NO4 370.1242, found 370.1260.
-[[(1-Carboxy-%$%+-naphthyl)ethyl]amino]-4-methylpentanoic acid hydrochloride
(191)
Compound 191 was obtained from 163 as a solid (11.8 mg, 22% overall yield).
LC/MS purity 100%, tR = 6.4, 7.2, dr 46:54); 1H NMR (500 MHz, DMSO): ' 0.76 [ 0.77
(m, 2.1H), 0.81 [ 0.91 (m, 3.9H), 1.60 [ 1.71 (m, 2.7H), 1.81 [ 1.87 (diastereomer B, m,
0.3H), 3.22 [ 3.36 (m, 2H), 3.42 [ 3.46 (m, 1H), 3.56 (s), 3.81 (s), 4.11 (s), 4.23 (s), 7.34
[ 7.39 (m, 2H), 7.48 [ 7.53 (m, 2H), 7.80 [ 7.86 (m, 2H), 7.88 [ 7.91 (m, 2H). 13C NMR
(500 MHz, DMSO): ' 21.6, 22.1, 22.2, 22.5, 24.1, 24.2, 57.4, 59.8, 125.6, 125.8, 126.0,
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126.1, 127.3, 127.4, 127.4, 127.7, 127.9, 127.9, 128.0, 128.2, 128.4, 131.9, 132.0,
132.0, 132.8, 132.8. HRMS calcd for (M + Na)+: C19H23NO4 352.1525, found 352.1525.
-[[(1-Carboxy-2-diphenyl)ethyl]amino]-4-methylpentanoic acid hydrochloride
(192)
Compound 192 was obtained from 164 as a solid (4.0 mg, 7% overall yield).
LC/MS purity 100%, tR = 4.9, 6.3 (dr 66:34); 1H NMR (500 MHz, DMSO): ' 0.60 (d, J =
5.9 Hz, 1.3H), 0.64 (d, J = 6.4 Hz, 1.3H), 0.80 [ 0.82 (m, 3.4H), 1.30 [ 1.44 (m, 2.5H),
1.66 [ 1.71 (m, 0.6H), 3.02 (s), 3.26 (s), 4.25 [ 4.34 (m, 1H), 7.16 [ 7.18 (m, 1H), 7.23 [
7.29 (m, 4H), 7.30 [ 7.34 (m, 2H), 7.38 [ 7.40 (m, 1H), 7.46 [ 7.49 (m, 2H). 13C NMR
(500 MHz, DMSO):    21.8, 22.0, 22.2, 23.8, 24.0, 57.3, 58.7, 62.9, 126.5, 126.8, 128.1,
128.2, 128.2, 128.3, 128.4, 128.5. HRMS calcd for (M + Na)+: C21H25NO4 378.1681,
found 378.1699.
-[[(1-Carboxy-%$'+-(2-chloropyridine))ethyl]amino]-4-methylpentanoic acid
hydrochloride (193)
Compound 193 was obtained from 165 as a solid (7.8 mg, 15% overall yield).
LC/MS purity 100%, tR = 3.8, 4.8 (dr 65:35); 1H NMR (500 MHz, DMSO): ' 0.86 [ 0.92
(m, 6H), 1.68 [ 1.77 (m, 2.3H), 1.85 [ 1.90 (m, 0.6H), 3.16 [ 3.40 (m, 2H), 3.93 (t, J =
6.6 Hz, 1.4H), 4.32 (t, J = 6.4 Hz, 0.6H), 7.51 [ 7.54 (m, 1H), 7.81 [ 7.84 (m, 1H), 8.34 [
8.35 (m, 1H). 13C NMR (500 MHz, DMSO): ' 21.2, 21.6, 22.2, 22.7, 24.1, 24.4, 57.6,
58.9, 123.9, 130.4, 140.8, 149.0, 150.6. HRMS calcd for (M [ H + 2Na)+: C14H18ClN2O4
359.0750, found 359.0761.
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Mono(phenylmethyl) -[[(1-Carboxy-3-phenyl)propyl]amino]-4-methylpentanoic
acid hydrochloride (194)
Compound 194 was obtained from 166 as a solid (11.0 mg, 22% overall yield).
LC/MS purity 95%, tR = 5.2, 6.2 (dr 53:47); 1H NMR (500 MHz, DMSO): ' 0.83 - 0.93 (m,
6H), 1.65 [ 1.79 (m, 2.2H), 1.88 [ 1.94 (m, 0.6H), 2.07 [ 2.18 (m, 2H), 2.64 [ 2.87 (m,
2H), 3.89 [ 3.92 (m, 1H), 7.21 [ 7.26 (m, 3H), 7.30 [ 7.34 (m, 2H). 13C NMR (500 MHz,
DMSO):    21.7, 22.1, 24.0, 30.5, 57.5, 58.3, 126.1, 128.1, 128.2, 128.2, 128.4, 132.9,
140.2. HRMS calcd for (M [ H + 2Na)+: C16H22NO4 338.1344, found 338.1346.
-[[(1-Carboxy-1-cyclohexyl)methyl]amino]-4-methylpentanoic acid hydrochloride
(195)
Compound 195 was obtained from 167 as a solid. LC/MS purity 100%, tR = 4.1,
5.7 (dr unavailable due to lack of chromaphore); 1H NMR (500 MHz, DMSO): ' 0.86 [
0.93 (m, 6H), 1.05 [ 1.30 (m, 4H), 1.61 [ 1.88 (m, 9H), 3.59 (s), 3.67 (s). 13C NMR (500
MHz, DMSO): ' 21.4, 21.8, 22.2, 22.2, 24.2, 25.1, 25.2, 25.3, 25.3, 25.6, 27.6, 27.8,
28.7, 58.2, 64.5, 172.0. HRMS calcd for (M [ H + 2Na)+: C14H24NO4 316.1501, found
316.1499.
-[[1-carboxy-1-(isobutyl)methyl]amino]hexanoic acid hydrochloride (196)
Compound 196 was obtained from 168 as a solid (8.9 mg, 21% overall yield).
LC/MS purity 100%, tR = 3.4 (dr unavailable due to lack of chromaphore); 1H NMR (500
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MHz, DMSO): ' 0.84 [ 0.92 (m, 9H), 1.23 [ 1.43 (m, 4H), 1.50 [ 1.54 (m ,1H), 1.57 [
1.68 (m, 2H), 1.72 [ 1.87 (m, 2H), 3.37 [ 3.41 (m, 1H), 3.58 [ 3.60 (m, 1H). 13C NMR
(500 MHz, DMSO): ' 13.5, 13.6, 13.7, 21.6, 21.7, 21.8, 22.0, 22.2, 24.1, 24.2, 26.7,
26.8, 30.3, 30.5, 57.2, 57.7, 38.4, 59.0. HRMS calcd for (M + H)+: C12H23NO4 246.1705,
found 246.1695.
-[[1-carboxy-2-(phenyl)ethyl]amino]benzenebutanoic acid hydrochloride (197)
Compound 197 was obtained from 169 as a solid (Diastereomer 1: 4.5 mg (8%
overall yield); Diastereomer 2: 3.7 mg (7% overall yield)). LC/MS purities: Diastereomer
1 [ 100%; Diastereomer 2 [ 100%, tR = 5.9 (Diastereomer 1) and 6.8 (Diastereomer 2);
Diastereomer 1 [ 1H NMR (500 MHz, DMSO): ' 1.56 - 1.72 (m, 2H), 2.09 - 2.10 (m#
2H), 2.36 [ 2.64 (m, 2H), 2.74 [ 2.87 (m, 2H), 3.07 [ 3.11 (m, 1H), 3.47 (t, J = 6.1 Hz,
1H), 7.13 [ 7.39 (m, 10H)$ Diastereomer 2 [ 1H NMR (500 MHz, DMSO): ' 1.72 [ 1.92
(m, 2H), 2.18 [ 2.32 (m, 1H), 3.07 [ 3.11 (m, 1.5H), 3.46 [ 3.50 (m, 0.5H), 7.00 (d, J =
7.2 Hz, 1H), 7.13 [ 7.19 (m, 1H), 7.22 [ 7.35 (m, 7H), 7.45 (d, J = 7.3 Hz, 1H). HRMS
calcd for (M + H)+: C19H21NO4 328.1549, found 328.1564 (diastereomer 1). HRMS calcd
for (M [ H + 2Na): C19H21NO4 372.1188, found 372.1196 (diastereomer 2).
-[[1-carboxy-2-(4-methylphenyl)ethyl]amino]benzenebutanoic acid hydrochloride
(198)
Compound 198 was obtained from 170 as a solid (Diastereomer 2: 12.0 mg, 21%
overall yield). LC/MS purity: Diastereomer 2 [ 100%; tR = 7.3; Diastereomer 2 [ 1H NMR
(500 MHz, DMSO): ' 1.94 (s, 2H), 2.26 (s, 3H), 2.46 [ 2.54 (m, 1H), 2.58 [ 2.64 (m, 1H),
3.00 [ 3.01 (m, 2H), 3.49 (s, 1H), 3.76 (s, 1H). 13C NMR (500 MHz, DMSO): ' 20.6, 30.7,
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58.3, 60.3, 125.8, 127.9, 128.2, 128.2, 128.7, 129.2, 135.6, 140.9, 172.5. HRMS calcd
for (M + H)+: C20H23NO4 342.1705, found 342.1715 (diastereomer 2).
-[[1-carboxy-2-(4-chlorophenyl)ethyl]amino]benzenebutanoic acid hydrochloride
(199)
Compound 199 was obtained from 171 as a solid (Diastereomer 2: 8.4 mg, 14%
overall yield). LC/MS purity: Diastereomer 2 [ 100%; tR = 7.7; 1H NMR (500 MHz,
DMSO): ' 1.72 [ 1.74 (m, 2H), 2.37 [ 2.48 (m, 2H), 2.79 [ 2.83 (m, 1H), 2.92 [ 2.95 (m,
1H), 3.13 [ 3.19 (m, 1H), 3.35 (s), 700 [ 7.02 (m, 2H), 7.14 [ 7.17 (m, 1H), 7.18 [ 7.35
(m, 6H). 13C NMR (500 MHz, DMSO): ' 30.7, 34.0, 58.4, 60.5, 125.6, 127.8, 127.9,
138.1, 128.2, 128.3, 130.9, 131.2, 141.5. HRMS calcd for (M + H)+: C19H20ClNO4
384.0979, found 384.0998.
Mono(phenylmethyl) -[[(1-Carboxy-%$%+-naphthyl)ethyl]amino]benzenebutanoic
acid hydrochloride (201)
Compound 201 was obtained from 173 as a solid (Diastereomer 1: 5.0 mg (8%
overall yield); Diastereomer 2: 6.0 mg (10% overall yield)). LC/MS purities: Diastereomer
1 [ 100%; Diastereomer 2 [ 100%, tR = 7.6 (Diastereomer 1) and 8.1 (Diastereomer 2);
Diastereomer 1 [ 1H NMR (500 MHz, DMSO): ' 1.04 [ 1.23 (m, 1H), 1.43 [ 1.49 (m,
1H), 1.94 [ 2.36 (m, 4H), 2.56 [ 2.66 (m, 2H), 7.02 [ 7.33 (m, 6H), 7.41 [ 7.55 (m, 3H),
7.78 [ 7.95 (m, 3H). Diastereomer 2 [ 1H NMR (500 MHz, DMSO): ' 2.00 [ 2.15 (m,
2H), 2.47 [ 2.54 (m, 1H), 2.60 [ 2.64 (m, 1H), 3.08 [ 3.15 (m, 1H), 3.25 [ 3.30 (m, 1H),
6.63 (s, 0.3H), 7.06 [ 7.10 (m, 1.5H), 7.17 [ 7.31 (m, 4H), 7.45 [ 7.61 (m, 2.5H), 7.71 [
7.82 (m, 1H), 7.85 [ 7.93 (m, 2H), 8.00 [ 8.01 (m, 0.5H), 8.42 (s, 0.3H). 13C NMR (500
MHz, DMSO): ' 30.8, 58.3, 127.4, 127.6, 128.1, 128.1, 128.2, 128.2, 128.2, 128.3,
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128.4, 132.8. HRMS calcd for (M + H)+: C23H23NO4 378.1705, found 378.1704
(diastereomer 1) and 378.1720 (diastereomer 2).
-[[(1-Carboxy-2-diphenyl)ethyl]amino]benzenebutanoic acid hydrochloride (202)
Compound 202 was obtained from 174 as a solid (Diastereomer 1: 3.6 mg (5%
overall yield); Diastereomer 2: 4.3 mg (7% overall yield)). LC/MS purities: Diastereomer
1 [ 100%; Diastereomer 2 [ 100%, tR = 7.4 (Diastereomer 1) and 8.5 (Diastereomer 2);
1H NMR (500 MHz, DMSO): ' 1.88 (s, 2H), 2.52 [ 2.64 (m, 2H), 3.34 (s, 1H), 4.41 (s,
1H), 7.10 [ 7.37 (m, 13H), 7.50 (d, J = 7.5 Hz, 2H). Diastereomer 2 [ 1H NMR (500
MHz, DMSO): ' 1.63 [ 1.81 (m, 2H), 2.14 [ 2.28 (m, 2H), 3.08 [ 3.11 (m, 1H), 4.18 [
4.20 (m, 1H), 6.98 (d, J = 7.2 Hz, 2H), 7.14 [ 7.16 (m, 3H), 7.23 [ 7.28 (m, 6H), 7.41 (d,
J = 7.4 Hz, 2H), 7.48 (d, J = 7.5 Hz, 2H). HRMS calcd for (M + H)+: C25H25NO4 404.1862,
found 404.1869 (diastereomer 1) and 404.1879 (diastereomer 2).
-[[(1-Carboxy-     -(2-chloropyridine))ethyl]-amino]benzenebutanoic acid
hydrochloride (203)
Compound 203 was obtained from 175 as a solid (Diastereomer 1: 3.5 mg (6%
overall yield); Diastereomer 2: 41. mg (7% overall yield)). LC/MS purities: Diastereomer
1 [ 100%; Diastereomer 2 [ 100%, tR = 7.4 (Diastereomer 1) and 8.5 (Diastereomer 2);
1H NMR (500 MHz, DMSO): ' 2.10 [ 2.17 (m, 2H), 2.60 [ 2.66 (m, 1H), 2.79 [ 2.85 (m,
1H), 3.15 [ 3.27 (m, 1H), 3.32 [ 3.40 (m, 1H), 3.98 (s, 1H), 4.34 (s, 1H), 7.04 [ 7.11 (m,
1H), 7.16 [ 7.35 (m, 2H), 7.44 [ 7.54 (m, 1H), 7.81 [ 7.90 (m, 1H), 8.35 [ 7.36 (m, 1H).
Diastereomer 2 [ 1H NMR (500 MHz, DMSO): ' 1.84 [ 2.01 (m, 2H), 2.35 [ 2.54 (m,
2H), 3.17 [ 3.31 (m, 2H), 3.37 (t, J = 6.1 Hz, 0.4H), 4.48 [ 4.53 (m, 0.6H), 7.07 (d, J =
6.4 Hz, 1H), 7.17 [ 7.23 (m, 2H), 7.27 [ 7.49 (m, 2H), 7.46 [ 7.54 (m, 1H), 7.77 [ 7.82
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(m, 0.4H), 7.90 [ 7.92 (m, 0.6H), 8.17 [ 8.18 (m, 0.6H), 8.43 [ 8.44 (m, 0.6H). HRMS
calcd for (M [ H + 2Na)+: C18H18ClN2O4 407.0750, found 407.0765 (diastereomer 1) and
407.0758 (diastereomer 2).
Mono(phenylmethyl) -[[(1-Carboxy-3-phenyl)propyl]amino]benzenebutanoic acid
hydrochloride (204)
Compound 204 was obtained from 176 as a solid (Diastereomer 1: 5.5 mg (10%
overall yield); Mixture: 8.5 mg (15% overall yield). LC/MS purities: Diastereomer 1 [
100%, Diastereomer 2 [ 100%, tR = 6.6, 7.4 (dr 14:86). Diastereomer 1 [ 1H NMR (500
MHz, DMSO): ' 1.83 [ 1.91 (m, 4H), 2.64 [ 2.67 (m, 4H), 3.26 (s, 2H), 7.16 [ 7.23 (m,
6H), 7.26 [ 7.31 (4H)$ Mixture 2 [ 1H NMR (500 MHz, DMSO): ' 1.88 [ 2.19 (m, 4H),
2.60 [ 2.79 (m, 4H), 3.89 [ 3.90 (m, 0.5H), 7.17 [ 7.32 (m, 10H). 13C NMR (500 MHz,
DMSO): ' 30.9, 31.2, 31.8, 58.2, 64.8, 125.8, 126.1, 128.2, 128.2, 128.3, 128.4, 140.4,
141.2, 171.5. HRMS calcd for (M + H)+: C20H24NO4 342.1705, found 342.1709
(diastereomer 1) and 342.1714 (diastereomer 2).
-[[(1-Carboxy-1-cyclohexyl)methyl]amino]benzenebutanoic acid hydrochloride
(205)
Compound 205 was obtained from 177 as a solid (Diastereomer 1: 6.8 mg, (13%
overall yield); Diastereomer 2: 4.6 mg (9% overall yield)). LC/MS purities: Diastereomer
1 [ 100%; Diastereomer 2 [ 100%, tR = 6.0 (Diastereomer 1) and 7.0 (Diastereomer 2);
Diastereomer 1 [ 1H NMR (500 MHz, DMSO): ' 1.08 [ 1.17 (m, 5H), 1.58 [ 1.61 (m,
3H), 1.68 [ 1.74 (m, 3H), 1.80 -1.91 (m, 2H), 2.58 [ 2.92 (m, 2H), 3.89 [ 3.97 (m, 1H),
7.16 [ 7.33 (m, 5H)$ Diastereomer 2 [ 1H NMR (500 MHz, DMSO): ' 0.98 [ 1.24 (m,
100
5H), 1.39 [ 1.45 (m, 0.5H), 1.60 [ 1.73 (m, 5H), 1.89 [ 1.97 (m, 1.5H), 2.08 [ 2.17 (m,
2H), 2.62 [ 2.87 (m, 2H), 3.76 [ 3.77 (m, 1H), 3.90 [ 3.92 (m, 1H), 7.20 [ 7.25 (m, 3H),
7.29 [ 7.33 (m, 2H). 13C NMR (500 MHz, DMSO): ' 24.7, 25.2, 25.6, 27.7, 28.5, 30.9,
31.4, 31.7, 126.1, 128.2, 128.4, 140.6, 170.6, 171.5. HRMS calcd for (M + H)+: C18H25-
NO4 320.1862, found 320.1873 (diastereomer 1) and 320.1852 (diastereomer 2).
-[[1-Carboxy-3-phenyl)propyl]amino]hexanoic acid hydrochloride (206)
Compound 206 was obtained from 178 as a solid (Mixture 1: 10.7 mg, (22%
overall yield); Diastereomer 2: 4.4 mg (9% overall yield)). LC/MS purities: Diastereomer
2 [ 100%, tR = 5.5 (Diastereomer 1) and 6.3 (Diastereomer 2); Mixture 1 [ 1H NMR (500
MHz, DMSO): ' 0.89 (m, 3H), 1.29 [ 1.33 (m, 3H), 1.37 [ 1.42 (m, 1H), 1.63 [
1.67 (m, 0.6H), 1.73 [ 1.78 (m, 1H), 1.82 [ 1.86 (m, 0.4H), 1.92 [ 2.14 (m, 2H), 2.54 [
2.87 (m, 2H), 3.40 (s, 1H), 3.65 (s, 1H), 7.19 [ 7.24 (m, 3H), 7.27 [ 7.32 (m, 2H). 13C
NMR (500 MHz, DMSO): ' 13.6, 13.7, 21.7, 21.8, 26.7, 26.9, 27.3, 30.7, 30.8, 58.6,
59.1, 126.0, 128.1, 128.2, 128.2, 128.3, 128.3, 128.4, 140.7, 171.7. Diastereomer 2 [ 1H
NMR (500 MHz, DMSO): ' 0.85 [ 0.89 (m, 3H), 1.26 [ 1.33 (m, 3H), 1.49 [ 1.44 (m,
1H), 1.76 (s, 2H), 2. 00 [ 2.06 (m, 2H), 2.63 [ 2.67 (m, 1H), 2.76 [ 2.79 (m, 1H), 3.68 (s,
1H), 3.93 [ 3.99 (m, 0.5H), 4.11 [ 4.14 (m, 0.2H), 7.19 [ 7.24 (m, 3H), 7.29 [ 7.32 (m,
2H). HRMS calcd for (M [ H + 2Na)+: C16H22NO4 338.1344, found 338.1352 (mixture 1).
HRMS calcd for (M + H): C16H22NO4 338.1344 294.1705, found 294.1703 (diastereomer
2).
101
5.9 General Procedure for the Preparation of Ethyl Ester Intermediate 209 and Hydrolysis to the
Amino Diacid
The benzophenone imine of glycine resin (BIG-Wang, 180 mg, 150 )mol, 0.84
mmol/g) was weighed into a 5-mL reaction vessel and swelled in CH2Cl2 for 30 min. The
solvent was drained and a solution of 0.2 M BTPP in NMP (1.5 mL, 300 )mol, 2 equiv)
was added to the resin and allowed to mix with the resin for 5 min. A solution of 0.2 M of
2-chloro-5-(chloromethyl)pyridine (147) in NMP (1.5 mL, 300 )mol, 2 equiv) was then
added, and the reaction was rotated at room temperature for 24 hrs.
The reagents were filtered off, and the resin was washed with NMP (2 x 2 mL)
and THF (2 x 2 mL). The benzophenone imine was hydrolyzed by the addition of 1 N
HCl/THF (2 mL, 1:2) to the reaction vessel and rotating the resin for 20 min. The
hydrolysis solution was filtered off, and the resin was washed with THF (2 x 2 mL), 10%
DIEA/CH2Cl2 (3 x 2 mL), and DMF (3 x 2 mL). To the reaction vessel was added a 0.4 M
solution of ethyl 2-bromopropanoate in DMF (1.5 mL, 600 )mol, 4 equiv), followed by
triethylamine (31 )L, 225 )mol. 1.5 equiv). The reaction was heated in an oven at 55 °C
for 3 d.
The reagents were filtered off, and the resin was washed with DMF (2 x 2 mL),
THF (2 x 2 mL), and CH2Cl2 (3 x 2 mL). The product was cleaved from the resin by
adding 95% TFA/H2O (2 mL) to the reaction vessel and rotating at room temperature for
1 h. The cleavage solution was collected in a tared vial, the resin was washed with
CH2Cl2 (1 x 2 mL), the washes were collected in the tared vial, and the solution was
evaporated under a stream of nitrogen to give a crude yield of 66 mg. The LC/MS of the
crude mixture showed 58% of the product.
The crude product was analyzed by cyano-silica gel TLC with acetone-hexanes
(1:3) and purified by loading the crude product (66 mg) onto a dry 1 g cyano-silica
cartridge with acetone (300 )L) and allowing the column to dry with a stream of nitrogen
for 1.5 h. The column was equilibrated with hexanes (2 x 2 mL) and eluted with a
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gradient of 10-40% acetone/hexanes. Fractions were analyzed by cyano-silica TLC
(30% acetone/hexanes) and pooled to afford product 209 as a mixture of diastereomers
(14.0 mg, 31%).
-[[2-oxo-2-(ethoxy)-1-(methyl)ethyl]amino]-&$'+-(2-chloro-pyridinyl)-propanoic
acid (209)
LC/MS purity of purified product 100%, tR = 4.4, 4.6 (dr unavailable due to
overlapping peaks). 1H NMR (500 MHz, CDCl3): ' 1.17 [ 1.25 (m, 3H), 1.49 [ 1.52 (m,
3H), 3.25 [ 3.36 (m, 2H), 3.75 [ 3.76 (m, 0.4H), 3.90 [ 3.95 (m, 1.5H), 4.03 [ 4.20 (m,
2H), 7.20 [ 7.21 (m, 1H), 7.72 [ 7.76 (m, 1H), 8.59 [ 8.66 (m, 1H). 13C NMR (500 MHz,
CDCl3): ' 14.0, 15.3, 16.6, 33.2, 55.5, 55.8, 61.0, 62.6, 62.7, 124.5, 130.4, 131.0, 140.7,
150.2, 150.3, 150.4, 150.5, 170.4, 171.2, 171.3. HRMS calcd for (M + H)+: C13H17ClN2O4
301.0955, found 301.0959.
To the ethyl ester intermediate 209 was added to 6 N HCl (2 mL) and the mixture
was heated at 95 °C in an oil bath for 24 h. The sample was cooled to room temperature
and an aliquot was analyzed by LC/MS, showing 100% of the amino diacid product 186.
The reaction mixture was concentrated under vacuum, frozen in water (1 mL) and then
lyophilized to give product 186 as a yellow solid (15.7 mg, 34% overall yield).
-[[(1-Carboxy-1-methyl)ethyl]amino]-&$'+-(2-chloropyridinyl)propanoic acid
hydrochloride (186)
LC/MS purity 100%, tR = 2.86, 3.08 (dr unavailable due to overlapping peaks). 1H
NMR (500 MHz, DMSO): ' 1.540 [ 1.53 (m, 3H), 3.21 [ 3.26 (m, 1H), 3.38 (dd, J = 14.6
Hz, J = 5.7 Hz, 0.6H), 3.48 (dd, J = 14.3 Hz, J = 5.2 Hz, 0.4H), 4.09 [ 4.14 (m, 1H), 4.31
[ 4.34 (m, 0.4H), 4.36 [ 4.39 (m, 0.6H), 7.51 [ 7.53 (m, 1H), 7.84 [ 7.88 (m, 1H), 8.36 [
8.37 (m, 1H). 13C NMR (500 MHz, DMSO): ' 14.7, 15.4, 31.6, 31.8, 54.4, 547, 58.7,
58.7, 124.4, 124.5, 130.9, 131.4, 141.2, 141.4, 149.5, 149.6, 151.1, 151.2, 169.6, 169.6,
171.0, 171.1. HRMS calcd for (M + H)+:C11H113ClN2O4 273.0642, found 273.0650.
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Appendix A. NMR Spectra
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Appendix B. 2D NMR Experiments
Table 7. Correlation of Proton and Carbon Shifts from the 2D NMR Experiments.
Carbon
Shift
Carbon
Number
Proton
Shift
Proton
Letter
Carbon
Shift
Carbon
Number
Proton
Shift
Proton
Letter
174.3 7 ---- ---- 127.9 14, 15,16 7.31-7.39 HD
174.1 7 ---- ---- 127.8 14, 15,16 7.31-7.39 HD
174.1 11 ---- ---- 127.7 14, 15,16 7.31-7.39 HD
173.6 11 ---- ---- 123.4 3 7.41 HC
150.4 2 8.24 HB 123.3 3 7.41 HC
150.3 2 8.24 HB 65.7 12 5.06 HE
148.2 1 ---- ---- 65.5 12 5.12 HE
148.1 1 ---- ---- 59.4 8 3.47 HG
140.6 5 7.70 HC 59.2 8 3.47 HG
140.4 5 7.70 HC 54.1 9 3.43 HF
135.9 13 ---- ---- 54.1 9 3.39 HF
135.9 13 ---- ---- 34.5 6 2.88, 2.80 HH
133.1 4 ---- ---- 34.2 6 2.90, 2.82 HH
133.1 4 ---- ---- 18.4 10 1.18 HI
128.3 14, 15, 16 7.31-7.39 HD 18.3 10 1.14 HI
127.9 14, 15,16 7.31-7.39 HD
Red = More abundant diastereomer
Green = Less abundant diastereomer
Black = Indistinguishable
